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Late-onset Alzheimer’s disease (LOAD) is an age-related chronic neurodegenerative disorder traditionally 
characterized by the presence of neurotoxic amyloid beta (Aβ) plaques, neurofibrillary tangles, and 
progressive, irreversible cognitive decline. Though extensively studied, the molecular mechanisms 
underlying the onset of AD-related neuropathologies are not understood. Moreover, over 200 clinical trials 
have failed to produce a viable therapeutic treatment strategy in the last 15 years. The inability to generate 
a treatment for clinical AD has led to a shift in focus from disease treatment to disease prevention and early 
intervention in the preclinical stage of AD development (pAD). As sex, genetics, and epigenetic influence 
have been identified as key contributors to early neurophysiological changes, it is imperative that research 
be conducted to elucidate  intersecting risk mechanisms that would allow for the development of novel 
therapeutic entities that could be targeted in pAD. Clusterin (CLU), initially identified in 1983, is a 
multifaceted, nearly ubiquitously expressed homeostatic regulator that is postulated to exist as multiple 
protein isoforms including a glycosylated mature/secreted form (mCLU) and smaller non-modified nuclear 
and/or intracellular forms. CLU, also known as apolipoprotein J (APOJ) which belongs to the same protein 
family as APOE, is currently listed as the third most potent genetic risk factor for the development of 
LOAD. However, despite many clinical observations of CLU SNPs-conferred increased AD risk, an 
extensive gap exists pertaining to the basic molecular properties of CLU in the healthy brain. Therefore, 
this dissertation focuses on the neurophysiological characterization of brain CLU with specific emphasis 
on understanding the expression, distribution, and potential physiological function(s) of individual CLU 
protein isoforms. The data indicate that at least two CLU mRNAs are generated from the CLU gene which 
are translated to 3 different CLU pre-proteins. These pre-proteins, which are differentially modified by N-
linked glycosylation, are targeted to distinct cellular compartments in both adult rodent brain and embryonic 
brain cell types. Moreover, we observe a distinct difference in the CLU protein expression profile between 
astrocytes and neurons with astrocytes generating and secreting extracellular mCLU and neurons primarily 
generating intracellular CLU protein isoforms. Of particular significance, we demonstrate for the first time 
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that CLU protein isoforms are integrally associated with brain mitochondrial function. Specifically, we 
identify a previously unknown mitochondria-targeted CLU protein isoform that is localized to the 
mitochondrial matrix where it directly interacts with a key component of the MICOS complex. In addition, 
the data indicate that non-mitochondrial CLU regulates some aspect of brain mitochondrial respiration in 
young adult female mice. Furthermore, we show for the first time that the mCLU pre-protein is significantly 
and positively regulated by estrogen in the brain. Specifically, the data indicate direct ligand-mediated 
regulation via estrogen receptor beta (ERβ) signaling through one or more previously unidentified estrogen 
receptor response elements on the CLU promoter. Collectively, these data suggest a possible hypothesis 
whereby CLU SNPs, which are associated with reduced circulating CLU, may contribute increased AD risk 
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Late-onset Alzheimer’s disease (LOAD): current status and challenges.  
Alzheimer’s disease (AD) currently affects 35 million people worldwide, including 5.4 million Americans; 
a number that is estimated to triple by the year 2050 (Alzheimer's, 2015). As the prevalence of AD increases 
the AD-associated economic burden will also increase. In 2015 the direct costs associated with the care of 
AD patients in the United States reached $226 billion. This number is predicted to reach $1.1 trillion by the 
year 2050 making AD one of the most costly chronic illnesses in the world (Alzheimer's, 2015). At present, 
AD is the 6th leading cause of death in the United States and is the only leading cause of death that cannot 
be prevented or cured. There are currently 5 FDA approved drugs available to treat AD-related symptoms, 
however, these drugs do not address the underlying cause of AD. Moreover, these drugs provide only 
temporary therapeutic relief in a 
fraction of the patients to whom they 
are administered making them 
relatively inefficient. Driven by the 
lack of an effective treatment, an 
extensive amount of clinical trials 
aimed at treating AD have been 
performed in the last 15 years; all of 
which have failed (McBride, 2012; 
Schnabel, 2013). These unanticipated 
challenges combined with the 
estimated rapid increases in AD 
prevalence stress the importance of 
identifying novel therapeutic entities 




One such strategy that has emerged in the last decade is to prevent or delay the onset of clinically 
diagnosable LOAD by identifying the molecular mechanisms that trigger neurocognitive decline in the 20-
30 year period prior to the onset of AD; a period of time now classified as preclinical AD. While the 
molecular mechanism(s) that trigger the initial onset of neurocognitive decline are still not known, studies 
have indicated irregularities in both amyloid and glucose metabolism several years prior to diagnosis. These 
findings, and many more, point to the preclinical phase of AD as a novel therapeutic window of opportunity 
in the treatment and/or prevention of LOAD (Schematic 1).   
 
An overview of LOAD-associated risk factors 
There are two types of AD: early-onset familial AD (fAD) and late-
onset sporadic AD (LOAD). fAD is rare and mostly caused by 
inherited genetic mutations that result in abnormal overproduction 
of neurotoxic β-amyloid (Aβ) peptides. Alternatively, LOAD, the 
most common form of AD representing 95% of human cases, 
develops after age 60 and involves a heterogeneous and 
multifactorial etiology.  It is now widely accepted that a person’s 
risk for developing LOAD is primarily influenced by a combination 
of complex interactions between multiple genetic and 
environmental risk factors including age, sex, genetic 
predisposition, and epigenetic influence (Schematic 2). Each LOAD 
risk factor will be discussed briefly in the following section.  
 
Age. At present, age remains the most predominant risk factor for LOAD. It is estimated that 1 in 9 (11.1%) 
senior citizens age 65 or older have been diagnosed with LOAD; a number that increases to 1 in 3 (33.3%) 




LOAD doubles every 5 years past the age of 65 (Aging, 2015). Additionally, epidemiologic studies from 
the NIA estimate that the total percentage of senior citizens in the U.S. will increase 7% by 2030 making 
senior citizens the fastest growing age group in the U.S. and consequently the most at-risk population 
(Aging, 2015).  
 
Sex. Of the 5.4 million Americans currently living with AD, approximately 65% are women (Alzheimer's, 
2015). It was originally postulated that the higher percentage of women living with AD was due to an 
increased life span of the female population, however, as the average world-wide life expectancy of men 
and women differs by only 4 years, this presumption is incorrect. A meta-analysis of 7 sex-specific clinical 
studies revealed that women are 1.5 times more likely to develop AD than age-matched men, indicating 
that the female sex confers AD risk independent of age (Gao, Hendrie, Hall, & Hui, 1998). In addition to a 
higher incidence of AD, it is now well-established that sex influences both the development and progression 
of LOAD. For example, female AD patients have been shown to exhibit more severe cognitive decline than 
men during the progression of AD pathology (Chapman et al., 2011; Irvine, Laws, Gale, & Kondel, 2012; 
Schmidt et al., 2008). While the exact mechanisms underlying this sex bias are currently unknown, 
mounting evidence suggests that female vulnerability to AD is largely associated with the irreversible 
decline of female sex hormones during the onset of menopause (Zhao & Brinton, 2005; Zhao, Mao, & 
Brinton, 2009; Zhao, Wu, & Brinton, 2004). However, despite these findings, the precise molecular 
mechanisms underlying female vulnerability remain uncharacterized.  
 
Epigenetic Influence.  Epigenetics is loosely defined as a heritable or acquired change in gene expression 
and/or function that does not result from a change in the DNA sequence. It is suggested that these heritable 
changes in gene expression are passed through generations and are strongly influenced by environmental 
factors [Reviewed in (Amy S. Yokoyama, 2017)]. Epigenetics, a broad term that encompasses aspects of 
DNA methylation, histone modification, and non-coding RNA, is also now hypothesized to significantly 




hydroxyl-methylation in un-related individuals discordant for LOAD and have consistently observed 
alterations in global DNA methylation and hydroxy-methylation in a brain region-specific (Bradley-
Whitman & Lovell, 2013; Chouliaras et al., 2013; Coppieters et al., 2014; Mastroeni et al., 2010; Rao, 
Keleshian, Klein, & Rapoport, 2012) and cell type-specific (Hof & Morrison, 1990; Phipps, Vickers, 
Taberlay, & Woodhouse, 2016) manner. However, perhaps the best evidentiary support for the impact of 
environmental factors on LOAD development arises from the examination of DNA methylation in 
monozygotic twins with opposing neuropathological outcomes (i.e. one with AD and one neurologically 
normal). One such study from Mastroeni and colleagues, which examined 5–methylcytosine levels in a set 
of monozygotic twins, revealed a significant decrease in global DNA methylation in two brain regions of 
the twin with AD. As one of the only key differences between the twins pertained to the twin with AD 
being exposed to pesticides on a regular basis, it was postulated that the alterations in brain DNA 
methylation were the result of environmental influence (Mastroeni, McKee, Grover, Rogers, & Coleman, 
2009). In addition to DNA methylation and hydroxyl-methylation, non-coding RNAs, which comprise 
nearly 98% of the genome, are also being recognized for the contribution to neurological function or 
dysfunction [Reviewed in (Esteller, 2011)]. Micro RNAs (miRNAs) are short non-coding RNAs the 
function to regulate RNA silencing and post-transcriptional gene regulation. Within the brain, it has been 
demonstrated that miRNA dysregulation significantly impacts dendritic spine formation and neurite 
outgrowth (Cao, Yeo, Muotri, Kuwabara, & Gage, 2006) and thus significantly contributes to multiple CNS 
disorders including ataxia, multiple sclerosis, Parkinson’s and Alzheimer’s Disease [Reviewed in (Esteller, 
2011).  
  
Genetic risk factors. A long-standing observation in the field of LOAD research is the significantly 
increased AD risk associated with possession of the human apolipoprotein E ε4 allele (APOE ε4) (Saunders 
et al., 1993); a mutation that now represents the most predominant genetic risk factor for LOAD. Possession 
of the ε4 allele is clinically associated with an increased rate and severity of cognitive decline, a younger 




1993; C. C. Liu, Kanekiyo, Xu, & Bu, 2013). Moreover, the ε4 allele has been shown to reduce brain 
glucose utilization (Langbaum et al., 2009), increase neuronal inflammation (Lynch et al., 2003), and is 
associated with increased Aβ dyshomeostasis (Drzezga et al., 2009; Drzezga et al., 2005). In addition to 
these data, studies have demonstrated that the APOE ε4-associated AD risk is significantly more 
pronounced in the female population. For example, a recent clinical study conducted in a cohort of 8,084 
elderly individuals (healthy controls: n=5,496; MCI cases: n=2,588) demonstrated that the risk of clinical 
conversion from healthy aging to MCI or from MCI to AD conferred by the ε4 allele was significantly 
greater in women than in men; a finding that corresponds with several earlier reports (Altmann, Tian, 
Henderson, Greicius, & Alzheimer's Disease Neuroimaging Initiative, 2014; Farrer et al., 1997; Fleisher et 
al., 2005; Payami et al., 1994; Payami et al., 1996).  
 
In addition to APOE ε4,  two of the largest genome-wide association studies ever conducted have recently 
identified several other genetic risk factors that confer significant LOAD risk (Harold et al., 2009; Lambert 
et al., 2009). Of the genetic risk factors identified in these studies and the data collected from 1395 studies 
that collectively discuss 695 genes and over 2000 polymorphisms, clusterin (CLU), also known as 
apolipoprotein J (APOJ), has been established as the third most predominant genetic risk factor for LOAD. 
CLU, which belongs to the same protein family as APOE, has been demonstrated to regulate inflammation, 
oxidative stress, and amyloid homeostasis in the brain. Moreover, a pilot study conducted in our laboratory 
indicated a significant and irreversible decline in CLU mRNA in the early aging female, but not male, brain 
(Zhao, Mao, Woody, & Brinton, 2016). These data suggest that, similar to APOE ε4, CLU is also influenced 
by sex in the brain aging process and the pathogenesis of LOAD. Therefore, while numerous alternative 
genetic risk factors do exist, the remainder of this dissertation will focus on CLU. The following sections 





Clusterin: from form to function 
Clusterin: discovery and nomenclature 
In 1983, Blaschuk et al. identified a high molecular weight protein in ram rete testis fluid (Fritz, Burdzy, 
Setchell, & Blaschuk, 1983). Further analyses indicated that this unknown protein was capable of eliciting 
the “clustering” of Sertoli cells, TM-4 cells, and erythrocytes resulting in the name clusterin. In 1984, 
Griswold and colleagues purified a dimeric acidic glycoprotein (DAG) from the Sertoli cells of rat testes 
(Sylvester, Skinner, & Griswold, 1984). This abundantly expressed but uncharacterized protein was 
detected at several molecular weights via reducing chromatography (41 kDa and 29 kDa), Western blot (27 
kDa, 21 kDa), and immunoprecipitation (70 kDa) (Sylvester et al., 1984). In 1988, another study identified 
a “novel” protein in human serum. This heterodimeric protein had a molecular mass of 80 kDa, was 
composed of two 40 kDa chains, and was sequentially unique to all other proteins. Furthermore, it was 
concluded that this protein, which was deposited in the renal glomeruli of patients with glomerulonephritis, 
was integrally involved in kidney health (Murphy, Kirszbaum, Walker, & d'Apice, 1988). As a result of 
these observations, Murphy and colleagues named this protein serum protein 40 kDa,40 kDa (SP-40,40) 
(Murphy et al., 1988). In 1990 and the years following, Harmony and colleagues identified and extensively 
characterized a component of high density lipoproteins in human plasma which was referred to as 
apolipoprotein J (ApoJ) (de Silva, Stuart, et al., 1990). However, upon the advent of DNA sequencing 
technology, it was determined that clusterin, DAG, SP-40,40, and ApoJ were in fact the same protein. In 
addition, clusterin was also “re-discovered” and subsequently re-labeled with alternative names including 
testosterone-repressed prostrate message-2 (TRPM-2) (Wong et al., 1993), KU70-binding protein 1 
(KUB1) (Yang et al., 1999), complement lysis inhibitor (CLI) (Jenne & Tschopp, 1989) and sulfated 
glycoprotein-2 (SGP2) (Purrello et al., 1991). In 1992, a forum conducted at Cambridge University 






Clusterin: from gene to protein 
 
Generation of CLU mRNA and Protein Isoforms. CLU is a single copy gene located on the short arm of 
chromosome 8 in humans (8p21-12) (Dietzsch, Murphy, Kirszbaum, Walker, & Garson, 1992; Tobe et al., 
1991) where it spans approximately 18,115 base pairs. Upon the splicing of 8 introns this 9-exon product 
spans approximately 2,877 base pairs, and is transcribed into at least 2 distinct mRNA isoforms with 1-3 
canonical translational start sites (Exon 1, Exon 2, and Exon 3). CLU mRNA Isoform 2 (NM_001831.3), 
the most extensively characterized CLU mRNA isoform, is translated into the mature/secreted isoform of 
CLU (mCLU) that has been predominantly identified and studied in the field of CLU research. This mRNA 
isoform is translated into a 449 amino acid pre-protein beginning at a canonical translational start site 
located at base pair 187 in exon 2 (Schematic 3, lower panel). This pre-protein contains an N-terminal 22 
amino acid endoplasmic reticulum (ER) signaling peptide (Exon 2, amino acids 1-22 or bp 187-252) and 
two nuclear localization sequences in exon 3 (amino acids 78-81 or bp 418-429) and exons 8-9 (amino 
acids 443-447 or bp 1513-1528). Following translation, the pre-protein is targeted to the ER where the 22 
amino acid leader sequence (LS) is cleaved. Following LS cleavage, the peptide is heavily modified by N-
linked glycosylation and proteolytically processed between R227 and S228 to form the two individual CLU 
subunits: the alpha subunit (CLUα, 34-37 kDa) and the beta subunit (CLUβ, 36-39 kDa). These two 
subunits are subsequently linked by 5 disulfide bonds to form an anti-parallel heterodimer (Burkey, deSilva, 
& Harmony, 1991) which, in non-reducing SDS-PAGE, is indicated to resolve at a molecular weight of 75-
80 kDa (Stewart et al., 2007).  
 
While the generation of mCLU is relatively well characterized in the literature, significant controversy still 
exists pertaining to the generation of alternative CLU mRNA isoforms. For instance, it is postulated that at 
least 1 alternative CLU mRNAs isoform is generated that lacks Exon 2.  The most prominent of the 




transcript would therefore begin at the translational start site in exon 3 and would result in the production 
of a CLU protein isoform that lacks the ER signaling peptide but retains the nuclear localization sequences. 
This alternative CLU isoform, which would be non-ER targeted and therefore unglycosylated, is speculated 
to shuttle between the cytoplasm and the nucleus and is generally referred to in the literature as “nuclear” 
CLU (Schematic 3, middle panel). In contrast, some studies postulate that this secondary transcript lacks 
Exon 2 but contains both Exon 1 and Exon 3 with translation beginning in either Exon. To complicate 
matters, some studies indicate the generation of multiple minor CLU mRNA isoforms which lack portions 
of exon 2 and/or exon 5. The proteins translated from these relatively uncharacterized mRNA isoforms are 
generally referred to in the literature as “intracellular” CLU (Leskov, Klokov, Li, Kinsella, & Boothman, 
2003; Prochnow et al., 2013; Reddy, Jin, Karode, Harmony, & Howe, 1996).  
 
mRNA and Protein Distribution. Initial characterization by Harmony et al. indicated the expression of 
CLU mRNA in liver, lung, spleen, heart, reproductive tissues, and brain with predominant expression in 
brain and reproductive tissues (de Silva, Harmony, Stuart, Gil, & Robbins, 1990). Since this initial 




expression in nearly all cell lines and tissue types tested. Moreover, CLU appears to be ubiquitously 
expressed on the subcellular level with multiple studies demonstrate CLU protein expression in the cytosol 
(Nizard et al., 2007), nucleus (Leskov et al., 2003), ER, Golgi apparatus, and mitochondria (Trougakos et 
al., 2009; H. Zhang et al., 2005). Within the brain, CLU expression has been detected within neurons 
(Pasinetti, Johnson, Oda, Rozovsky, & Finch, 1994), astrocytes (Cordero-Llana et al., 2011; Pasinetti et al., 
1994; Zwain, Grima, & Cheng, 1994), microglia (Xie et al., 2005), and within the extracellular space 
(Kumita et al., 2007). Though the exact physiological functions of CLU in the brain remain a mystery, the 
nearly ubiquitous nature of CLU indicates the significance of this protein in cellular homeostasis. 
 
Protein Structure. Despite being studied for over 35 years, very little information is available regarding 
the structure of CLU: a challenge that is likely due to the promiscuous nature of CLU as a 
binding/interacting partner (A. R. Wyatt, Yerbury, & Wilson, 2009) and tendency for CLU to self-aggregate 
(Fritz et al., 1983). For example, it has been previously demonstrated that CLU forms high molecular weight 
dimers and tetramers depending upon the pH of the cellular environment (Poon et al., 2002). This self-
aggregating nature combined with the high levels of N-linked glycosylation have rendered the acquisition 
of replicable X-ray structures relatively difficult. Moreover, as the protein turnover time for mCLU is 
estimated to be approximately 30 minutes, the acquisition of sufficient quantities of pure recombinant 
heterodimerized mCLU have only been recently achieved (Dabbs & Wilson, 2014). However, despite these 
challenges some information is available pertaining to the primary, secondary and tertiary structure of CLU. 
For example, it is established that the primary structure of CLU, or the amino acid sequence of CLU, is 
highly homologous across species, with the highest degree of homology occurring within the disulfide 
bonding region (Londou, Mikrou, & Zarkadis, 2008; Purrello et al., 1991). Moreover, several studies using 
IR spectroscopy have indicated that nearly 60% of the secondary structure of CLU is comprised of α-helices 
(Rohne, Prochnow, Wolf, Renner, & Koch-Brandt, 2014; Stewart et al., 2007) with follow-up in silico 




& Griswold, 2001). Regarding the tertiary structure of CLU, a study from Dunker et al. indicates that 
mCLU, which contains at least 2 flexible hydrophobic molten globule domains, is classified as a member 
of the intrinsically disordered protein family (Dunker et al., 2001). This family of proteins is defined by a 
general lack of tertiary structure. In reference to mCLU, this disorganized tertiary arrangement results in 
the exposure of molten globule domains to the cellular environment allowing for diverse hydrophobic 
interactions (Bailey et al., 2001). Despite these findings, CLU protein isoforms are yet to be crystallized in 
their entirety meaning that there is still an extensive amount of information that could be gleaned from this 
field of research. 
 
Transcriptional regulation of CLU. Though the gene promoter of CLU is highly conserved across 
species, the transcriptional regulation of CLU is complex and controversial as the predominant CLU 
transcriptional regulators appear to differ between tissue and cell type. However, despite the controversy in 
the literature, it is generally agreed that CLU is primarily upregulated by cellular injury, cytotoxic insult, 
and various stress stimuli (Loison et al., 2006; Michel, Chatelain, North, & Brun, 1997; Trougakos & 
Gonos, 2006).  For instance, Loisen and colleagues demonstrated that the CLU gene promoter contains an 
MG132 responsive region and a heat-shock element (HSE) indicating that proteasomal stress directly 
influences CLU transcription (Loison et al., 2006). Another study demonstrated that the CLU gene promoter 
contains both HSEs and an activator protein-1 (AP-1) response element indicating direct transcriptional 
regulation by stimuli derived from cellular proliferation and differentiation (Trougakos & Gonos, 2006). In 
addition to these data, alternative stress-related transcription factor response elements have been identified 
in the CLU gene promoter including a cAMP response element (CRE), an AP-2 response element, a 
specificity protein-1 (SP1) response element, and a glucocorticoid response element (GRE) (Michel et al., 
1997; Wong et al., 1993). It has also been demonstrated that apoptotic stimuli, modulates CLU 
transcription, specifically in cancer. An early study from Cervellera et al. identified a MYB binding site in 
the 5’ flanking region of CLU and that B-MYB, a MYB family member that regulates cellular proliferation 




transcription is also regulated by several different growth factors including nerve growth factor (NGF) and 
transforming growth factor beta (TGFβ) (Gutacker, Klock, Diel, & Koch-Brandt, 1999; Jin & Howe, 1997, 
1999). For instance, it has been demonstrated that TGFβ induces the upregulation of CLU gene expression 
by stimulating the interaction between the CLU gene promoter and AP-1 (Jin & Howe, 1997). An extension 
of these studies demonstrated that TGFβ deficiency resulted in the repression of CLU gene expression via 
interaction between c-Fos and the CLU gene promoter; an interaction that was abrogated upon cellular 
stimulation with TGFβ (Jin & Howe, 1999). 
 
Post-translational modification. In addition to transcriptional regulation, CLU is also regulated by several 
types of post-translational modification (PTM); the most predominant type being N-linked glycosylation. 
N-linked glycosylation, the addition of oligosaccharides to the N in the side chain of an asparagine residue, 
occurs in the ER/golgi body (Schematic 4) and is known to influence a myriad of cellular processes by 
mediating the response to extra- and intracellular signaling cues. mCLU is N-glycosylated at 6-7 asparagine 
residues (N86, N103, N145, N291, N354, and N374) during ER-Golgi processing: a modification that 
comprises approximately 20-25% of the total mass of mCLU (Kapron et al., 1997). While glycosylation 
status was originally thought to have little to no impact on CLU function (Dunker et al., 2001; Stewart et 
al., 2007) a recent study demonstrated that the chaperone activity of mCLU is dependent upon mCLU 
glycosylation (Rohne et al., 2014). This study also demonstrated that the glycosylation of a non-secreted 
CLU protein isoform did not result in chaperone activity indicating that glycosylation-mediated effects are 
specific to the mCLU isoform. It has also been established that complete deglycosylation of mCLU results 
in a 70-90% decrease in mCLU chaperone activity and a significant decrease in the number of α-helices in 
the secondary structure of CLU. These data suggest that the lack of chaperone activity in deglycosylated 
mCLU could be, in part, due to the significant changes in secondary structure. Additionally, this study 
indicates that partially glycosylated mCLU retains chaperone activity suggesting that the core glycan is 




5) (Rohne et al., 2014). Parallel to these findings, a study from Kang et al. indicated that ER stress, which 
inhibits protein glycosylation, resulted in rapid retro-translocation of mCLU from the ER yielding several 
hypo-glycosylated CLU isoforms. These hypo-glycosylated isoforms, which are misfolded and generally 





degradation. However, if the proteasome is chemically inhibited following ER stress, hypo-glycosylated 
CLU accumulates in the cytosolic compartment resulting in cytotoxicity. Collectively, these studies indicate 
that glycosylation is crucial for specifically mCLU chaperone activity. CLU is also a primary target for 
ubiquitination and phosphorylation. It has been demonstrated that “nCLU” is a target for K63 ubiquitination 
through the ubiquitin E3 ligase, product of von Hippel-Lindau (pVHL). However, contrary to the canonical 
function of protein ubiquitination, K63-linked ubiquitination of CLU does not target CLU for destruction, 
rather it promotes CLU translocation to the nuclear compartment for reasons that are currently unknown 
(Xue et al., 2012). Pertaining to CLU phosphorylation, a recent proteomics study which focused on the 
identification of the serum phospho-proteome has identified three different phosphorylation sites at residues 
Thr393, Ser394, and Ser39 within the CLU protein. Additionally, a more recent study indicated that 
treatment of hepatocytes with 10 mM glucose and fructose significantly increased the levels of mCLU 
serine phosphorylation. This same study demonstrated increased mCLU serine phosphorylation in both the 
skeletal muscle and the liver of rats that were orally administered high doses of glucose and/or fructose 
indicating that phosphorylated CLU may interact with or respond to the activation of glucose-sensitive 
cellular bioenergetic pathways. In addition to phosphorylation and ubiquitination, an early report indicated 
that CLU is iodinated at 1 of the 12 tyrosine residues within the CLU protein. This iodination occurs within 




gland can conserve iodine, which is relatively rare in the body (Lemansky, Brix, & Herzog, 1999). It is also 
suggested that CLU activity is regulated by both sialylation (Ghosh, Hale, & Lakshman, 2001), most likely 
through N-linked glycosylation,  and acetylation (Nuutinen, Suuronen, Kyrylenko, Huuskonen, & 
Salminen, 2005), however, definitive acetylation sites have not been identified. 
   
Clusterin in Cancer: Current understanding  
Perhaps one of the most thoroughly understood areas of CLU research is the role of mature secreted 
CLU in cancer development. Findings from multiple cancer cell and tumor types consistently 
indicate a role for CLU specifically in regards to cancer cell survival, tumor metastasis, and 
chemoresistance. The following sections will briefly discuss the current understanding of CLU in 
cancer and the potential of CLU inhibition as a therapeutic option.  
 
Clusterin in cancer development. Increased sCLU expression is often associated with aggressive chemo-
resistant cancers [Reviewed in (Koltai, 2014)]. Clinical studies indicate that higher levels of CLU are often 
found in aggressive or highly metastatic tumors derived breast cancer carcinoma (Redondo et al., 2000) and 
triple negative breast cancer (D. Zhang et al., 2012), ovarian cancer (Yang, Li, & Xie, 2009), prostate cancer 
[Reviewed in (Higano, 2013)] as well as several other cancer/tumor types (He et al., 2009; Hoeller et al., 
2005; Lau et al., 2006; Miyake, Gleave, Kamidono, & Hara, 2002; Miyake, Gleave, Arakawa, Kamidono, 
& Hara, 2002). In contrast cancer cell and/or tumor types with low endogenous CLU expression exhibit 
increased chemosensitivity. For example, human testicular seminoma, which exhibits relatively low CLU 
expression, is highly sensitive to both radio- and chemotherapy (B. Liu et al., 2013; Tang et al., 2013). 
sCLU expression levels are also associated with tumor aggressiveness and metastatic potential. For 
instance, increased sCLU expression in clear cell renal carcinoma results in aggressive tumor behavior 
mediated via induction of extracellular signal-regulated kinase (ERK)1/2 signaling and matrix 




and invasion, and decreased tumor metastasis (X. Wang, Luo, Dong, Yu, & Zhao, 2014). In prostate cancer 
cells, sCLU has been shown to regulate the ubiquitination and degradation of COMM domain-containing 
protein 1 (COMMD1) and inhibitor of kappa B (IκB) which results in the increased translocation of NF-
κB to the nucleus and subsequent up-regulation of NF-κB target genes. Parallel to these findings, 
knockdown of sCLU results in the sequesterization of NF-κB to the cytosol via stabilization of COMMD1 
and IκB (Essabbani, Margottin-Goguet, & Chiocchia, 2010; Zoubeidi et al., 2010). In epithelial ovarian 
cancer cells, sCLU is correlated with increased angiogenesis (Fu et al., 2013) and increased 
chemoresistance (Wei et al., 2009) while depletion of sCLU is associated with reduced proliferation, 
invasion, and migration in human breast adenocarcinoma (Li et al., 2012; Niu et al., 2012) and renal 
carcinoma (Shi et al., 2013) cells and increased tumor sensitivity to Paclitaxel (Hassan et al., 2011) and 
Cisplatin treatment (C. H. Lee et al., 2002).    
 
Two primary models exist to explain the sCLU-mediated cancer survival and chemoresistance. First, studies 
pertaining to Paclitaxel-resistant ovarian cancer have demonstrated that sCLU mediates chemoresistance 
by physically binding the drug paclitaxel thereby decreasing drug bioavailability (Park et al., 2008). 
However, as tumors with high CLU levels are known to exhibit chemoresistance to multiple 
chemotherapeutic agents, most of which do not physically interact with CLU, this interaction does not fully 
explain the pro-survival properties of increased sCLU. It is now widely accepted that the primary 
mechanism of sCLU-mediated cancer cell survival revolves around the interaction between sCLU, Ku-70, 
and the pro-apoptotic protein Bax. It has been repeatedly demonstrated that elevated sCLU levels increase 
cancer cell and/or tumor survival by interfering with Bax-mediated apoptosis. Specifically, sCLU 
sequesters Bax to the cytosol via interaction with Ku-70 thus inhibiting Bax translocation to the outer 
mitochondrial membrane (Hsu, Wolter, & Youle, 1997; Trougakos et al., 2009; H. Zhang et al., 2005). 
While there are several other minor pathways suggested to play a role in sCLU-mediated cancer cell 




here clearly indicate that overexpression of sCLU results in enhanced tumor aggressiveness and survival 
by inhibiting intrinsic apoptosis while knockdown of sCLU results in increased chemosensitivity.    
 
Clusterin as a therapeutic target for cancer treatment. As sCLU expression clearly plays a prominent 
role in cancer cell and tumor survival, therapeutic strategies designed to inhibit or repress sCLU expression 
in combination with multi-drug treatment are now being investigated. In vitro administration of CLU-
targeting siRNA or shRNA have indicated a reduction in the metastatic potential of cancer cells and thus 
provide promising preliminary data for the development of CLU inhibitors. These data along with others 
resulted in the generation of Custirsen (OGX-011); a second generation 2'-methoxyethyl modified 
phosphorothioate antisense oligonucleotide inhibitor of CLU. Custirsen, which blocks the generation of 
90% of serum CLU protein at a dose of 640 mg, was found to be relatively well tolerated by patients and 
distributed evenly throughout intended tissues in phase I clinical trials (Chi et al., 2005; Chi et al., 2008)  
Furthermore, 6 phase II clinical trials performed on patients with non-small cell lung cancer (Laskin et al., 
2012), metastatic breast cancer (Chia et al., 2009), and metastatic castration-resistant prostate cancer 
(CRPC) (Chi et al., 2010; Saad et al., 2011) successfully confirmed the safety and efficacy of Custirsen in 
combination with various chemotherapy regimens. Moreover, 33% of patients in the breast cancer trial and 
31% of patients in the lung cancer trial responded to therapies involving co-treatment with Custirsen and 
exhibiting consistently reduced serum CLU levels. These findings were consistent with those from the 
prostate cancer studies which concluded that that clusterin is a useful therapeutic target in the treatment of 
CRPC [Reviewed in (Xiu, Dong, Li, & Li, 2015)]. With successful Phase I/II trials completed Custirsen 
has recently been the focus of three randomized, global, phase III trials: the SYNERGY trial 
(NCT01188187), the AFFINITY trial (NCT01578655) and the ENSPIRIT trial (NCT01630733). The 
SYNERGY trial, which was completed in 2014, investigated the impact of adding Custirsen to standard 
first-line docetaxel/prednisone for men with CRPC (Chi et al., 2015). The AFFINITY trial, which was 




a second-line chemotherapy in prostate cancer (Beer et al., 2017). Unfortunately, results from both studies 
indicate that, while the treatments were well-tolerated, overall survival was not significantly impacts in 
patients treated with Custirsen and chemotherapeutic regimens, when compared with patients treated with 
chemotherapeutic agents alone (Beer et al., 2017; Chi et al., 2015). While the ENSPIRIT trial is still 
ongoing, it is crucial that investigators attempt to understand possible reasons why these clinical trials, 
which had reasonably large study populations (600-1100 patients), were not successful. One key 
contributing factor could be the stage of cancer in the study populations. As the studies in question 
investigated the impact of Custirsen in only those patients with advanced metastatic cancers, it is highly 
possible that disease progression in the study population was beyond the stage where inhibition of CLU 
protein expression would yield beneficial effects; however this hypothesis requires further testing.   
 
Clusterin in Late-onset Alzheimer’s disease: clinical findings 
The clinical association of CLU with AD pathology has recently been a matter of significant 
interest with numerous clinical trials and meta-analyses examining the association of CLU SNPs 
with AD risk in various ethnic populations. In addition, it has been suggested that circulating CLU 
levels may be used as a predicative biomarker for rate and/or severity of neurocognitive decline, 
though results on this topic are inconsistent. The following sections will review the literature 
pertaining to CLU SNPs and AD risk as well as literature pertaining to CLU as an AD biomarker.  
 
Clusterin gene polymorphisms in LOAD. Since the initial determination of CLU SNP-associated AD 
risk by Harold et al. and Lambert et al. (Harold et al., 2009; Lambert et al., 2009), there have been 
approximately 40 independent follow-up meta-analyses and case-control studies that have examined the 
association between CLU SNPs and AD risk. These reports were located using the following search and 
filter parameters: a PubMed search focused on articles pertaining to CLU SNPs in AD was performed. 




population demographics, and a thorough description of statistical analysis in which ApoE status was 
included as a variable are included in this comparison. Though conflicting evidence exists, the majority of 
the studies indicate that genetic variation in CLU increases the risk of developing AD independent of APOE 
ε4 status. There are approximately 355 identified SNPs in the CLU gene (Masoodi, Al Shammari, Al-
Muammar, Alhamdan, & Talluri, 2013), however, it appears that the primary risk-conferring CLU SNP is 
the C allele of the rs11136000 SNP. Of the 33 studies examined, 25 studies either include or exclusively 
focus on the impact of the rs11136000 SNP on AD risk; however, the results are inconsistent. 13 studies 
conclude that possession of rs11136000 does confer increased AD risk (Braskie et al., 2011; Chen et al., 
2012; Corneveaux et al., 2010; Ferrari et al., 2012; Harold et al., 2009; G. Jun et al., 2010; Lambert et al., 
2009; Lancaster et al., 2011; Ma et al., 2011; Schurmann et al., 2011; Seshadri et al., 2010; Thambisetty et 
al., 2013) while 10 studies conclude no significant association between rs11136000 and AD (Golenkina et 
al., 2010; Kamboh et al., 2012; Klimkowicz-Mrowiec et al., 2013; Komatsu et al., 2011; J. H. Lee et al., 
2011; Lu et al., 2014; Yu et al., 2010; Yu et al., 2013). Moreover, 2 studies conclude that possession of the 
rs11136000 SNP reduces risk of AD development (Lin et al., 2012; Pedraza et al., 2014). A possible 
explanation for these discrepancies may be found by examining the population ethnicities. Of the 13 studies 
that conclude rs11136000 confers AD risk, 11 studies are performed in a predominantly or exclusively 
western European or American Caucasian population. Alternatively, 9 of the 10 studies that conclude no 
significant association (NSA) between rs11136000 and AD were performed in Asian, eastern European and 
Russian, Middle Eastern, or Hispanic populations indicating that the risk associated with the rs11136000 
SNP may vary based on ethnicity. Contrary to these data, 2 separate studies performed in exclusively 
German and American Caucasian populations found NSA between rs11136000 and AD risk. Moreover, 
the notion that rs11136000 does not confer AD risk in Asian populations is contradicted by 2 independent 
studies that indicate rs11136000-mediated AD risk in exclusively Chinese populations. As all the presented 
studies performed in Asian populations are adjusted for age, gender, and APOE status, and are comprised 
of numerically similar sample sizes, it is difficult to identify the exact reason underlying these discrepancies. 




specific nucleotide substitution located at the rs11136000 SNP site (i.e. C,T substitution) while others have 
examined only rs11136000 carriers vs. non-carriers. The failure to stratify study populations based on the 
rs11136000 allele/genotype would have a significant impact on study outcome as the C allele of rs11136000 
is considered the risk-conferring allele while the T allele is considered normal and neuroprotective, 
respectively (i.e. C = risk allele, T = protective). Specifically, studies have indicated that one copy of the C 
allele confers a 1.16-fold increased chance of developing LOAD and is present in 88% of Caucasians 
(Harold et al., 2009; Lambert et al., 2009) while 2 copies of the C-allele are present in 36% of the Caucasian 
population (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007; Braskie et al., 2011). From a clinical 
standpoint, possession of the C allele is associated with faster cognitive decline in pre-clinical AD 
(Thambisetty et al., 2013) and lower memory scores in healthy elderly controls and elderly AD patients 
(Masoodi et al., 2013). In addition, young healthy carriers of the C allele exhibit neural hyper-activation in 
memory-associated brain regions during working memory tasks (Lancaster et al., 2011), neural inefficiency 
in memory-related pre-frontal and limbic areas during working memory (Lancaster et al., 2015), and 
reduced coupling between hippocampus and pre-frontal cortex during memory processing (Erk et al., 2011). 
Structurally speaking, possession of the C allele is associated with diminished white matter integrity in 
several brain regions (Thambisetty et al., 2012) and increased longitudinal ventricular expansion in elderly 
patients independent of APOE ε4 and dementia status (Roussotte et al., 2014). Taken together, these data 
indicate that the rs11136000 SNP is significantly associated with the development of AD in predominantly 
Caucasian populations and that the rs11136000 AD-associated risk may be initiated several decades prior 
to the onset of AD.  
 
In addition to rs11136000, another CLU SNP, rs9331888, which was also identified by Lambert and 
colleagues in the original GWAS, has also been repeatedly investigated as an AD risk SNP. Of the 33 
studies examined, 7 clinical studies and 2 meta-analyses focus on the association of rs9331888 with AD 




Rios et al., 2015; Xing et al., 2012; Yu et al., 2010; S. Zhang et al., 2015). However, similar to that of 
rs11136000, the results vary and appear to be dependent upon population ethnicity. For instance, two 
separate meta-analyses conclude that rs9331888 confers AD risk in Caucasian but not Asian populations 
(Shuai et al., 2015; S. Zhang et al., 2015). However, 2 separate case-control studies performed in 
exclusively Chinese populations both indicate that rs9331888 is significantly associated with AD risk (Xing 
et al., 2012; Yu et al., 2010). In addition to differing and/or small sample sizes, one possible confounding 
factor could be sex of the study population. As sex modulates an individual’s risk for LOAD, it is likely 
that stratification of study populations by sex will have a significant impact on the study results. In 
conclusion, future studies should strongly consider variables such as ethnicity and gender stratification to 
accurately gauge AD risk conferred by CLU SNPs.    
 
Clusterin as an AD biomarker. In 1992, it was suggested that peripheral CLU (then referred to as SGP-
2) expression may serve as a potential genetic biomarker for predicting the onset and/or severity of 
neurodegenerative disorders such as LOAD (Michel, Chabot, Moyse, Danik, & Quirion, 1992). Though 
this concept was proposed over 20 years ago, the possibility of CLU as an AD biomarker is only recently 
being examined. Since 2010, 10 different studies have been performed with the aim of determining the 
validity of CLU as an AD biomarker. However, the conclusions of these studies are contradictory at best. 
Of the 10 studies examined, 6 studies conclude that increased plasma CLU levels are associated with 
increased rate of cognitive decline (Sattlecker et al., 2014), increased white matter atrophy (Song et al., 
2012), increased risk for AD (Jongbloed et al., 2015), and were indicative of greater fibrillar Aβ burden 
(Schrijvers, Koudstaal, Hofman, & Breteler, 2011). However, contrary to these findings, 4 studies conclude 
that CLU levels are not significantly different between control subjects and subjects with AD, dementia, 
depression or MCI suggesting that peripheral CLU is unreliable as an AD biomarker (Dukic et al., 2016; L 
et al., 2011; Mukaetova-Ladinska et al., 2015; Mukaetova-Ladinska et al., 2012; Silajdzic, Minthon, 




for CLU concentration. The 6 studies concluding that CLU would be a reliable biomarker utilize plasma 
samples for analysis whereas the 3 of the 4 studies indicating no difference between control and AD subjects 
measure serum or platelets. Another key difference between these conflicting reports is the sample size. In 
3 of the 4 studies concluding that CLU would not be a reliable AD biomarker, the sample size per group is 
less than 70 subjects whereas most of the studies indicating the possibility of CLU as a peripheral biomarker 
contain several hundred subjects per group. Therefore, it is also possible that these differences are the result 
of inadequate sample size. Despite these discrepancies, these studies collectively suggest that at least 
plasma CLU could provide a predictive biomarker for determining the risk for AD.   
 
Clusterin in the brain: proposed mechanisms of action 
Of the identified and postulated CLU protein isoforms, mCLU is by far the most studied and has been 
described as a chaperone-like protein that clears misfolded proteins, cellular debris, and protein aggregates 
from the cytosol and extracellular space (Bailey et al., 2001; Bartl, Luckenbach, Bergner, Ullrich, & Koch-
Brandt, 2001; Kounnas et al., 1995; Lakins et al., 2002; Law & Griswold, 1994; Leeb, Eresheim, & Nimpf, 
2014; Poon et al., 2002; A. Wyatt, Yerbury, Poon, Dabbs, & Wilson, 2009). In contrast, the alternative 
CLU protein isoforms (nCLU and icCLU in the literature) are suggested to exhibit solely pro-apoptotic 
characteristics, though these results are inconsistent at best (Debure et al., 2003; Dia & Mejia, 2010; 
Kimura, Asami, & Yamamoto, 1997; Leskov et al., 2003; Prochnow et al., 2013). This section will review 
the available literature pertaining to CLU isoforms in the brain with particular emphasis on the molecular 
mechanisms by which CLU protein isoforms regulate amyloid homeostasis, inflammation, and apoptosis.  
 
Clusterin and the regulation of Aβ. In the early 1990s, CLU mRNA and protein levels were found to 
be significantly elevated in AD brain, specifically in the frontal cortex and hippocampus of post-mortem 




demonstrated robust CLU immunoreactivity within senile plaques (McGeer, Klegeris, Walker, Yasuhara, 
& McGeer, 1994). It was further demonstrated that mCLU bound soluble Aβ proteins in the cerebral spinal 
fluid (CSF) (Ghiso et al., 1993) and that CLU expression increased the solubility of Aβ and prevented Aβ 
aggregation (Matsubara, Soto, Governale, Frangione, & Ghiso, 1996). These data strongly suggested that 
CLU may play an important role in the pathogenesis of AD via regulation of brain amyloid burden. 
However, contrary to these findings, it has also been demonstrated that increased CLU expression 
exacerbated Aβ1-42-induced neurotoxicity (Oda et al., 1995). Moreover, DeMattos et al. demonstrated that 
Aβ plaque formation was facilitated by CLU in an animal model of AD suggesting that brain CLU is pro-
amyloidogenic in nature (DeMattos et al., 2002). These literary contradictions continued to persist until 
2007 when a study from Yerbery and colleagues provided a possible explanation for the simultaneously 
pro- and anti-amyloidogenic effects associated with mCLU (Yerbury et al., 2007). This study indicated that 
the pro-amyloidogenic effects of mCLU were restricted to conditions in which Aβ1-42 was present in molar 
excess. Under these conditions, mCLU, which functions as a chaperone-like protein to temporarily stabilize 
misfolded proteins (Poon, Easterbrook-Smith, Rybchyn, Carver, & Wilson, 2000), bound to and stabilized 
Aβ1-42 thereby facilitating Aβ aggregation. Alternatively, when mCLU was present at much higher but still 
substoichiometric levels, mCLU provided substantial anti-amyloidogenic effects by inhibiting plaque 
formation (Yerbury et al., 2007). These data suggest that CLU may exhibit neuroprotective characteristics 
in preclinical or early stages of AD when brain amyloid burden is significantly lower. Alternatively, CLU 
may exert a negative impact during later stages of AD when brain amyloid burden is extensive, though this 
hypothesis is yet to be tested. Parallel to this notion, a more recent study performed in rat brains indicated 
that mCLU prevented Aβ42-induced learning and memory impairments, reduced Aβ42-induced glia 
inflammation, and reduced Aβ42-mediated neuronal degeneration when Aβ42 oligomers were incubated 
with mCLU prior to brain injection. However, these effects were not observed in rats injected with pre-
formed Aβ42 oligomers and mCLU without pre-incubation indicating that mCLU does prevent Aβ42-
induced neurotoxicity prior to extensive Aβ42 oligomerization (Cascella et al., 2013).  In addition to these 




demonstrated that the rate of Aβ clearance was increased by as much as 83% when bound to CLU. This 
same study further demonstrated that CLU-bound Aβ is transported across the blood-brain barrier 
specifically through LRP2-mediated transport while APOE-bound Aβ was transported through LRP-1 
 
 (Bell et al., 2007) (Schematic 6). While, the regulation of Aβ by mCLU is relatively well characterized, 
one question that remains unanswered is whether alternative CLU isoforms exert some impact on amyloid 
homeostasis. It has been demonstrated that Aβ toxicity induces the expression of intracellular CLU protein 
isoforms in neurons, however, the physiological impact of increased icCLU expression was not determined 
in this study (Killick et al., 2014). At present, no literature specifically implicates a role for alternative CLU 
protein isoforms in the regulation of Aβ, however, as these isoforms are reportedly induced by cellular 
stress in multiple peripheral cell lines and upon treatment with exogenous Aβ, it is likely that these CLU 
protein isoforms mediate some unknown effect on amyloid homeostasis in the brain, however more research 





Clusterin and Brain Inflammation. It has been postulated that persistent inflammation, likely caused by 
the deposition of neurotoxic protein aggregates in the brain, is a key component of LOAD (Akiyama et al., 
2000). Early studies suggest that CLU inhibits the activation of the complement system in the brain (Choi, 
Mazda, & Tomita, 1989; Choi, Nakano, Tobe, Mazda, & Tomita, 1990; Kirszbaum, Bozas, & Walker, 
1992; Murphy et al., 1988). For instance, CLU (then referred to as SP-40,40) was demonstrated to prevent 
the formation of the membrane attack complex (MAC), suggesting that increased CLU would suppress 
initiation of acute inflammation. However, these data were contradicted by a more recent study that 
demonstrated CLU-mediated activation of the major histocompatibility complex class II (MHC II) antigen 
in primary cultures of rat microglia. This same study showed that administration of exogenous CLU resulted 
in the direct activation of microglia in the brain and the subsequent secretion of pro-inflammatory cytokines 
such as tumor necrosis factor alpha (TNF-α) indicating that increased CLU expression induces the acute 
inflammatory response (Xie et al., 2005). These findings were corroborated by another study that 
demonstrated increased CLU staining within reactive microglia in the cortices of rats following cerebral 
ischemia (Van Beek et al., 2000). Collectively, these studies suggest that increased CLU expression results 
in the activation of glial cells and the subsequent secretion of pro-inflammatory mediators. Therefore, it is 
possible that the increased secretion of cytokines such as TNF-α could contribute to chronic inflammation 
in AD brain, however this hypothesis requires further testing.  
 
Clusterin in Neurotoxicity, Oxidative Stress, and Apoptosis. Several studies performed in human cancer 
cell lines have demonstrated that mCLU and the intracellular “nCLU” protein isoforms exhibit opposing 
effects on cell death pathways. mCLU has been shown to protect cells from oxidative stress and inhibit 
intrinsic apoptosis by interacting with and stabilizing the KU-70-Bax protein complex (H. O. Jun et al., 
2011; N. Kim, Han, et al., 2012; Miyake, Chi, & Gleave, 2000; Trougakos et al., 2009; H. Zhang et al., 
2005). In contrast, the proposed nCLU isoform is suggested to initiate intrinsic apoptotic pathways resulting 




isoforms appear to also exist in the brain, however, unlike cancer-focused studies, relatively few brain-
based investigations have included an examination of the apoptotic characteristics of alternative CLU 
protein isoforms. An early study from Schreiber et al. demonstrated that CLU (then referred to as SGP-2) 
mRNA expression was rapidly and transiently increased in astrocytes, but not CA3 and CA1 neurons, 
following administration of kanic acid (KA), a neurotoxic seizure-inducing compound (Schreiber, Tocco, 
Najm, & Baudry, 1993). Another study performed in WT, human CLU overexpressing (hCLU-OE) mice, 
and Clu-knockout (CLU-KO) mice subjected to middle cerebral artery occlusion (MCAO) indicated that 
CLU overexpression resulted in reduced brain injury. Specifically, this study demonstrated a 30-50% 
increase in CLU mRNA expression 7 days post-ischemia in the ischemic brain hemisphere specifically in 
the penumbral area (the area that separates necrotic from normal brain tissue). Morphometric analysis of 
the ischemic hemisphere revealed that the penumbra was significantly thinner in hCLU-OE mice and 
significantly thicker in CLU-KO mice when compared with WT mice indicating an inverse relationship 
between CLU mRNA expression and brain injury (Wehrli et al., 2001). Collectively, these two studies 
strongly support a neuroprotective role for CLU in the brain following significant brain injury. In contrast, 
ethanol-mediated toxicity has been shown to significantly increase CLU expression in the cortex and 
amygdala. This up-regulated CLU, which was shown to interact with Bcl-XL, was translocated to the 
nucleus upon exposure to ethanol, and was associated with increased cell death suggesting that these effects 
were mediated by an intracellular CLU protein isoform (N. Kim, Han, et al., 2012). Another study 
performed in neonatal mice subjected to hypoxic-ischemic brain injury indicated that CLU accumulated in 
dying neurons following brain injury. Moreover, this study indicated that CLU deficient mice exhibited 
50% less brain injury when compared to wild-type controls indicating that CLU expression exacerbates 
neuronal cell death following brain injury (Han et al., 2001). Collectively, these studies indicate that 
intracellular CLU protein isoforms may be associated with increased cell death following traumatic brain 





Significance of this Dissertation 
Clinical studies have clearly indicated the association of the rs11136000 SNP (CC) with the development 
of LOAD. Moreover, studies in cancer cell lines have demonstrated that at least 1 CLU protein isoform 
(mCLU) plays a significant role in cellular survival and resistance to drug-induced apoptosis. In addition, 
mCLU is known to significantly regulate the levels and aggregation of extracellular Aβ in a mechanism 
that is thought to confer some type of neuroprotection. However, despite these findings, significant gaps 
exist in the field of brain based CLU research.  For instance, it is known that alternative “intracellular” CLU 
protein isoforms are generated, however, the number of CLU mRNAs that are transcribed from the CLU 
gene and the corresponding translated protein isoforms are yet to be identified. Moreover, while studies 
demonstrate the expression of CLU mRNA and protein in rodent brain, neurons, and astrocytes from an 
early age, a full characterization of the CLU protein isoform expression profile in the brain and brain cell 
types is not currently available. Furthermore, as CLU protein has been detected in multiple subcellular 
compartments in immortalized cells, it is feasible to assume that brain CLU protein is localized to individual 
cellular organelles; though this characterization is also missing from the currently available literature. In 
addition to the presence of several research gaps, the currently available literature contains several 
controversies pertaining to the basic molecular properties of CLU protein. One such controversy is the 
presence of a “nuclear” CLU protein isoform (usually deemed nCLU in the literature), and the mRNA 
isoform from which this protein is translated. Numerous studies suggest that the nCLU isoform is generated 
from Exon 3-9 CLU mRNA and remains unglycosylated. In contrast, other studies suggest that the nCLU 
isoform is derived from Exon 1, 3-9 CLU mRNA while some have concluded that no such nCLU protein 
isoform exists. Another key controversy is the notion that brain CLU is solely generated and secreted by 
astrocytes and that the presence of CLU in neurons is the result of neuronal uptake of astrocytic CLU.  
However, several publications indicate the expression of CLU in primary cultures of neurons where no 





In reviewing the literature and the deficiencies therein it is clear that many of the unanswered molecular 
questions and controversies may be resolved through a thorough characterization of CLU in the brain. 
Moreover it is clear that several research methodologies need to be changed in order to gain a thorough and 
translational understanding of this complex protein. (1) One such method that is used consistently in the 
field of CLU research is the preferential examination of CLU mRNA rather than protein. As CLU protein 
isoforms are speculated to exhibit opposing effects on cellular function and are thought to be derived from 
multiple CLU mRNAs this research application does not provide an accurate representation of fluctuations 
and/or cellular responses by individual CLU protein isoforms. (2) Those studies that do examine CLU 
protein expression in response to a cellular stimuli or pathological condition, are often conducted in 
immortalized cancer cell lines. As the environment in a tumor-derived cell line is remarkably different from 
physiological conditions, the use of only immortalized cells lines in the study of CLU protein function may 
contribute to the controversies that currently exist in this field. Moreover, as mCLU is a key contributor to 
cancer cell survival and is known to be highly upregulated in multiple cancer cell lines, it is highly unlikely 
that the expression profile of healthy non-stressed neurons and/or astrocytes can be accurately represented 
in this manner. (3) In addition to using immortalized cell lines, my review of the literature indicates that the 
predominant amount of CLU studies rely on the use of a single polyclonal CLU antibody. As different CLU 
antibodies are shown to recognize distinct CLU protein isoforms by both the commercial vendor and 
previously published studies, the use of a single antibody may provide only a partial picture of the response 
of CLU to a certain pathology or stress signal. Therefore the purpose of this dissertation is to provide an in-
depth characterization of brain CLU mRNA and protein isoforms under physiological conditions. This 
analysis will include a characterization of brain, neuronal, and astrocytic CLU protein expression and is 
expected to provide insight into the function and distribution of individual CLU protein isoforms and their 
in healthy cells. In order to obtain the full CLU protein expression profile, multiple antibodies will be used 
in to evaluate CLU protein expression in each experiment. The data generated from these studies will 
provide key foundational information that is required for researchers to understand how CLU mRNA and 




Materials and Reagents 
All materials and reagents used in this dissertation are listed in the following tables. Chemicals are listed in 
Table 1, buffers and solutions are listed in Table 2, and antibodies, sera, and immunoglobulins are listed 
in Table 3, and cell culture media and supplements can be found in Table 4.   
Chemicals  
 
Commercially Available Chemicals 
Chemical Name  Vendor Catalog # 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES)  Sigma  H4034 
Adenosine Diphosphate (ADP) Sigma A2754 
Agarose, PCR Grade Biorad  161-3103 
Albumin from Bovine Serum (BSA) Sigma A7906 
Ammonium Acetate (NH4OAc) MP Biomedicals  194000 
Ammonium Bicarbonate (NH4HCO3) Sigma A-6141 
Ammonium Persulfate Biorad  161-0700 
Ampicillin Sodium Salt Sigma A9518 
Antimycin A Sigma A8674-25MG 
Blotting-Grade Blocker Biorad  170-6404 
Boric Acid Sigma B6768 
Calcium Chloride (CaCl2) Sigma C4901-100G 
Calcium Chloride x 2H2O Sigma C-3881 
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
(FCCP) Sigma C2920-10MG 
Deoxycholic Acid Alfa Aesar B20061 
Digitonin Sigma D141 
Dithiothreitol (DTT) GE HealthCare 17-1318-01 
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-
tetraacetic acid (EGTA) Sigma E3889 
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific S311 
Gelatin Biorad  170-6537 
Glucose Sigma G8270 
Glycine Sigma G8898 
Iodoacetamide (IAA) Sigma I1149-5G 
LB Agar, Miller (Granulated) Fisher Scientific BP9724 
LB Broth, Miller (powder) Fisher Scientific BP1426 
L-Glutamic acid monosodium salt hydrate Sigma  G5889 




Table 1. Chemicals. A list of all commercially available powdered chemicals used in this dissertation   
Magnesium Chloride (MgCl2) Sigma M8266-100G 
Malic acid  Sigma 112577 
Mannitol Sigma M1425 
Monopotassium phosphate (KH2PO4) Fisher Scientific P285-500 
Oligomycin Sigma O4876-5MG 
Poly-D-Lysine Sigma P7280 
Potassium Chloride (KCl) Sigma P3911 
Protease and Phosphatase Inhibitor (PPI) Thermo Scientific 88669 
Rotenone Sigma R8875-1G 
Sodium Bicarbonate Sigma S6014 
Sodium Chloride (NaCl) Sigma S9888 
Sodium Deoxycholate  Sigma D5670-5G 
Sodium Dodecyl Sulfate (SDS) JT Baker 4095-02 
Sodium phosphate monobasic Fisher Scientific S397-500 
Sodium Pyruvate Sigma P2256-5G 
Sodium Tetraborate Decahydrate (Borax) Fisher Scientific BP175 
Styptic powder Arc Laboratories 463501 
Disodium Succinate Sigma W327700 
Sucrose Fisher Scientific S5-500 
Thiourea Acros  A0326078 
Tris Base  Fisher Scientific BP152 
Tris Hcl Fisher Scientific BP153 
Trypsin, sequencing grade  Roche 1418475 
 
 
Buffers and Solutions 
Commercially Available Solutions and Buffers 
Solution/Buffer  Name Vendor Catalog # 
6X DNA Loading Buffer Promega G1881 
Acetone Sigma-Aldrich 650501 
Isopropanol 70% RICCA Chem. Co.  4210-1 
Hydrochloric Acid Fisher Scientific A144-212 
50X TAE Buffer BioRad 161-0743 
50% Polyethyleneimine Sigma P3143 
Dimethyl Sulfoxide ATCC 4-X 
20X PBS Amresco E703 
16% Paraformaldehyde Electron Microscopy Sciences 15710-S 
Ethidium Bromide Biorad 1610433 
Triton X-100 Acros A0341006 




100 % Glycerol Biorad 170-6537 
100% Percoll Solution Sigma P1644 
5N Sodium Hydroxide Solution (NaOH) Fisher Scientific 55256 
1N Potassium Hydroxide (KOH) Fisher Scientific SP208-500 
Tween-20 Solution Biorad 161-0781 
Tissue Protein Extraction Reagent Thermo Scientific 78510 
Neuronal Protein Extraction Reagent Thermo Scientific 87792 
Mammalian Protein Extraction Reagent Thermo Scientific 78503 
Lower Tris (Resolving Gel Buffer) Biorad 161-0798 
Upper Tris (Stacking Gel Buffer) Biorad 161-0799 
TEMED Biorad 161-0801 
30% Acrylamide/Bis Solution 29:1 Biorad 161-0156 
Precision Plus Protein Standards Biorad 1610374 
Western Blot Stripping Buffer Thermo Scientific 21063 
2X Laemmli sample Biorad 161-0737 
β-mercaptoethanol BioRad 161-0710 
SYPRO Ruby Stain Invitrogen S12000 
Methanol Fisher Scientific A412 
Glacial Acetic Acid Fisher Scientific BP2401 
100% MeCN Fisher Scientific A998-4 
Trifluoroacetic Acid Fisher Scientific O4902-100 
TRIzol Reagent Life Technologies 15596026 
Chloroform MP Biomedicals 2194002 




PowerUP SYBR Green MasterMix Thermo Scientific A25741 
UltraPure Distilled Water Invitrogen 10977-015 
Ethanol 200 Proof Decon Labs 2301 2701 
Lab-generated Solutions and Buffers 
Solution/Buffer  Name Solution/Buffer Recipe 
Genotyping Solution A 25 mM NaOH, 0.2 mM EDTA 
Genotyping Solution B 40 mM Tris-HCl 
1X TAE Buffer 
980 mL ddH2O + 20 mL 50X TAE Buffer + 8 µL 
Ethidium Bromide 
Borate Buffer 
3.1 g Boric Acid and 4.74 g Borax to 950 mL ddH2O - 
adjust pH to 8.3 
0.1% Polyethylenimine 
2 g of 50% PEI + 100 mL Borate Buffer - dissolve and 
bring to 1L with ddH2O 
Poly-D-Lysine Stock (100 µg/mL) 5mg poly-D-lysine + 50 mL ddH2O 
Poly-D-Lysine Working Solution (50 
µg/mL) 
25 mL Poly-D-Lysine Stock Solution + 25 mL ddH2O 




1X PBST 1X PBS supplemented with 0.1 % Triton X-100 
ICC Blocking Solution 
1X PBST supplemented with 5% Normal Goat Serum 
(NGS) 
Antigen Preservation Solution 
50% PBS, 50% ethylene glycol and 1% polyvinyl 
pyrrolidone, pH 7.0 
IHC Blocking Buffer 
1X PBS supplemented with 5% NGS and 0.3% Triton X-
100 
1 M Acetic Acid 15 ml Glacial Acetic Acid + 235 mL ddH2O 
1 M Ammonium Acetate 19.27 g Ammonium Acetate + 250 mL ddH2O 
Acetate Buffer - pH 4.9 
15 mL 1 M Acetic Acid + 35 mL 1 M Ammonium 
Acetate 
Acetate Buffer - pH 6.0 
1.875 mL 1 M Acetic Acid + 48.125 mL 1 M Ammonium 
Acetate 
Subbing Solution 
0.5 g Gelatin in 100 mL ddH2O - stir at 60 °C until 
dissolved 
95% Ethanol (EtOH) 95 mL 100% EtOH + 5 mL ddH2O 
IHC Mounting Medium 
2 mL Subbing Solution + 50 mL 95% EtOH + 12 mL 
Acetate Buffer (6 mL of each pH) + 188 mL ddH2O 
Cytosolic Extraction Buffer 
10 mM HEPES, 60 mM KCl, 1 mM EDTA, and 0.075% 
(v/v) Igepal 
Nuclear Extraction Buffer 
20 mM TrisHCl , 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 25% (v/v) glycerol , 0.5% Igepal 
Lysis Buffer A 
150 mM NaCl, 50 mM HEPES, pH 7.4, 25 µg/mL 
Digitonin (freshly added) 
Lysis Buffer B 150 mM NaCl, 50 mM HEPES pH 7.4, 1% v/v Igepal 
Lysis Buffer C 
150 mM NaCl, 50 mM HEPES pH 7.4, 0.5% w/v Sodium 
Deoxycholate, 0.1% w/v SDS 
Mitochondria Isolation Buffer 
320mM Sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH – 
adjusted to 7.4 
Stock Isotonic Percoll 90 mL Percoll Solution + 10 mL 1.5 M NaCl 
15% Percoll 1.5 mL Stock Isotonic Percoll + 8.5 mL MIB without PPI 
23% Percoll 2.3 mL Stock Isotonic Percoll + 7.7 mL MIB without PPI 
40 % Percoll 4 mL Stock Isotonic Percoll + 6 mL MIB without PPI 
Mitochondria Subfractionation Buffer 
220 mM Mannitol, 70 mM Sucrose, 2 mM HEPES, pH 
adjusted to 7.4 with KOH, 
1.6 % Digitonin 16 mg Digitonin + 1 mL ddH2O 
1X HEPES Buffer 
100 mM  NaCl, 2.0 mM  KCl,  2.5 mM CaCl2, 1.0 mM 
MgCl2,  1.0 mM NaH2PO4, 4.2 mM NaHCO3, 12.5 mM   
HEPES, 10.0 mM glucose, pH 7.4 
IP Buffer 
50 mM Tris, pH 7.4, 100 mM NaCl, 0.5% Triton X-100 
and 10 mM EGTA 
Co-IP Buffer 
50 mM Tris-HCl, 10 mM EGTA, 10 mM NaCl, 0.5% 
(v/v) Triton X-100 
20% APS 100 mg ammonium persulfate + 500 µL ddH2O 




1X Western Blot Running Buffer 
100 mL 10X Western Blot Running Buffer + 890 mL 
ddH2O + 10 mL 10% SDS 
Western Blot Transfer Buffer 
100 mL 10X Western Blot Running Buffer + 200 mL 
100% Methanol + 700 mL ddH2O 
2% Blocking Buffer 2 grams non-fat dry milk + 100 mL 1X TBST 
10X TBS 200 mM Tris, 1.5 mM NaCl, pH 7.6 
10% SDS 10 g SDS powder + 90 mL ddH2O 
1X TBST 
100 mL 10X TBS + 890 mL ddH2O + 10 mL 10% 
Tween-20 Solution 
1X PBS (non-cell culture grade) 50 mL 20X PBS + 950 mL ddH2O 
70% Ethanol 700 mL 100% Ethanol + 300 mL ddH2O 
LB Broth 25 g LB Broth Powder in 1L of ddH2O - Autoclaved 
Fixing Solution 7% acetic acid v/v, 10% methanol v/v in water 
1 M NH4HCO3 Stock Solution 1.186g/15 mL H2O, no pH adjustment (actual pH 8.5-8.8) 
50 mM CaCl2 Stock Solution 100 mg CaCl2 x 2H2O + 13.6 mL ddH2O 
100 mM NH4HCO3 1.5 mL of 1 M stock + 13.5 mL ddH2O 
TD Washing Solution 200 mM NH4HCO3/50% (v/v) MeCN 
TD Reducing Solution 3.1 mg DTT + 2 mL of 100 mM NH4HCO3 
TD Alkylating Solution 38 mg IAA + 2 mL of 100 mM NH4HCO3 
TD Digestion Buffer 50 mM NH4HCO3, 5 mM CaCl2, 6 ng trypsin/ul 
1 M Pyruvate 88.06 mg Pyruvic Acid + 1 mL ddH2O, pH-7.2 
0.4 M Malate 53.6 mg L-malic acid + 1 mL ddH2O, pH 7.3 
1 M Succinate 162.05 mg disodium succinate in 1 mL, pH-7.2  
200 mM ADP 85.44 mg ADP + 1 mL ddH2O 
10 mg/mL Oligomycin Stock 5 mg Oligomycin + 500 µL DMSO 
1 mg/mL Oligomycin 
10 μL 10 mg/mL Oligomycin Stock + 90 μL 
Mitochondrial Respiration Buffer 
10 mM FCCP Stock 10 mg FCCP + 3.93 mL DMSO 
100 µM FCCP 
1 µL 10 mM FCCP Stock + 999 µL Mitochondrial 
Respiration Buffer 
100 mM Rotenone Stock 1 g + 25 mL DMSO 
1 mM Rotenone 
10 µL 100 mM Rotenone Stock + 990 µL Mitochondrial 
Respiration Buffer 
10 mM Antimycin A Stock 25 mg Antimycin A + 4.68 mL DMSO 
1 mM Antimycin A 
100 µL 10 mM Antimycin A Stock + 900 µL Calibration 
Buffer 
Mitochondrial Respiration Buffer 
210 mM Mannitol, 70 mM Sucrose, 1 mM EDTA, 5 mM 
HEPES, 0.5 mg/mL BSA –  pH a 7.2 
Calibration Buffer 
80 mM KCl, 10 mM Tris-HCl, 3 mM MgCl2, 1 mM 
EDTA, 5 mM KH2PO4 – pH 7.2 
ChIP Fixing Solution 1.23 mL 37% Formaldehyde in 43.76 mL 1X PBS 
1 M Glycine Stock Solution 75.066 g Glycine + 100 mL ddH2O 




Table 2. Buffers and Solutions A list of all commercially available and lab generated buffers and 
solutions used in this dissertation  
ChIP Lysis Buffer 
150 mM NaCl, 1% v/v NP-40, 0.5% w/v Sodium 
deoxycholate,0.1% w/v SDS, 50 mM Tris-Cl pH 8.0, and 
5 mM EDTA 
ChIP Dilution Buffer 
0.01% (w/v) SDS, 1.1% (v/v) Triton X-100, 1.2 mM 
EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl 
Low Salt Wash Buffer 
0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 15 mM NaCl 
High Salt Wash Buffer 
0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 500 mM NaCl 
Lithium Chloride Wash Buffer 
0.25 M LiCl, 1% (v/v) NP-40, 1% deoxycholic acid, 1 
mM EDTA, 10 mM Tris-HCl, pH 8.1 
TE Wash Buffer 10 mM Tris-HCl, pH 7.5, 1 mM EDTA 
ChIP Elution Buffer 1% SDS, 0.1M NaHCO3 
5M NaCl 29.22 g NaCl + 100 mL ddH2O 
5X Protein Digestion Buffer 50 mM Tris-HCl, pH 7.5, 25 mM EDTA, 1.25% SDS 
7.5 M NH4OAc 57.81 g NH4OAc into a total of 100 mL ddH2O 
 
 
Antibodies, Sera, and Immunoglobulins 
Primary Antibodies 
Antibody Species Vendor Catalog # Lot # 
Actin Beta Rabbit Pierce PA5-16914 SF2405982E 
APOE Goat Millipore 178479 2626398 
Bax Rabbit Cell Signaling 2772T 10 
Beta-Tubulin  (TBN06 (Tub 2.5)) Mouse Pierce MA5-11732 QK2115682 
Calnexin (H70) Rabbit Santa Cruz sc-11397 I1914 
Calreticulin (D3E6) Rabbit Cell Signaling 12238 2 
Clusterin (H-330) Rabbit Santa Cruz sc-8354 F0316, F0515 
Clusterin - α (M18) Goat Santa Cruz sc-6420 L3113, D0815 
Clusterin - α (C-18) Goat Santa Cruz sc-6419  
Clusterin - α (A-11) Mouse Santa Cruz sc-166831 B1012 
Clusterin - α (B-5) Mouse Santa Cruz sc-5289 J2913 
COX IV (3E11) Rabbit Cell Signaling 4850 7 
Cytochrome C Rabbit Cell Signaling 119402 3 
Estrogen Receptor α (HC-20) Rabbit Santa Cruz sc-543 F0515 
Estrogen Receptor β (H150) Rabbit Santa Cruz sc- 8974 K0513 
GAPDH Mouse Santa Cruz sc3223 C1315 
GFAP Rat Calbiochem 345860  
GPR30 (N-15) Rabbit BioRad sc- 48525-R B1115 
GRP75 Mouse BioRad VMA00084T 140715 
GRP78 (H-129) Rabbit Santa Cruz sc-13968  




Table 3. Antibodies, Sera, and Immunoglobulins. A list of all primary and secondary antibodies, 
sera, and non-specific immunoglobulins used in this dissertation. However, as dilutions were 
customized for individual experimental purposes, antibody dilutions and incubation conditions can be 
found in the corresponding figure captions.  
Immt Rabbit ProteinTech 10179-1-AP  
Lamin A/C (4C11) Mouse Cell Signaling 4777 4 
MAP2 Mouse Thermo Fisher MA1-25043 RB2160802 
TAU Mouse Thermo Fisher MA5-12808 PL1952344 
Tom70 Rabbit ProteinTech 14528-1-AP  
Tri-methyl Histone H3 (K4) 
(C42D8) 
Rabbit Cell Signaling 9751T 10 
V5-Tag Rabbit Cell Signaling 13202S 2 
VDAC (D73D12) Rabbit Cell Signaling 4661 6 
HRP-Conjugated Secondary Antibodies 
Antibody Vendor Catalog Number Lot # 
Goat anti-mouse IgG (H+L) HRP Pierce 31430 PA196831 
Goat anti-rabbit IgG (H+L) HRP Pierce 31462  
Rabbit anti-goat IgG (H+L) HRP Pierce 31402 RI2271393 
Fluorophore-Conjugated Secondary Antibodies 
Antibody Vendor Catalog Number Lot # 
Goat anti-mouse IgG (H+L) 
FITC 
Abcam ab6785 GR6891-23 
Goat anti-rabbit IgG (H+L) Cy3 
preadsorbed 
Abcam ab6939 GR1836606-3 
Goat anti-rabbit IgG - FITC Abcam ab97050 GR216167-1 
Goat anti-rat IgG (H+L) Cy5 
preadsorbed 
Abcam ab6565 GR117398-3 
Goat anti-rat IgG Alexa Flour 
568 
Abcam ab175710 GR146096-1 
Sera and Antibody Controls 
Product Description Vendor Catalog Number Lot # 
Normal Goat Serum Vector Laboratories s-1000 ZB1027 
Rabbit IgG Santa Cruz sc-2027 D1415 
Goat IgG Santa Cruz sc-2028 J2114 





Cell Culture Media and Supplements   
Culture Medium and Supplements Vendor  Catalog Number  
Neurobasal Medium GIBCO   12348-017 
DMEM/F12 - Phenol red-free GIBCO  21041-025 
DMEM - Phenol red-free GIBCO  21063-029 
DMEM GIBCO  11965-092 




Table 6. Cell Culture Media and Supplements. A list of all cell culture reagents and lab-generated 
maintenance mediums used in this dissertation  
GlutaMAX Supplement GIBCO  35050-061 
Penicillin-Streptomycin Solution GIBCO  15140-122 
Fetal Bovine Serum GIBCO  10437028 
1X PBS - pH 7.4 GIBCO  10010-023 
1X HBSS  GIBCO  14170-112 
OptiMEM GIBCO  11058-021 
0.25% Trypsin-EDTA GIBCO  25200056 
Lab Generated Maintenance Media 
Neuron Growth Medium 
NBM, B27, 1% Pen-Strep, 0.5 mM glutamine and 25 μM glutamate  
Neuron Maintenance Medium 
NBM, B27, 1% Pen-Strep, and 0.5 mM glutamine  
Astrocyte Maintenance Medium  
DMEM/F12, 10% FBS, 1% Pen-Strep 
Neuro-2a Maintenance Medium  




Animal Models. The use of animals was approved by the Institutional Animal Care and Use Committee 
at the University of Kansas and followed NIH guidelines for the care and use of laboratory animals. 
Clusterin-knockout (CLU-KO) mice.  ApoJ-deficient (CLU-KO) mice were developed using standard 
techniques of homologous recombination as previously discussed (McLaughlin et al., 2000). Briefly, a 
targeting vector, deemed pApoJ-KO3, was constructed in pBluescript II to include 2 homology fragments: 
(1) a 7.2 kb BsaHI-EcoRI long 
homology restriction fragment 
which contained the hypoxanthine 
phosphoribosyl-transferase 
(HPRT) cassette under the control 
of the mouse phosphoglycerol 
kinase (PGK) promoter and ApoJ Schematic 7: Schematic of the Mutant CLU Construct used in the 




exons 3-7 in the same orientation as the endogenous ApoJ gene, and (2) a 5’ EcoRI-AgeI short homology 
fragment. The targeting vector was then electroporated into 129S2/SvPas-derived D3 embryonic stem (ES) 
cells and successfully targeted ES cells were injected into C57BL/6J blastocysts followed by implantation 
into pseudopregnant (C3H/HeN x C57BL/6J) F1 females. Resulting chimeric males were then back-crossed 
to ensure germ-line transmission to F1 females followed by successive backcrossing of resultant 
heterozygotes with Swiss Black Mice for 1 generation and with C57BL/6J for more than 7 generations. The 
resultant CLU-KO animals, should exhibit no protein or mRNA expression in either serum, heart, or liver 
tissue and are physically and reproductively normal (McLaughlin et al., 2000). All animals used in this 
dissertation were derived from 3 heterozygous breeding pairs purchased from The Jackson Laboratories 
(JAX stock #005642). Heterozygotes were allowed to breed and at 21 days of age, the resulting pups were 
tagged for purposes of identification and a 2 mm tail segment was removed for genotyping. Successfully 
generated CLU-KO animals were bred for 2 generations prior to the initiation of any experimentation and 
genotyping was performed consistently to ensure the validity of animal models.      
Genomic DNA Isolation. 80 µL Genotyping Solution A was added to each tail segment and samples were 
centrifuged briefly to bring solution and tail snips to the bottom. Samples were then incubated at 95 °C 1 
hr. Following incubation, 80 µL Genotyping Solution B was added to each tube and samples were vortexed 
on max speed for 30 seconds. Samples were centrifuged at 2,000 rpm for 5 min at RT and 100 µL of the 
cleared supernatant was removed and pipetted into a new labeled centrifuge tube. 1 µL of the resulting 
crude genomic DNA was used for PCR amplification.    
DNA Oligonucleotides. DNA oligonucleotide sequences were provided from The Jackson Laboratories 
for successful identification of WT, heterozygous and homozygous knockout animals. All DNA 
oligonucleotides were purchased from Integrated DNA Technologies. For both WT and mutant animals, a 
common forward primer is used with reverse primers providing the genotype differentiation. Primers used 




Table 5. Genotyping PCR Reaction Components. A list of items and their corresponding volumes, 
vendors, and catalog numbers for all components included in PCR Reactions for CLU-KO mouse line 
genotyping  
– 3’, WT Reverse (200 bp amplimer): 5’ - CTT TCT GGA AGC CTA GAG GTG – 3’ and Mutant Reverse 
(180 bp amplimer): 5’ - GCC AGA GGC CAC TTG TGT AG – 3’.  
Genotyping.  As PCR reactions could not be combined due to the close size in resulting amplimers, two 
PCR reactions were assembled for each tail snip. Assembly of PCR reactions was performed as indicated 
in Table 5. PCR reactions were performed in thin-walled 0.2 mL PCR Strips (Molecular BioProducts,  
 
 
Cat. #3418) using a T100 Thermal Cycler (BioRad) with the following conditions: 95 °C for 5 min, 1 cycle 
of 95 °C – 20 sec, 65 °C – 60 °C (0.5 °C decrease with each cycle (total of 10 cycles)) – 30 sec, and 72 °C 
– 30 sec, followed by 28 cycles of 95 °C – 15 sec, 60 °C – 30 sec, and 72 °C – 30 sec with a final polishing 
step of 72 °C for 10 min. Following PCR, amplimers were removed from the Thermocycler and 2 µL of 
6X DNA Loading Buffer was added to each tube. Samples were run on a 2% agarose gel (1 g Agarose in 
50 mL 1X TAE Buffer) for 40 min 
at 120 V and bands were visualized 
using the Gel Doc EZ Imaging 
System (BioRad) equipped with a 
UV Tray (BioRad, Cat. #1708271). 
Guidelines for the successful 
identification of animal genotypes 
are as follows: WT animals: 1 
Genotyping PCR Reaction Components 
Component Volume (per rxn) Vendor Catalog # 
Genomic DNA 1 µL N/A N/A 
iTaq DNA Polymerase 0.0625 µL BioRad 170-8870 
10X iTaq Buffer 1.25 µL BioRad 170-8870 
50 mM MgCl2 0.375 µL BioRad 170-8872 
10 mM PCR Nucleotide Mix 0.25 µL Promega C114G 
Forward Primer 100 ng IDT N/A 
Reverse Primer 100 ng IDT N/A 
ddH2O 7.56 µL N/A N/A 
Schematic 8: Confirmation of WT, Heterozygous, and CLU-




amplimer at 200 bp with no amplification occurring in the mutant reaction, heterozygous animals: 200 bp 
amplimer in WT reaction and 180 bp amplimer in mutant reaction, and CLU-KO animals: 1 amplimer at 
180 bp with no amplification occurring in the WT reaction. An example of the appropriate results for WT, 
Heterozygous, and CLU-KO mice is provided in Schematic 8.  
 Estrogen receptor beta-knockout (Erβ-/-) rats. Two ERβ knockout rat models were generated and 
generously provided by Dr. Karim Rumi (Institute for Reproductive Health and Regenerative Medicine, 
Kansas University Medical Center). The rat models were generated using zinc finger nuclease (ZFN)-
mediated genome editing to target deletion of exon 3 (Ex 3−/−) or exon 4 (Ex 4−/−) in the ERβ gene. The 
Ex 3−/− mutation results in a frameshift and null mutation whereas Ex 4−/− is translated into a DNA-
binding domain deficient form of ERβ (Rumi et al., 2017). Confirmation of successful deletion of 
targeted sequences was achieved through reverse transcription-PCR (RT-PCR) using primers within 
exons flanking the targeted exons 3 and 4 while alterations in the open reading frames (ORFs) were 
determined via DNA sequencing. Animals were euthanized according to the appropriate AUS and at 6 
and 10 months of age and brain tissue sections were extracted as indicated (n=5 animals/genotype). Ex 
3−/− and Ex 4−/− animals can be obtained from the Rat Resources & Research Center at the University of 
Missouri in Columbia, MO.   
 
Cell Culture Techniques. Primary rat neurons and astrocytes were isolated in sterile conditions under a 
Labconco type A2 Biological Safety Cabinet and maintained at 37 °C with 5% CO2. All surgical 
instruments were sterilized by autoclaving 2 days prior to animal euthanasia. On the morning of isolation, 
all components of the isolation procedure, with the exception of culture media, were placed in the Biological 
Safety Cabinet and subjected to UV light sterilization for 30 min. All immortalized cell lines were cultured 
and maintained according to the guidelines set forth by ATCC or the cell line donors. Individual protocols 




Isolation of Primary Rat Cortical and Hippocampal Neurons. Primary cultures of rat hippocampal and 
cortical neurons were isolated from Day 18 Embryonic rat pups as previously described (Zhao et al., 2004). 
Briefly, cortical and hippocampal tissues were dissected from the brains of rat fetuses and treated with 
0.02% trypsin in Hank's balanced salt solution (HBSS) for 5 min at 37 °C. Tissues were dissociated by 
repeated passage through a series of fire-polished constricted Pasteur pipettes. Cortical neurons were plated 
onto polyethyleneimine (PEI)-coated 100 mm dishes at a density of 5x105 for biochemical analysis. For 
morphological analyses, hippocampal neurons were plated onto poly-D-lysine coated 22 mm glass 
coverslips (NeuVitro) at a density of 2x105 in covered 35 mm petri dishes. Neurons were grown in Neuron 
Growth Medium at 37 °C in a humidified 5% CO2 atmosphere for the first 3 days and Neuron Maintenance 
Medium (Neuron Growth Medium without Glutamate) afterwards. Cultures grown in serum-free Neuron 
Maintenance Medium yield approximately 99.5% neurons and 0.5% glial cells. 
Isolation of Primary Rat Cortical Astrocytes. For isolation of primary cortical astrocytes, euthanasia, 
dissection, and dissociation were performed as indicated in the previous paragraph. Following dissociation, 
tissues were centrifuged for 10 min at 170 x g and re-suspended in 50 mL Astrocyte Medium. Cells were 
plated at a density of 1x106 in poly-d-lysine coated T75 flasks and allowed to incubate for 7 days at 37 °C 
in a humidified 5% CO2 atmosphere. On day 7, medium was replaced with fresh Astrocyte medium and 
the flasks were incubated for 16 hrs on an orbital shaker at a speed of 220 rpm at 37 °C. The next day, 
medium containing dead neurons, oligodendrocytes, and microglia was aspirated and isolated astrocytes 
were passaged using 2 mL 0.25% Trypsin and plated on poly-d-lysine coated dishes in Astrocyte Medium. 
Astrocytes were allowed to grow for 2 weeks prior to use during which time astrocytes were passaged 2 
times. For biochemical analysis, astrocytes were plated in 100 mm dishes at a density of 2 x 105 and for 
immunohistology astrocytes were plated in 8 well glass-bottom chamber slides.     
Mouse Neuroblastoma (Neuro-2a) Cells. Mouse neuroblastoma (Neuro-2a) cells were purchased from 
ATCC (ATCC® CCL-131™) and cultured according to the established guidelines. Briefly, cells were 




Medium. Cells were allowed to grow in cell-culture treated T-75 flasks at 37 °C in 5 % CO2 until 80% 
confluency. At 80% confluency cells were passaged using 3 mL 0.25% trypsin and re-plated using 10-20% 
of the trypsinized cells. N2a cells were used until passage number 25 after which time cells were discarded. 
siRNA-mediated Knockdown of CLU. siRNA constructs targeting Exon 2 (Life Technologies, Cat. 
#AM16708, siRNA Construct #70870) and Exon 3 (Life Technologies, Cat. #4390771, siRNA Construct 
#s201172) of rodent CLU were purchased and re-suspended in supplied ddH2O to a concentration of 100 
µM. To facilitate dilution for transfection, a 4.5 nm stock solution was generated by serial dilutions and the 
100 µM solution was stored at -20 °C. Gapdh siRNA targeting murine Gapdh (positive control, Life 
Technologies, Cat. # AM4624) and Scramble siRNA (negative control, Life Technologies, Cat. #AM4611) 
were both supplied as 50 µM stock solutions. 4.5 nM stock solutions were generated by serial dilutions and 
remaining stock tubes were stored at -20 °C. For transfection, Neuro-2a cells were plated at 1 x 105 cells/mL 
(2 mL/well) and allowed to attach overnight at 37 °C at 5% CO2 in antibiotic-free Neuro-2a Maintenance 
Medium. The following day, medium was replaced with 1.7 mL OptiMEM and allowed to incubate for 30 
min at 37 °C prior to transfection. siRNAs and corresponding positive and negative controls were 
transfected at concentrations ranging from 25 pM to 600 pM for 18 hr at 37°C. Following transfection, 
medium was replaced with antibiotic containing Neuro-2a Maintenance Medium and cells were incubated 
for another 48-72 hrs. Following incubation cells were harvested using the Whole Cell Protein Extraction 
protocol provided below and analyzed for CLU immunoreactivity via SDS-PAGE. Sequences for the CLU 
targeting siRNA constructs are as follows: Exon 2 Targeting: Sense: 5’-
GGUCUCUGACAAUGAGCUCtt– 3’ Antisense: 5’-GAGCUCAUUGUCAGAGACCtc– 3’   Exon 3 
Targeting: Sense: 5’- GCUCAACAGUUUAGAGGAAtt – 3’ Antisense: 5’- 
UUCCUCUAAACUGUUGAGCaa – 3’       
Human Bone-Marrow Neuroblastoma (SH-SY5Y) Cells.  Human bone marrow derived neuroblastoma 
cells were a kind gift from Dr. Russell Swerdlow at The University of Kansas Medical Center. Cells were 




penicillin-streptomycin at 37 °C in 5% CO2. For trypsinization, cells were processed as previously indicated 
in the Neuro-2a section.  
 
Immunocytochemistry. For purposes of immunocytochemistry primary neurons were plated on 25 mm 
poly-D-lysine coated coverslips (NeuVitro) individually placed in 35 mm cell culture dishes at a density of 
2 x 105 cells/mL (300 µL). Tools required for mounting of neuron coated coverslips are as follows: 1.0 mm 
thick Plain Microscope Slides (Fisher Scientific, Cat. #12-550B), 4” Coverslip Forceps (VWR, Cat # 
470018-968), and 22 G needles. Primary astrocytes were plated at a density of 1.5 x 105 (200 µL) in optical 
quality plastic iBiTreated 8-well chamber slides (ibidi, Cat. # 80826-G500). Control staining was performed 
for each staining paradigm by incubating one coverslip or well in 1X PBST supplemented with 1% NGS 
without primary antibody. Concentrations and incubation conditions were kept identical for secondary 
antibody staining across control and experimental groups resulting in a secondary antibody control. This 
control allows for the visualization of auto-fluorescence caused by the secondary antibody alone and is 
essential to ensure the specificity of chosen primary antibodies in immunostaining.  
Mitotracker staining. Prior to the initiation of Mitotracker staining, 1 tube of Mitotracker Deep Red FM 
(Life Technologies, Cat. #M22426, Lot # 1654296) or Mitotracker Red CMXRos (Life Technologies, Cat. 
# M7512) was reconstituted to a concentration of 1 mM in cell culture grade dimethyl sulfoxide (DMSO). 
Stock concentration was then diluted in pre-warmed neuronal or astrocytic maintenance medium to a 
concentration of 250 nM. DIV 9 primary hippocampal neurons or DIV 16 primary cortical astrocytes were 
then incubated in Mitotracker Red supplemented medium for 25 min at 37°C. Medium was aspirated and 
neurons/astrocytes were washed with 1X PBS, pH 7.4 2 x 5 min at RT.  
Fixing, Permeabilization, and Blocking. 1X PBS (if stained with Mitotracker Red) or culture medium (if 
no Mitotracker Red staining) was aspirated and neurons/astrocytes were fixed in freshly prepared 4% 




PBS, pH 7.4. Following fixation and washing, samples were permeabilized in 1X PBST for 5 min at RT. 
Following incubation, samples were washed 3 x 5 min in 1X PBS, pH 7.4. Permeabilized cells were then 
blocked in ICC Blocking Solution for 30 min at RT with continual rocking followed by 1 x 5 min wash in 
1X PBS.  
Double Labeling of Primary Hippocampal Neurons. MAP2/CLU: Fixed, permeabilized, and blocked 
primary hippocampal neurons were incubated overnight with continual rocking in 1X PBST supplemented 
with 1% NGS and the primary antibodies mouse monoclonal anti-MAP2 (1:750) and rabbit polyclonal anti-
Clusterin H-330 (1:500) The next morning, samples were washed 3 x 5 min with 1X PBS and incubated 
for 1 hr at RT in 1X PBST supplemented with 1% NGS and the fluorophore conjugated secondary 
antibodies Goat anti-rabbit Cy3 (1:1000) and Goat anti-mouse FITC (1:1000). CLU/Mitotracker Red: 
Mitotracker Deep Red stained primary neurons were incubated over night with continual rocking in 1X 
PBST supplemented with 1% NGS and rabbit polyclonal anti-Clusterin H-330 (1:500). The next morning, 
samples were washed 3 x 5 min with 1X PBS and incubated for 1 hr at RT in 1X PBST supplemented with 
1% NGS and the fluorophore conjugated secondary antibodies Goat anti-rabbit Cy3 (1:1000) for 1 hr at RT 
with continual rocking protected from light.  
Double Labeling of Primary Cortical Astrocytes. GFAP/CLU: Fixed, permeabilized, and blocked 
primary cortical astrocytes were incubated overnight with continual rocking in 1X PBST supplemented 1% 
NGS and the primary antibodies rat polyclonal anti-GFAP (1:500) and rabbit polyclonal anti-Clusterin H-
330 (1:500) The next morning, samples were washed 3 x 5 min with 1X PBS and incubated for 1 hr at RT 
in 1X PBST supplemented with 1% NGS and the fluorophore conjugated secondary antibodies Goat anti-
rat Cy5 (1:1000) and Goat anti-rabbit FITC (1:1000). Samples were incubated with continual rocking and 
were protected from light. CLU/Mitotracker Red: Mitotracker Red CMXRos stained primary astrocytes 
were incubated over night with continual rocking in 1X PBST supplemented with 1% NGS and rabbit 
polyclonal anti-Clusterin H-330 (1:500). The next morning, samples were washed 3 x 5 min with 1X PBS 




secondary antibodies Goat anti-rabbit FITC (1:1000) for 1 hr at RT with continual rocking protected from 
light.  
DAPI Staining and Coverslip Mounting. Neurons: Following immunolabeling of fixed cells, all samples 
were washed 3 x 5 min with 1X PBS and mounted on glass microscopy slides using 1 drop of Vectashield 
Hardset Mounting Medium containing DAPI (Vector Laboratories). Briefly, residual PBS was removed 
with a P1000 pipette and the coverslip was gently lifted off the dish using a 22 G needle and coverslip 
tweezers. Excess PBS was removed by dabbing the edge of the coverslip on a kim wipe and the coverslip 
was inverted and placed on the microscopy slide containing mounting medium. Mounting medium was 
allowed to dry overnight protected from light before imaging. Astrocytes: Following immunolabeling, all 
samples were washed 3 x 5 min with 1X PBS and 1 drop of Vectashield Hardset Mounting Medium 
containing DAPI (Vector Laboratories) was added to each well of the chamber slide. Mounting medium 
was allowed to dry overnight protected from light before imaging. 
 
Immunohistochemistry. Tools utilized in the removal of free floating brain sections from antigen 
preservation solution are as follows: Hockey Sticks for section transfers (NeuroScience Associates, Histo 
Tools Cat. # 10015) and #1 and #3 sized paint brushes (American Painter, Cat. #4000-1T). All 
immunostaining was performed in 80 x 40 mm Crystallizing Dishes (ChemGlass, Cat. # CG-8276-P80) 
equipped with a Small Section Transfer Basket (NeuroScience Associates, Histo Tools Cat. # 10014). Brain 
sections were mounted on 2” x 3” Subbed Slides (NeuroScience Associates, Histo Tools Cat. # 10004) and 
cover slipped with 2” x 3” coverslips (NeuroScience Associates, Histo Tools Cat. # 10088). 
Multi-brain sectioning. Rat brain hemispheres were sectioned using MultiBrain processing at 
NeuroScience Associates as previously described (Zhao et al., 2011). Briefly, hemispheres were dissected 
and treated with a solution of 20% glycerol and 2% DMSO to prevent freeze-artifacts. Hemispheres were 




frozen by immersion in −70 ◦C and mounted on a freezing stage of an AO 860 sliding microtome. The 
block of rat hemispheres was sectioned at 40 µm in the coronal plane through the hippocampus 
(Bregma−1.5 to−6.5 mm). Cut sections were collected sequentially into 12 containers filled with Antigen 
Preservation Solution.  
Triple Labeling of Mouse and Rat Brain Hemispheres. Free-floating rat hemisphere sections were 
removed from the freezer and allowed to acclimate to RT. Hockey sticks and #1 paint brushes were used 
to carefully remove brain sections from antigen preservation solution after which sections were washed    2 
x 5 min with PBST in a crystallizing dish equipped with a small section transfer basket. Brain sections were 
then incubated in IHC Blocking Buffer at RT for 1 h. Sections were incubated overnight at 4 ◦C in PBST 
supplemented with 1% NGS and a mixture of primary antibodies containing mouse monoclonal anti-MAP2 
(1:1000), rat anti-GFAP (1:500), and rabbit polyclonal anti-Clusterin H-330 (1:500). The following day, 
brain sections were washed 3 x 5 min with PBST and subsequently incubated at RT for 1 hr in PBST 
supplemented with 1% NGS and a mixture of secondary antibodies containing goat-anti-mouse FITC 
(1:1000), goat-anti-rabbit Cy3 (1:1000), and goat-anti-rat Cy5 (1:750). Sections were washed 3 x 5 min 
with 1X PBST and mounted on 2” x 3” Subbed Slides immersed in IHC Mounting Medium. 3 drops of 
Vectasheild Mounting Medium containing DAPI was added to corresponding 2” x 3” coverslips and 
coverslips were placed over mounted tissue sections and sealed with clear nail polish.   
Equipment and Image Analysis. For imaging cells: Confocal images were acquired using a customized 
Olympus IX81/spinning disk confocal inverted microscope equipped with an Olympus 40X 0.95 NA air 
objective or an Olympus 60X NA 1.42 oil objective (Olympus). Images were collected and analyzed using 
the Slidebook Software Version 6.0 with 15-20 image stacks with a 0.1 μm step size through the cells. For 
imaging of tissue sections: Confocal images were acquired using a customized Olympus IX81/spinning 
disk confocal inverted microscope (Olympus, Yokogawa) equipped with an Olympus 40X 0.95 NA air 
objective (Olympus). Images were collected and analyzed using the Slidebook Software Version 6.0 





Tissue Isolation. All tissues were extracted on ice using sterile surgical tools. Following dissection, 
selected tissues were immediately frozen on dry ice. Tools used for dissection of rodent brain and peripheral 
tissues are as follows: Bone Pliers (Fine Science Tools, Cat. #16025-14), Lempert Rongeurs (Fine Science 
Tools, Cat. #16004-16), Tungsten Carbide Straight Bone Scissors (Fine Science Tools, Cat. #16030-12), 
Micro Spoons (Fisher Scientific, Cat. #21-401-15), Dissecting Tissue Forceps (Fisher Scientific, Cat. #13-
812-36), Curved Precision Tip Forceps (Fisher Scientific, Cat. #16-100-123), and a Metal Scalpel (Fisher 
Scientific, Cat. #08-920B).  
Brain Region Dissection. Female Erβ-/- rats aged 6 months or 10 months (n=5 animals per age group), 
male and female CLU-KO (variable ages) mice and corresponding age-matched WT controls were 
euthanized via CO2 asphyxiation. Following euthanasia, animals were decapitated and the upper portion of 
the skull was immediately removed using fine tipped rongeurs (rats) or fine tipped curved forceps (mice). 
The entire brain was carefully removed with a sterile micro spoon and immediately placed ventral side up 
on a sterile pre-chilled dissection board. The whole hypothalamus was removed first using sterile curved 
tip forceps. The edges of the forceps were placed directly around the hypothalamus and pinched together 
to gently lift the hypothalamic tissue from the brain. The tissue was placed in a labelled tube and 
immediately snap frozen on dry ice. Following removal of the hypothalamus, the brain was placed dorsal 
side up and the cerebellum was removed by placing the fine edge of the scalpel between the cerebellum 
and the cortices. The whole cerebellum was placed in a labeled tube and snap frozen on dry ice. The 
remaining brain tissue was divided into the left and right hemispheres by cutting down through the 
longitudinal fissure. Each hemisphere was placed medial side up and the remaining white matter was 
removed. Left and right hippocampi were gently removed using two sterile micro spoons, placed in the 
appropriate tubes and snap frozen on dry ice. The remaining left and right cortices were divided into 4 




Peripheral Tissue Dissection. Selected peripheral tissues were dissected from indicated animals following 
CO2 euthanasia. Briefly, the abdominal cavity was opened using scissors and one lobe of the liver was 
extracted and snap frozen in a labeled tube. The rib cage was then severed using sterile bone scissors 
allowing for the extraction of lung and heart tissues. The pancreas was removed by gently severing the 
connection between the pancreas and intestines and lastly selected reproductive tissues were removed. All 
tissue samples were snap frozen on ice and stored in -80 °C until tissue processing.    
 
Protein Extraction Techniques  
Whole Tissue Protein Extraction. 30 mg tissue from indicated peripheral organs or brain regions was 
homogenized using the Bullet Blender 24 Homogenizer (Next Advance, Averill Park, NY) with 100 µL 0.5 
mm glass beads in variable volumes of Tissue Protein Extraction Reagent (TPER) supplemented with 
protease and phosphatase inhibitors according to the manufacturer’s instructions. Briefly, whole tissues 
were combined with glass beads and TPER and homogenized at speed 8 for 3 min at 4 °C. Following 
homogenization, lysates were cleared via centrifugation at 10,000 x g for 10 min at 4 °C. Protein 
concentrations were then assessed using the commercially available BCA Assay (Pierce Biotechnology)   
Whole Cell Protein Extraction. Whole neuron or neuro-2a cell extracts were collected using the 
commercially available Neuronal Protein Extraction Reagent (NPER) according to the manufacturer’s 
instructions. Briefly, cell-type-specific maintenance medium was removed and cells were washed 1 time 
with sterile 1X PBS. PBS was aspirated and 100-200 µL NPER supplemented with PPI was added to each 
well of neurons/neuro-2a cells and allowed to incubate on ice for 5 min. Following incubation, cells were 
removed by scraping and collected in labeled 1.5 mL centrifuge tubes. Tubes were sonicated for 10 seconds 
followed by centrifugation at 10,000 x g for 10 min at 4 °C. Remaining supernatants were transferred to 




Subcellular Fractionation of Cultured Cells. Cultured neurons, astrocytes, or neuro-2a cells were washed 
1 time with 1X PBS. PBS was aspirated and cells were removed from dishes by gently scraping in 1 mL 
1X PBS. Cell suspensions were collected and cells were pelleted by centrifugation at 4,000 x g for 5 min 
at 4 °C. PBS was aspirated and cell pellets were resuspended in 200 µL Cytosolic Extraction Buffer (CEB). 
Samples were incubated for 10 min at 4 °C with rotation followed by 8 passes through a 22 G needle. 
Samples were centrifuged at 1,500 x g for 8 min at 4 °C and the supernatant was removed and placed in a 
separate tube. The supernatant was then centrifuged at 8,000 x g for 10 min at 4 °C after which the 
supernatant (cytosolic proteins) was pipetted into a new labeled tube. The remaining pellet from this spin 
(crude mitochondrial fraction) was resuspended in 30 µL Mammalian Protein Extraction Reagent (MPER) 
supplemented with PPI and stored at -80 °C. The pellet from the first spin (nuclear proteins) was 
resuspended in 200 µL Nuclear Extraction Buffer and sonicated 2 x 10 sec with 10 sec intervals on ice. 
Following sonication, the samples were cleared of cellular debris by centrifugation at 10,000 x g for 10 min 
at 4 °C and supernatants were placed in a new labeled centrifuge tube.     
Three-Buffer Tissue Fractionation. Cytosolic, organelle, and nuclear proteins were extracted from freshly 
dissected brain tissue sections using a previously described three-buffer extraction system (Baghirova, 
Hughes, Hendzel, & Schulz, 2015) with slight modifications. Briefly, cortical tissues were dissected from 
indicated animals as previously described (Brain Tissue Dissection). Tissues were minced into smaller 
sections using a scalpel and homogenized 5 times with Pestle A in a 2 mL Dounce Homogenizer containing 
1 mL Lysis Buffer A supplemented with PPI. Tissue suspension was then placed in a 1.5 mL centrifuge 
tube and centrifuged at 500 x g for 10 min at 4 °C. The supernatant was placed in a new centrifuge tube 
and incubated on an end-over-end rocker for 10 min at 4 °C. Following incubation the tissue suspension 
was centrifuged at 4,000 x g for 10 min at 4 °C and the supernatant (Cytosolic Fraction) was removed and 
placed in a sterile labeled centrifuge tube. The remaining pellet was then re-suspended in 500 µL Lysis 
Buffer B supplemented with PPI. Samples were incubated for 30 min at 4 °C on an end-over-end rotator 




contains proteins from membrane-bound organelles (mitochondria, endoplasmic reticulum, Golgi, etc.) 
except those from the nucleus, was stored in a labeled tube at -80 °C until use. The remaining pellet was 
then re-suspended in 500 µL Lysis Buffer C supplemented with PPI and incubated for 10 min at 4 °C on 
an end-over-end rocker followed by centrifugation at 6,800 x g for 10 min at 4 °C. The supernatant (Nuclear 
Fraction) was removed and stored at -80 °C until use.     
 
Mitochondria Isolation Techniques. All mitochondrial samples were isolated from freshly harvested 
cortical tissues extracted from female WT mice between 5-7 months of age. All isolation procedures were 
performed on ice with pre-chilled buffers or in pre-chilled refrigerated centrifuges.   
Discontinuous Percoll Gradient. 5-7 month old female WT mice were euthanized (2 mice/isolation) and 
whole cortical tissues were dissected as previously described. Brain sections were washed for 10 seconds 
by gently swirling tissues in 20 mL ice cold Mitochondria Isolation Buffer (MIB) without PPI or BSA. 
Tissues were then transferred to a small weigh boat and minced into 8-10 small pieces. Brain tissue was 
then transferred to a 5 mL glass dounce homogenizer containing 5 mL ice cold MIB supplemented with 
PPI and 0.05% BSA (added fresh) and gently homogenized using 10 slow strokes on ice. The homogenate 
was then transferred to a 30 mL polycarbonate tube on ice and centrifuge at 1,330 x g for 8 min at 4°C 
(Spin 1). The supernatant was pipetted into a separate polycarbonate tube and placed on ice and the 
homogenization was repeated on the pellet followed by centrifugation 1,330 x g for 8 min at 4°C (Spin 2). 
Supernatants from Spin 1 and Spin 2 were combined and centrifuged once more at 1,330 x g for 8 min at 
4°C (Spin 3). The supernatant from Spin 3 was pipetted into a sterile 30 mL polycarbonate tube and a 100 
µL aliquot was removed and stored in a labeled tube (WCL). The remaining supernatant was centrifuged 
at 21,200 x g for 10 min at 4°C (Spin 4). The supernatant was discarded and the remaining pellet was 
resuspended by pipetting in 6 mL 15% Percoll. The resuspended pellet was centrifuged at 21,200 x g for 
10 min at 4°C (Spin 5). Using a P-1000 pipette, the loose pellet of ‘crude’ mitochondria (~1-2 ml) on the 




gradient was centrifuged at 40,000 x g for 18 min at 4°C (Spin 6). The cloudy white interface between the 
two percoll layers was removed with a glass pasteur pipette and placed into a new 15 mL polycarbonate 
tube. In addition, the upper layer of the percoll gradient containing crude mitochondria was also removed 
and placed into a second 15 mL polycarbonate tube. MIB without protease inhibitors was added to a total 
of 10 mL and the mitochondrial samples were centrifuged at 21,700 x g for 13 min at for 4°C (Spin 7). The 
loose pellet at the bottom of the tube was removed and pipetted into a sterile labeled 1.5 mL centrifuge tube 
and centrifuged at 6,600 x g for 8 min at 4°C (Spin 8) in a table top centrifuge. The supernatant was removed 
and the remaining mitochondrial pellets were re-suspended in 50-100 µL MIB. Protein concentration was 
determined via BCA Assay and samples were analyzed as indicated.  
Digitonin Mitochondrial Subfractionation. Pure mitochondria were isolated from female mouse brain 
tissue as previously indicated (previous paragraph) and subjected to a Digitonin-based Mitochondrial 
Subfractionation (Tropschug et al., 1988) in a protocol adapted from Nair et. al (Nair & McGuire, 2005). 
Mitochondria were resuspended in 200 uL Mitochondria Subfractionation Buffer (MSF Buffer) 
supplemented with 0.5 mg/mL BSA. The mitochondrial suspension was then separated into 4 50 µL 
aliquots and 50 µL of either MSF Buffer (Control) or 0.2%, 0.4%, or 0.6% Digitonin (diluted from a 1.6% 
stock solution in MSF Buffer) was added to respective tubes to yield a final concentration range of 0-0.3% 
Digitonin (100 µL total volume). Tubes were incubated for exactly 5 minutes on ice and quickly diluted 
with 100 µL cold MSF Buffer. Samples were transferred to polypropylene tubes and centrifuged at 50,000 
x g for 25 min at 4°C in a Beckman SW-41 Ti Swinging Bucket Rotor. Supernatants were carefully removed 
and the pellet was resuspended in 30 µL MPER supplemented with PPI. Pellet suspensions were analyzed 
via SDS-PAGE to examine the expression profile of CLU against those of specific mitochondrial 
subfraction markers: VDAC (outer mitochondrial membrane), Cyt. C (intermembrane space), CoxIV (inner 





Table 6.  Deglycosylation Reaction Composition. A list of components included in 
deglycosylation reactions.   
Enzymatic Deglycosylation.  Deglycosylation of CLU protein isoforms was achieved using 2 separate 
commercially available endoglycosidases according to the manufacturer’s instructions. Briefly, 10-15 µg 
of selected cellular or tissue fraction lysates were incubated in Denaturing buffer for 10 min at 95 °C in a 
10 µL reaction volume. Samples were then cooled to RT and deglycosylation reactions were assembled as 
indicated in Table 7. Reactions were incubated for 75 min at 37 °C. Following incubation, 20 µL Reducing 
2X Laemmli Sample Buffer was added to each reaction and samples were analyzed for CLU 
immunoreactivity using SDS-PAGE. Denaturing Buffer, corresponding glycol buffers, and NP-40 were 
provided by NEB with the corresponding endoglycosidase.  
Deglycosylation Reactions 
PNGase F  
(Total removal of all glycans) 
Endo H  
(High Mannose Glycans) 
10 uL denatured protein sample 
2 µL 10X Glyco Buffer 2 2 µL 10X Glyco Buffer 3 
2 µL 10% NP-40 -- 
1 µL PNGase F 
(NEB, Cat. # P0704S, 500,000 units/mL) 
2 µL Endo H 
(NEB, Cat. # P0702S, 500,000 units/mL) 
5 µL ddH2O 6 µL ddH2O 
Total Reaction Volume = 20 µL 
 
 
Glutamate Toxicity. Primary cortical neurons were cultured as described and plated at a density of 5x105 
on PEI-coated 100 mm dishes (3 dishes per time point). At DIV7 neurons were exposed to 100 µM 
glutamate for 5 min at RT in pre-warmed 1X HEPES buffer. Following glutamate exposure, neurons were 
gently washed 1 time with 1X HEPES Buffer. HEPES Buffer was aspirated and 8 mL pre-warmed Neuron 
Maintenance Medium was added to each dish. Neurons were returned to the incubator and allowed to 
incubate for indicated time points. Neurotoxicity was assessed prior to cell harvest using the commercially 
available LDH Cytotoxicity Assay Kit (Pierce) according to the manufacturer’s instructions. Following the 
confirmation of neurotoxicity, neurons were harvested using the previously described Subcellular 




Table 7. BCA Standard Curve Layout. BCA Protein Standard Layout for analysis of protein 
concentration.   
Immunoprecipitation. For neuronal lysate immunoprecipitation, primary cortical and hippocampal 
neurons were isolated and grown to maturity as previously described and lysed NPER supplemented with 
protease and phosphatase inhibitors as previously described. Protein concentration was determined and 1 
mg of lysate was brought to a volume of 500 µL with IP Buffer and pre-cleared using 50 µL of Protein-A 
conjugated Dynabeads for 1 hr at 4°C with continuous rotation. Lysates were then divided into equal 
portions and incubated with either goat polyclonal anti-CLU C-18 (4 µg), rabbit polyclonal anti-CLU H-
330 (4 µg), or equal concentrations of species specific IgG overnight at 4°C with continuous rotation. The 
immune complex was pulled out of solution using 50 µL Protein-A conjugated Dynabeads for 2 hr at 4°C 
with continuous rotation. Beads were washed 3 times with 500µL IP buffer and protein was eluted using 
30 µL 2X SDS Sample Buffer at 37°C for 10 min. Eluted proteins were then analyzed via SDS-PAGE as 
indicated.  
 
SDS-PAGE and Immunoblotting.  
BCA Protein Assay. Protein concentrations were determined via the commercially available BCA Assay 
according to the manufacturer’s instructions with minor modifications. Briefly, a standard curve was 
created using the guidelines provided in Table 7. 2 µL protein sample was used to measure total protein 
concentration. BCA Assay was incubated at 37 °C for 20 min and absorbance was measured at 562 nm. 
BCA Standard Curve Layout 
Row in 96 
well plate 
Volume of BSA (2mg/mL) 
stock solution to add to well 
Final protein 
amount in well 
Volume of BCA reagent 
mixture to add to well 
A 0 µL 0 µg 100 µL 
B 1.25 µL 2.5 µg 98.75 µL 
C 2.5 µL 5 µg 97.5 µL 
D 5.0 µL 10 µg 95.0 µL 
E 7.5 µL 15 µg 92.5 µL 
F 10.0 µL 20 µg 90.0 µL 
G 12.5 µL 25 µg 87.5 µL 






Table 8. Western Blot Gel Recipes. Western blot gel recipes for resolving and stacking gels used 
in SDS-PAGE.   
Preparation of Gels and Protein Samples. 7.5%, 10%, or 12.5 % resolving gels and stacking gels were 
generated using the recipes indicated in Table 8. Samples were diluted in appropriate buffers to an equal 
concentration and volume followed by the addition of 1 volume of 2X Reducing Laemli Sample Buffer. 
Prepared samples were then denatured by incubation at 95 °C for 5 min followed by centrifugation at 2,000 
x g for 5 sec at RT.  
Western Blot Gel Recipes 
Resolving Gels Stacking Gel 
 7.5% 10% 12.5%  
ddH2O   
(mL) 
6.0 5.0 4.0 3.25 
Lower Tris   
(mL) 
3.0 3.0 3.0 1.25 
(use Upper Tris) 
30% Acyrlamide  
(mL) 
3.0 4.0 5.0 0.55 
TEMED 12µL 12µL 12µL 10µL 
20% APS 28µL 28µL 28µL 20µL 










Electrophoresis and Immunoblotting. 20-50 μg of total protein sample isolated from tissue or cells was 
resolved via reducing SDS-PAGE. Gels were run for 15 min at 125 V followed by 40 min at 180 V in 1X 
Western Blot Running Buffer. Resolved proteins were then transferred to 0.2 μm pore-sized PVDF 
membranes for 1 Hr on ice in Western Blot Transfer Buffer and blocked with 2% Blocking Buffer in 1X 
TBST for 1 hr at RT. Membranes were incubated with customized dilutions of the indicated primary 
antibodies for indicated time points (ranging from 1 hr at RT to 4°C overnight), followed by incubation 
with the appropriate HRP-conjugated secondary antibody for 1 hr at RT. Membranes were washed 3 x 10 
min with continual rocking after each incubation with 1X TBST. Bands were visualized using 
chemiluminescence with an ECL detection kit (BioRad) and scanned using the C-Digit Blot Scanner (LI-
COR). Where applicable membranes were stripped and re-probed using a panel of fraction-specific markers 




image digitizing software, Image Studio Version 4.0. Specific information regarding antibodies used for 
western blotting including dilutions, catalog and lot numbers, and vendors are listed in the following 
section. 
3,3’,5,5’,-Tetramethylbenzidine Staining. For better visualization of protein isoform molecular weights, 
cellular fractionations, enzymatic deglycosylations, and tissue panels were stained using TMB Peroxidase 
(HRP) Substrate Kit (Vector Laboratories, Cat. # SK-4400) following antibody based detection and blot 
acquisition. TMB allows for the visualization of secondary antibody bound proteins on the membrane by 
forming a blue precipitate on HRP-bound antigens. Following acquisition of immunoblots, excess 
chemiluminescence was washed off with 1X TBST for 10 min at RT with constant rocking. While the 
immunoblot was washing, TMB solution was generated by diluting 2 drops of buffering solution, 3 drops 
of TMB substrate, 2 drops of stabilizing solution, and 2 drops of H2O2 in 5 mL ddH2O. TBST was dumped 
and residual buffer was removed with a P1000 pipette. TMB Solution was added and blot was incubated 
for ~30 min – 1 hr at RT with continual rocking. Following incubation, TMB Solution was removed and 
the blot was washed 1 x 10 min at RT with continual rocking. Blots were dried for 30 min at 37 °C and 
scanned using a standard scanner.  
 
Gene Expression Studies. All gene expression studies were performed using the QuantStudio 7 Flex Real-
time PCR System (Applied Biosystems) equipped with a fast block. PCR reactions were loaded using 
Filtered Low Retention Pre-sterilized pipette tips (VWR, Cat. # 10017-060) into MicroAmp Fast Optical 
96-well Reaction Plates (Applied Biosystems, Cat. #4346906 and sealed with MicroAmp Optical Adhesive 
Film (Applied Biosystems, Cat. #4311971), and briefly centrifuged at 1,000 x g for 1 min at 4 °C before 
PCR was initiated. I would like to formally thank Jennifer Hackett at the University of Kansas Sequencing 




RNA Isolation. Total RNA was isolated from 30 mg cortical tissue harvested from CLU-KO mice or ERβ-
KO rats and corresponding WT controls using the commercially available Pure Link RNA Mini Kit with 
slight modifications. Briefly, 200 µL of TRIzol Reagent and 1 scoop of pre-chilled 400 µM Silica Beads 
(OPS Diagnostics, Cat. # BMBG 400-200-05) was added to 30 mg cortical tissue and homogenized using 
a pre-chilled Bullet Blender 24 Homogenizer for 1 min at speed 6. 400 µL TRIzol Reagent was added to 
each tube and samples were re-homogenized at speed 2 for 1 min. Samples were cleared of tissue debris 
via centrifugation at 10,000 x g for 1 min at 4 °C and 500 µL of the resulting supernatant was pipetted into 
a new sterile microcentrifuge tube. 100 µL Chloroform was added to each 500 µL sample and tubes were 
mixed by inversion for 15 seconds. Samples were centrifuged at 12,000 x g for 15 min at 4 °C and ~200 
µL of the upper aqueous portion was pipetted into a new microcentrifuge tube. 1 volume of 70% ethanol 
was added to each sample and mixed by vortexing at max speed for 15 seconds. RNA was then purified 
using the PureLink RNA Mini kit according to the manufacturer’s instructions. RNA quality was assessed 
and RNA with a RNA Integrity Number of 8 or above was used for reverse transcription.   
Reverse Transcription. 2 µg total RNA was reverse transcribed using the Applied Biosystems High 
Capacity RNA-to-cDNA Kit (Applied BioSciences, Cat. # 4387406) according to the manufacturer’s 
instructions. Reactions were performed in thin-walled PCR tubes (Molecular BioProducts, Cat. # 3418) on 
a T100 Thermo Cycler (BioRad). Reaction conditions were 37 °C for 1 hr followed by 95 °C for 5 min. 
Rt-QPCR. Total CLU (tCLU), Exon 1-containing CLU, and mCLU gene expression was evaluated in 10 
µL reactions containing 5 µL PowerUP SYBR Green MasterMix, 100 ng cDNA, 500 nM of forward and 
reverse primers (Table 9), and ultrapure ddH2O. In all gene expression studies, at least 2 control genes were 
also amplified and the gene that remained more consistent across groups was utilized: in this case β-Actin.  
Cycling conditions used are as follows: 50 °C for 2 min, 95 °C for 10 min followed by 40 cycles of 95 °C 
for 15 sec and 65°C for 1 min. To ensure the specificity of each primer, melt curve analysis was also 





Table 9. rt-qPCR Primer Sequences. Primers used to amplify CLU mRNAs and β-actin.    
Clusterin and Actin qPCR Primers 
Target Forward (5’3’) Reverse (5’3’) 
Exon 1 CTTCCAGAAAGCTCCTGGTG CTCCAGTGCGCTCCTCCT 
Mature CLU (mCLU) GCTGCTGATCTGGGACAATG ACCTACTCCCTTGAGTGGACA 
Total CLU (tCLU) CCTTGCTCAACAGTTTAGAGGAA CATCATGGTCTCGGTACACACTT 
β-actin GTGACGTTGACATCCGTAAAGA GCCGGACTCATCGGACTCC 
 
 
Mitochondrial Co-immunoprecipitation Studies. The following 10 methods paragraphs (pLX304-
hCLU-v5 Plasmid Description - Secondary Confirmation of Identified Interacting Partners) pertain to a 
single experimental study that is presented in Chapter 2 (Section 2.2) of the Results in this dissertation and 
are therefore grouped together for the convenience of the reader. I would to formally thank Dr. Yakov 
Mikhailovich Koen (University of Kansas) for performing the Trypsin Digestion and Dr. Antonio Artigues 
(University of Kansas Medical Center) for performing the LC-MS/MS Analysis (MudPIT). All other 
experiments and bioinformatics in this study were performed by me.  
pLX304-hCLU-v5 Plasmid Description. The plasmid construct used in these studies was generated by 
Dr. David Root and deposited into the DNASU Plasmid Repository • PSI:Biology-Materials Repository. 
Briefly, full length human CLU (Accession #: NM_001831.3) cDNA was inserted into the mammalian 
expression vector pLX304 to create a fusion protein. The resultant plasmid expresses full-length hCLU 
protein fused to a c-terminal V5 epitope tag and is referred to here as pLX304-hCLU-v5 (Clone: 
HsCD00435174, Schematic 9). Protein expression is driven by the CMV promoter and immunoblot analysis 
of transfected cells indicates robust expression of multiple CLU isoforms by both anti-CLU antibodies as 
well as the anti-V5 antibody.  
Plasmid Amplification and Isolation. LB ampicillin plates (18.5 g LB Agar, 12.5 g LB Broth, Miller, 100 
µg/mL Ampicillin) were inoculated with bacteria taken from the DNASU pLX304-hCLU-v5 stab culture 
and incubated for 16 hrs at 37 °C. The following morning, 5 mL LB Broth supplemented with 100 µg/mL 
ampicillin was inoculated with a single colony and allowed to grow for 8-10 hrs at 37 °C at 200 rpm on a 





over the course of 2 days at which time 2 mL bacterial suspension was removed, centrifuged, and the pellet 
was resuspended in LB Broth supplemented with 50% glycerol and 100 µg/mL Ampicillin in a 2 mL 
Cryopreservation tube. Tubes were labeled with colony ID and stored at -80 °C as a bacterial stock. The 




and purified using the commercially available QIAGEN Midi Kit according to the manufacturer’s 
instructions.  
pLX304-hCLU-v5 Overexpression. Neuro-2a cells were plated in 150 mm dishes in antibiotic-free 
Neuro-2a Maintenance Medium and allowed to grow at 37 °C until the confluency reached 40%. At 40% 
confluency 20 µg of pLX304-hCLU-v5 was transfected using Lipofectamine 3000 according to the 
manufacturer’s instructions. Briefly, 30 minutes prior to transfection, medium was replaced with 15 mL 
OptiMEM. 20 µg of plasmid was diluted in 500 µL OptiMEM supplemented with 80 µL P3000 Reagent 
(Tube A). In an additional tube (Tube B), 40 µL Lipofectamine 3000 Reagent was diluted in 500 µL Opti-
MEM. Both tubes were incubated at RT for 5 min, after which time Tube A and Tube B were combined to 
make 1 sample (Transfection mixture). The transfection mixture was incubated at RT for 45 min and added 
drop-wise to the 150 mm dish. Transfection was allowed to occur overnight at 37 °C. The following 
morning, the OptiMEM/Transfection Mixture was replaced with Neuro-2a Maintenance Medium and 
allowed to grow for 96 hrs prior to harvest.    
Co-immunoprecipitation. Crude mitochondria were isolated from N2a cells overexpressing pLX304-
hCLU-v5 using subcellular fractionation as previously indicated. The crude mitochondrial pellet was 
resuspended in 500 µL Co-IP Buffer supplemented with protease and phosphatase inhibitors and protein 
concentration was determined using BCA Assay. While protein concentration was being measured, 100 µL 
Protein G Dynabeads (Thermo Scientific) were washed 2 x 1 mL with cold Co-IP buffer and re-suspended 
in 100 µL cold Co-IP Buffer. Beads were kept on ice until pre-clearing step. 400 µg crude mitochondrial 
lysate was combined with 600 µL cold Co-IP buffer to bring the volume to 1 mL. 30 µL of pre-washed 
Protein G Dynabeads were added to the 1 mL sample and sample was incubated for 1 hr at 4°C with rotation. 
Following pre-clear, beads and cleared supernatant were separated and the supernatant was divided equally 
between 2 tubes. The volume in each tube was brought to 1 mL with cold Co-IP buffer and 4 µg of Rabbit 
IgG (Control) or Rabbit anti-V5-Tag (IP) was added. Samples were incubated overnight at 4°C with rotation 




were pulled out of solution using 30 µL pre-washed Protein G Dynabeads per immunoprecipitation. Bead-
antibody-antigen complexes were allowed for form by incubating mixtures for 2 hrs at 4°C with rotation. 
The supernatant was then removed and the beads were washed 5 times with 1 mL ice-cold Co-IP buffer. 
Beads were incubated for 4 min at 4°C with rotation between each wash. Following the 5th wash, all Co-IP 
buffer was removed and beads were resuspended in 40 µL 2X Laemmli sample buffer containing β-
mercaptoethanol and samples were incubated at 95 °C for 5 min. Following elution, beads were removed 
from samples and 30 µL of sample was resolved via SDS-PAGE. For purposes of LC-MS/MS analysis the 
resulting gel was stained with SYPRO Ruby as indicated in the following section. In addition, 5 µL of the 
eluted sample was analyzed for CLU expression to ensure the immunoprecipitation of CLU.  
SYPRO Ruby Staining. Following Co-IP of overexpressed pLX304-hCLU-v5 and electrophoresis of 
eluted proteins/protein complexes, gels were placed in Fixing Solution and incubated for 60 min at RT with 
continuous rocking.  Gels were then incubated in 50 mL SYPRO Ruby fluorescent gel stain (Bio-Rad) 
overnight at RT with constant rocking.  Following overnight incubation, SYPRO Ruby stain was removed 
and the gels were washed 3 times for 10 min with 50 mL ddH2O.    
Band Excision and Proteolytic Digestion. Following SYPRO Ruby staining, gels were visualized and 
protein bands specific to the IP lane (i.e. not present in the Control lane) were excised using a UV 
transilluminator and sterilized razor blades. Gel pieces were then minced into 2 mm square pieces and 
transferred to sterile microcentrifuge tubes and covered in deionized water and stored at 4°C until Trypsin 
digestion. On the day of trypsin digestion, samples were removed from 4 °C and allowed to acclimate to 
RT. Samples were then washed 2 times with 150 uL of freshly prepared TD Washing Solution by incubation 
in a shaking water bath at 30 C for 30 min. Following each incubation, samples were chilled at 4 °C for 3 
min then briefly centrifuged (3-5 sec) to collect condensation from tube caps. Following the second wash, 
the supernatant was completely removed from the gel pieces and gels were dehydrated by adding 150 uL 
100% MeCN. Samples were vortexed and incubated at RT for 5-7 min.  MeCN was then removed and gel 




Reducing Buffer to each tube. Samples were incubated at 50C in a shaking water bath for 60 min followed 
by a brief centrifugation (3-5 sec). Following centrifugation, the supernatant was completely removed. 
Immediately following the removal of TD Reducing Buffer, 70-90 µL TD Alkylating Buffer was added to 
each tube. To ensure this step was performed in haste, individual samples were processed successively in 
the following manner: Reducing Buffer was removed from first tube, Alkylating Buffer was immediately 
added, and sample was vortexed and placed in the dark. All samples were then incubated at RT in the dark 
for 45 min with occasional vortexing after which time the supernatant was removed. 100 µL 100 mM 
Ammonium Bicarbonate (Bicarb). Was added to each sample and tubes were briefly vortexed and incubated 
for 10 min at RT. Bicarb was removed and replaced with 100 µL 100% MeCN and incubated for 10 min. 
The 100% MeCN was removed and the Bicarb/MeCN cycle was repeated once again. Following the second 
Bicarb/MeCN cycle, dehydrated gel pieces were dried for 50-60 min in a fume hood with constant air flow. 
70-100 µL Digestion Buffer was added to each tube and samples were incubated for 15-20 min at RT to 
facilitate the re-swelling of gel pieces. Following incubation, 20-60 µL of Digestion Buffer without trypsin 
was added to each tube and samples were incubated at 37 °C in a shaking water bath overnight. The next 
morning, samples were briefly centrifuged to collect condensation and incubation was continued for a total 
incubation time of 19 hrs. Hydrolysis was terminated by placing tubes on ice for 3-5 min followed by brief 
centrifugation. Supernatants were collected (variable volumes) and transferred to sterile 1.5 mL Eppendorf 
tubes. 1% TFA was added to a final concentration of 0.1% and samples were vortexed and stored at -20°C 
until needed for analysis. A complete outline of buffers, 1% TFA added, and final digest volumes is 
provided in Table 10.   
Multidimensional Protein Identification Technology (MUDPit). Following enzymatic digestion, the 
extracted peptides were concentrated on a centrivac concentrator (Labconco) to a final volume of 20µl. The 
peptide extracts were analyzed using an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher 
Scientific) coupled to an uHPLC (nLC 1200, Thermo Fisher Scientific). In each run, the sample was 




Å, 5 µ, Magic C18 particles, Michrom Bioresources), and washed with 0.1% formic acid for 15 minutes at 
300 nl/min. The column was mounted on the electrospray stage of the mass spectrometer, and the peptides 
were eluted with a gradient of acetonitrile (solvent B: 90 % acetonitrile, 0.1% formic acid) in 0.1% formic 
acid in water (solvent A). The gradient profile was as follows:  0-5 min, 5-15% B; 5-60 min, 15-40% B; 
60-70 min, 40% B; 70-75 min, 40-75% B; 75-83 min 75% B. At the end of each chromatographic run, the 
column was washed with 100% B. The flow rate was maintained at 300 nl/min. The mass spectrometer was 
controlled by the Xcalibur software to perform continuously mass scan analysis on the Orbitrap in the range 
of 400-1900 m/z at 50,000 resolution, followed by MSMS scans on the ion trap, with a dynamic exclusion 
of one repeat scans of the same ion, 30 s repeat duration and 90 sec exclusion duration. Normalized collision 
energy for MS/MS was set to 35%. The isolation window used was 1.6 amu. For data analysis all MSMS 
scans were searched using Proteome Discoverer (version 2.0, Thermo Fisher Scientific) running the Sequest 
HT algorithm. Database search was conducted against a Mus musculus protein database derived from the 
NIBInr repository as in January 9, 2017. The refined data were subjected to database search using Trypsin 
cleavage specificity, with a maximum of 2 missed cleavages. The following variable modifications were 
selected: pyroglutamination from Q and E (N-terminal), oxidation of M, and deamidation of N, Q. 
Carboxymethylation of C was selected as a fixed modification, and a maximum of 3 modifications/peptide 
was allowed. Estimation of false positive rate (FDR) was conducted by searching all spectra against a decoy 
database consisting of the inverted sequences of all proteins in the original (direct) database. For peptide 
 a minimum of two unique peptides per protein was required 
for protein identification. Amino acid sequence assignment of all peptides of interest were subsequently 
inspected manually. 
STRING Pathway Analysis. Protein interaction networks were generated from the list of identified 
mitochondrial proteins listed in Table 14 using STRING Pathway Analysis Software. STRING is a 
database containing experimental and curated protein-protein interaction data from over 9 million 




collected from BIND, DIP, GRID, HPRD, IntAct, MINT, and PID while curated data is extracted 
from Biocarta, BioCyc, GO, KEGG, and Reactome. The probability of a given interaction, which 
was set to medium in our studies, is calculated by combining the probabilities from the different 
evidence channels and corrected for the probability of randomly observing an interaction (von 
Mering et al., 2005). For more information regarding specific aspects of the STRING software, 
please visit https://string-db.org/cgi/help.pl?UserId=MwnaiLZ0llBq&sessionId=f1dbaG6Rj9wg.   
Secondary Confirmation of Identified Interacting Partners. Fresh brain tissue was extracted from 6-
month-old female mice and minced in ice-cold Co-IP Buffer supplemented with PPI. Minced tissue was 
homogenized with 10 strokes using a glass handheld homogenizer and crude mitochondria were isolated 
using differential centrifugation as previously discussed. The crude mitochondrial pellet was re-suspended 
in 500 µL Co-IP Buffer and protein concentration was determined. 500 µg of crude mitochondrial lysate 
was utilized for each co-immunoprecipitation and each lysate was pre-cleared as previously described. Pre-
cleared lysates were subjected to immunoprecipitation overnight at 4 °C with rotation using the following 
antibodies: mouse anti-Grp75 (2 µg, BioRad), rabbit anti-Mitofilin (2 µg, ProteinTech), goat anti-Clusterin 
M-18 (4 µg), or rabbit anti-Tom70 (4 µg). In all experiments, control immunoprecipitations were performed 
using identical concentrations of the appropriate species-specific immunoglobulin. Following overnight 
immunoprecipitations, complexes were pulled out of solution using 30 µL pre-washed Protein G Dynabeads 
per immunoprecipitation. Bead-antibody-antigen complexes were allowed for form by incubating mixtures 
for 2 hrs at 4°C with rotation. The supernatant was then removed and the beads were washed 5 times with 
1 mL ice-cold Co-IP buffer. Beads were incubated for 4 min at 4°C with rotation between each wash. 
Following the 5th wash, all Co-IP buffer was removed and beads were resuspended in 40 µL 2X Laemmli 
sample buffer containing β-mercaptoethanol and samples were incubated at 95 °C for 5 min. Following 





Table 10. List of Samples Submitted for Protein Identification. List of buffers, 1% TFA added, and 
final digest volumes is provided for protein identification  
 
Mitochondrial Respirometry. The following 5 methods paragraphs (Equipment and Calibration – Data 
Analysis) pertain to a single experimental study that is presented in Chapter 2 (Section 2.4) of the Results 
in this dissertation and are therefore grouped together for the convenience of the reader. All experiments, 
calibration, troubleshooting, and analyses in this study were performed by me. 
Equipment and Calibration. Brain mitochondrial respiration was evaluated using the OROBOROS 
Oxygraph-2K Machine at 37 °C with constant stirring. Prior to use, the chambers were cleaned for 30 min 
with 2 mL freshly prepared 70% ethanol with constant stirring. Ethanol was removed and residual ethanol 
was washed from the chamber using 2.2 mL ultrapure ddH2O for 10 min with constant stirring. 2 mL sterile 
Calibration Buffer was then added to the machine and allowed to acclimate for 30 min with constant stirring 
















Co-IP 1 50 15 33.0 3.6 36.6 
Co-IP 2 50 15 32.0 3.4 35.4 
Co-IP 3 50 15 34.0 3.8 37.8 
Co-IP 4 50 15 35.0 4.1 39.1 
Co-IP 5 50 15 42.5 4.7 47.2 
Co-IP 6 50 15 45.0 5.0 50 
Co-IP 7 50 15 38.0 4.3 42.3 
Co-IP 8 50 15 32.0 3.4 35.4 
Co-IP 9 50 20 30.0 3.2 33.2 
Co-IP 10 50 15 36.0 4.0 40 
Co-IP 11 50 15 46.5 5.1 51.6 
Co-IP 12 50 15 40.0 4.4 44.4 
Co-IP 13 50 15 30.0 3.3 33.3 
Co-IP 14 50 15 28.5 3.0 31.5 
Co-IP 15 50 15 18.0 2.0 20 
Co-IP 16 50 45 55.0 6.1 61.1 
Co-IP 17 50 30 39.0 4.4 43.4 




to achieve a stable readings in both temperature and oxygen concentration. All solutions and mitochondria 
were injected into the calibrated chambers using Hamilton Glass Microsyringes. Before and after each 
injection, syringes were cleaned 2 times with 70% ethanol and 2 times with ultrapure ddH2O and tips were 
dried with a kim wipe. 
Mitochondrial Enrichment. Crude mitochondria were isolated from freshly dissected cortical tissues 
isolated from 6-month-old female WT and CLU-KO mice (n=5 animals/genotype) using the commercially 
available Abcam Mitochondria Isolation Kit with slight modifications. Briefly, cortical tissues were 
extracted as previously described and minced in ice cold kit provided mitochondrial isolation buffer 
supplemented with PPI. Minced brain tissue was transferred to a 2 mL kit provided glass dounce 
homogenizer and homogenized using 5 strokes with pestle A and 5 strokes with pestle B. The homogenate 
was transferred into 2 2.0 mL centrifuge tubes and the volume was brought to 2 mL with kit provided 
mitochondrial isolation buffer. Tubes were inverted 5 times slowly to mix the homogenates and then 
centrifuged at 1,000 x g for 10 min at 4°C (Spin 1). The supernatant from Spin 1 was pipetted into new 2.0 
mL centrifuge tubes, filled to 2 mL with mitochondrial isolation buffer and re-centrifuged (Spin 2). The 
supernatant from Spin 2 was removed and placed into 2 new 2.0 mL centrifuge tubes. Tubes were filled to 
2 mL with mitochondrial isolation buffer and centrifuge at 5,500 x g for 15 min at 4°C (Spin 3). The 
supernatant from Spin 3 was removed and saved in a new 2.0 mL centrifuge tube as the Cytosolic Fraction 
while the remaining pellets were gently resuspended in a total volume of 200 µL Mitochondrial Respiration 
Buffer. Protein concentration was then determined using a BCA Assay as previously described.   
Mitochondrial Substrates and Inhibitors. A complete list of mitochondrial substrates and inhibitors, 
solution concentrations (working and final), volumes added, as well as substrate/inhibitor targets in 






Table 11. Components Used in the Analysis of Mitochondrial Respiratory Capacity. Compounds, 
solution concentrations, and compound targets used in Mitochondrial Respirometry studies.     
Mitochondrial Respirometry Information – Substrates and Inhibitors 
Compound Working [] Volume added (µL) Final [] Target 
Pyruvate 1 M 20 10 mM Complex I 
Malate 0.4 M 10 2 mM Complex I 
Succinate 1 M 10 5 mM Complex II 
ADP 200 mM 20 2 mM Complex V 
Oligomycin 1 mg/mL 2 2 µM ATP Synthase 
FCCP 100 µM 2.5 125 nM Membrane 
Rotenone 1 mM 2 2 µM Complex I 
Antimycin A 1 mM 2 2 µM Complex III 
 
 
Analysis of Mitochondrial Respirometry. 300 µg crude mitochondria from WT and CLU-KO mice were 
injected into the 2 chambers of the Oxygraph using glass syringes. Following injection mitochondria were 
incubated in chambers for 8-10 minutes to allow for the generation of a stable baseline respiration reading. 
After baseline respiration was established substrates an inhibitors were injected into each chamber 
simultaneously in the following order: Pyruvate, Malate, Succinate, ADP, Oligomycin, FCCP, Rotenone, 
Antimycin A. For a complete list of volumes and concentrations of each compound, see Table 10. Following 
each injection, mitochondria were incubated for 2-3 min or until a stable signal was observed in the 
chamber. Following the completion of Antimycin A injection, mitochondria lysate was aspirated from the 
chamber and the chambers were cleaned and calibrated as previously described.  
Glutamate Dehydrogenase Activity Assay. Glutamate dehydrogenase-mediated production of NADH 
was assessed in 30 µg crude mitochondria isolated from female WT and mCLU-KO mice using the 
commercially available Glutamate Dehydrogenase Activity Assay (Sigma, Cat. #MAK099) as per the 
manufacturer’s instructions. Data were analyzed using Student’s T-test (n=4 animals/genotype)  
Data Analysis. The respirometry protocol used in these experiments allows for the visualization of baseline 
respiration, oxidative phosphorylation, maximal respiratory response, and non-mitochondrial respiration. 
OROBOROS DatLab software was used to calculate the OCRs and to generate the graphical representation 




performed by polarographic oxygen sensors which monitor alterations in oxygen concentration over time. 
The negative time derivative is accordingly corrected for instrumental background and resulting data is  
 
displayed simultaneously from both chambers in real time as oxygen flux. For comparisons between WT 
and CLU-KO, average values are collected from 25 time points approximately 1-2 min  following the 
addition of each compound (this is generally the time when a stable signal was generated) Averages for 
each compound taken from 3-4 independent comparisons are analyzed via Student’s T-Test where * = 
p<0.05 when compared to WT control .  
 
Sex Hormone Work. The following 6 methods paragraphs (Sex Hormone and Receptor-specific agonist 
Treatment - DNA Amplification and Calculation of Fold Enrichment) pertain to experimental studies 
presented in Chapter 3 (Sections 3.1-3.2) of the Results in this dissertation. All experiments, 
troubleshooting, and analyses in these studies were performed by me. 
Sex Hormone and Receptor-specific Agonist/Inhibitor Treatment. Following 7 days in vitro (DIV), 
primary cortical neurons were treated with customized concentrations of progesterone (P4, 10 nM – 100 




Table 12. Genomatix Software Promoter Analysis. Predicted estrogen receptor response elements 
in the human CLU promoter.      
nM,), or 2,3-bis(4-Hydroxyphenyl) propionitrile (DPN, 100 nM,) for 48 hours. For inhibitor studies, DIV 
7 neurons were pre-treated for 2 hours with 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-
piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP, 1 µM) followed by 48 hours co-treatment 
with MPP plus E2. Following treatment, neurons were harvested via Whole Cell Protein Extraction with 
NPER as indicated and analyzed for CLU expression via SDS-PAGE  
In silico Promoter Analysis. To determine (a) if the CLU promoter to contains one or more un-defined 
estrogen response elements (EREs) and (b) if the possibility of CLU EREs is consistent across species, 
human and murine CLU promoters were analyzed using Genomatix MatInspector Software. The 
Genomatix software is a tool that utilizes a large library of matrix descriptions for transcription factor 
binding sites to locate matches in DNA sequences. For more detailed information regarding the features of 




Generation of ER-specific primers. Genomatix promoter analysis indicated the presence of three possible 
EREs within the human and murine CLU promoters (Figure 6): two ER-alpha binding sites (1 proximal 
and 1 distal) and 1 ER-beta binding site. Information regarding the specific location and strand of predicted 
EREs is provided in Table 13. Using this information, we performed a search of all known CLU promoter 
analyses and were able to identify a previously published primer set that amplifies the region adjacent to 
the predicted ER-alpha binding site. The individual primers were developed by IDT and are deemed ER-
alpha Forward (5’ – CGGTGCTGCACCGGCCC - 3’) and ER-alpha Reverse (5’ – 
Genomatix MatInspector Promoter Analysis of Human CLU 















CTGGGAGGCGCCGTATTTATAGC - 3’). Following a search of the literature, we were unable to identify 
a primer set that would amplify the region with a predicted ER-beta binding site, therefore we purchased a 
primer set from Qiagen that amplifies a region approximately 100 bp downstream from the predicted ER-
beta binding site (EpiTect ChIP qPCR Primer Assay For Human CLU, NM_203339.1 (-)01Kb 
(GPH1026114(-)01A)) 
Crosslinking and Analysis of Sheared Chromatin. Human bone-marrow-derived neuroblastoma cells 
(SH-SY5Y) were treated with either Vehicle, DPN (100 nM), or PPT (100 nM) for 48 hours. Following 
treatment, DNA and protein were crosslinked for 15 min in 10 mL ChIP Fixing Solution at RT. Crosslinking 
was neutralized by the addition of 0.125 M Glycine followed by one wash in 1X PBS. Cells were scraped 
in 10 mL 1X PBS and pelleted at 1,000 x g for 5 min at RT. Cell pellets were re-suspended in 1 mL ChIP 
Lysis Buffer supplemented with protease and phosphatase inhibitors and sonicated 5 x 30 sec with 10 sec 
breaks between each sonication. Following sonication, insoluble particles were cleared from the lysate by 
centrifuging at 17,000 x g for 45 min at 4°C. To ensure the proper size of sheared chromatin fragments, 10 
μL sheared chromatin was purified by reversal of crosslinking (see below) and run on a 2% agarose gel.  In 
addition, purified DNA from treated and un-treated SH-SY5Y cells was utilized to validate the previously 
described ER-specific primers to ensure (a) primers amplified CLU DNA in SH-SY5Y cells and (b) sex 
hormone treatment did not significantly alter CLU amplification (Figure 7) 
Chromatin Immunoprecipitation. Following the analysis of sheared chromatin and validation of ER-
specific primers the remaining supernatants from the chromatin clearing step were pipetted into sterile 
microcentrifuge tubes and 10% of each supernatant (100 µL of each sample) was removed and combined 
into 1 tube to represent the total chromatin (Input). 100 µL of each sample was then placed into 3 separate 
tubes (300 µL total sample/tube) to represent the Positive ChIP Control, Antibody Control, and Total 
Negative Control. For experimental IP’s the remaining 600 µL of Vehicle-treated sample was divided into 
two tubes and 300 µL of either PPT- or DPN-treated DNA was added to 2 new tubes to represent 7 




Antibody Control, Total Negative Control, ERα-untreated, ERα-treated, ERβ-untreated, ERβ-treated. 700 
µL of ChIP Dilution Buffer supplemented with protease and phosphatase inhibitors was added to each tube 
to make the final volume 1 mL. 2 µg of antibody was added to the appropriate tubes as indicated here: 
rabbit monoclonal anti-Tri-Methyl-Histone H3 (Lys4) (Positive ChIP Control), non-specific Rabbit IgG 
(Antibody Control), no antibody (Total Negative Control), rabbit polyclonal anti-Estrogen Receptor alpha 
(ERα-untreated, ERα-treated) or rabbit polyclonal anti-Estrogen Receptor beta (ERβ-untreated, ERβ-
treated). Antibody-protein-DNA complexes were allowed to form via rotation overnight at 4 °C. Antibody 
complexes were pulled out of solution using 30 µL pre-washed Protein G Dynabeads for 4 hours with 
rotation at 4 °C. Following immunoprecipitation, beads were washed 2 x 1 mL with Low Salt Wash Buffer, 
2 x 1 mL High Salt Wash Buffer, 1 x 1 mL Lithium Chloride Wash Buffer, and 5 x 1 mL TE Wash Buffer. 
Protein-DNA complexes were eluted from beads by vortexing beads for 15 min in 200 µL ChIP Elution 
Buffer. The first eluate was removed and the elution process was repeated a second time with the eluates 
being combined into 1 sample (400 µL/tube) at the end of the elution process.  
Reverse Crosslinking and DNA Purification. To reverse protein-DNA crosslinks, 5M NaCl was added 
to a final concentration of 0.3M to each of the immunoprecipitated eluates and total chromatin (Input) 
sample and incubated at 65 °C for 16 hours. Following incubation, samples were removed and briefly 
centrifuged to bring the liquid to the bottom of the tube. 100 µL 5X Protein Digestion Buffer (50 mM Tris-
HCl, pH 7.5, 25 mM EDTA, 1.25% SDS) and 40 µg/mL proteinase K (1.25 µL/tube from 20 mg/mL stock 
solution) was added to each tube and samples were incubated for 1 hr at 45 °C to digest residual proteins. 
1 volume of Phenol:Chloroform:Isoamyl Alcohol 25:24:1 was added to each tube and tubes were vortexed 
on max speed for 15 seconds followed by centrifugation at 17,000 x g for 10 min at 4 °C. 450 µL of the 
upper aqueous phase was pipetted into a new tube and mixed with 2 volumes 100% Ethanol and ½ volume 
7.5 M NH4OAc. Samples were mixed by tapping and incubated at -80°C for 1 hour. Following incubation, 
precipitated DNA was pelleted via centrifugation at 17,000 x g for 30 min. The supernatant was carefully 




Table 13. Calculation of Fold Enrichment. Example of calculation of Fold Enrichment used in 
Chromatin Immunoprecipitation studies      
for 10 min. Tubes were carefully inverted to remove ethanol and a P200 pipette tip was used to remove 
large drops of residual liquid. Samples were incubated at 37 °C for 10 min and pellets were re-suspended 
in 12 µL (immunoprecipitated samples) or 120 µL (input sample) ultrapure ddH2O. 
DNA Amplification and Calculation of Fold Enrichment. rt-QPCR was used to amplify any 
immunoprecipitated CLU using the previously described ER-alpha and ER-beta primer sets with 2 µL 
purified DNA/reaction. To quantify the results, Fold Enrichment was calculated using a two-step process. 
In step 1, Data was adjusted for non-specific Fold Enrichment by subtracting the Mock (IgG) Ct value from 
the Experimental (ER-alpha or ER-beta) Ct value (ΔCt): ((CtExperimental)-(CtIgG)). The Fold enrichment was 
then calculated using the following equation 2-(ΔCt). An example of the full procedure is provided in Table 
14. 
ChIP Fold Enrichment Calculations 
  Step 1 Step 2 
Group Ct Value ΔCt Value 2-(ΔCt) 
Mock (IgG) 33.6 0 1 
+ control 29.5 -4.1 17.14838 
ER-beta - Vehicle 33.3 -0.3 1.231144 







Results and Conclusions 
Chapter 1: Clusterin Protein Isoforms in the Brain 
1.1. Multiple CLU Protein Isoforms with Distinct Subcellular Localizations are Expressed in 
Rodent Brain Tissue. 
Previous studies indicate that CLU mRNA is expressed in multiple tissue types with predominant 
CLU mRNA expression in the brain or CNS (Connor et al., 2001; de Silva, Harmony, et al., 1990). 
However, as robust mRNA levels do not necessarily translate to robust protein levels, CLU protein 
levels were first examined in a panel of rodent tissues known to contain CLU mRNA. Brain, liver, 
heart, lung, and reproductive tissues harvested from 6-month-old male and female C57Bl/6 mice 




immunoreactive bands throughout each tissue tested. Specifically, a whole brain lysate reveals 5 
individual CLU immunoreactive bands: CLU_150 kDa, CLU_49 kDa, CLU_45 kDa, CLU_39 
kDa, and CLU_36 kDa (Figure 1.1.1).  
Parallel to findings in previously published mRNA studies, CLU immunoreactive bands are also 
detected in peripheral tissues, however, the CLU protein expression profile of the peripheral tissues 
tested appears to differ from that of brain tissue. Moreover, while fold change in protein expression 
levels cannot be calculated from this study, it is noteworthy to mention that the tissue-specific 
CLU protein expression profiles do not differ between male and female animals (data not shown). 
These data validate early northern blot analyses and confirm the robust expression of CLU protein 
isoforms in brain tissue. To determine if CLU protein isoforms are expressed in a brain region-
specific manner, CLU protein expression was examined within in the hippocampus, hypothalamus, 
cortex, and cerebellum of 6-month-old WT mice. Consistent with the CLU protein expression 
profile observed in a whole brain tissue lysate, 5 CLU immunoreactive bands of similar molecular 
weight were observed in each brain region analyzed indicating that CLU protein isoforms are 
expressed throughout most of the brain (data not shown). As the brain-specific protein expression 
profiles do not differ between sexes and LOAD more frequently impacts the female population, 
female animals were utilized throughout the remainder of this dissertation. Moreover, as the CLU 
protein expression profile previously detected in a whole brain lysate appears to be consistent 
across all brain regions tested and LOAD predominantly impacts the hippocampus and cortex, the 
remaining studies in this dissertation were performed primarily in cortical and hippocampal tissues 
and/or primary cortical neurons or astrocytes.  
Several controversies currently exist concerning basic molecular properties of brain CLU protein 








presence of a nuclear CLU protein isoform and the cell type from which brain CLU is derived or 
produced (neurons, glia, etc.…). In order to determine if CLU immunoreactivity is localized to a 
specific brain cell-type, 40 μM thick rodent brain sections were co-stained for CLU 
immunoreactivity (red) and the neuronal marker MAP2 (green) or the astrocytic marker, GFAP 
and visualized using confocal microscopy. The data indicate robust CLU immunoreactivity 
localized to both the nuclear and cytosolic compartment of neurons (Figure 1.1.2.) with low CLU 
immunoreactivity present in GFAP-positive astrocytes (data not shown). These data indicate that 
CLU immunoreactivity is expressed in neurons in at least 2 subcellular compartments (nucleus 
and cytosol). Collectively, these data and findings from the currently available literature suggest 
that CLU protein isoforms are localized to both astrocytes and neurons and thus provide rationale 
for investigating the expression and localization of CLU protein isoforms within both cell types. 
Moreover, the presence of CLU in both the nucleus and cytosol suggests that CLU protein isoforms 
may have distinct subcellular localizations.  
In order to determine if the previously observed CLU protein isoforms are localized to specific 
subcellular compartments, freshly harvested cortical tissues were subjected to a Three Buffer 
Tissue Fractionation. This technique allows for the release of cytosolic proteins, organelle-encased 
proteins, and nuclear proteins in a successive manner. Harvested samples were analyzed via 
immunoblotting and probed with 3 different CLU antibodies (H-330, M-18, and B-5) to obtain a 
full CLU protein expression profile. To confirm isolation of indicated fractions, western blots were 
stripped and re-probed for fraction-specific markers: Grp75 (mitochondria), Calnexin and 
Calreticulin (Endoplasmic reticulum), Lamin C (Nucleus), and Gapdh (cytosol). Following 
acquisition, immunoblots were stained with TMB to confirm molecular weights of identified CLU 








cytosolic fraction (CLU_150 kDa, CLU_70 kDa, CLU_60 kDa, CLU_53 kDa, CLU_45 kDa, 
CLU_39 kDa, and CLU_36 kDa), 8 CLU immunoreactive bands in the organelle fraction 
(CLU_150 kDa, CLU_70 kDa, CLU_60 kDa, CLU_53 kDa, CLU_49 kDa, CLU_45 kDa, 
CLU_39 kDa, and CLU_36 kDa), and 2 CLU immunoreactive bands specific to the nuclear 
fraction (CLU_80 kDa and CLU_68 kDa) of cortical tissue (Figure 1.1.3.). It is important to note 
that several other CLU immunoreactive bands are detected in the nuclear fraction (CLU_150 kDa, 
CLU_70 kDa, CLU_60 kDa, CLU_39 kDa, and CLU_36 kDa), however, analysis with fraction-
specific markers suggests that these CLU-immunoreactive bands are likely due to the minor 
amounts of cytosolic and/or organelle contamination in the nuclear fraction. These data suggest 
that CLU protein isoforms have different subcellular targets.  
To further investigate the expression and distribution of CLU protein isoforms in the brain and to 
examine brain cell type-specific CLU protein expression profiles, primary cortical and 
hippocampal neurons or  astrocytes were isolated from embryonic rat pups, grown to maturity, 
harvested via subcellular fractionation and analyzed for CLU protein isoform expression using two 
different CLU antibodies (H-330 and M-18). Similar to that of tissue samples, the purity of isolated 
fractions was analyzed using fraction-specific biochemical markers (Gapdh (cytosol), Grp75 
(mitochondria), and Lamin A (nucleus)) and the isolation of indicated cell types was confirmed 
via immunocytochemistry using cell-type specific antibodies (MAP2 (neurons), GFAP 
(astrocytes)). Analysis of primary neurons indicates the expression of 4 CLU immunoreactive 
bands in the cytosolic fraction (CLU_150 kDa, CLU_80 kDa, CLU_49 kDa, and CLU_60 kDa), 
2 CLU immunoreactive bands in the crude mitochondrial fraction (containing ER and 
mitochondria; CLU_80 kDa, and CLU_68 kDa), and 4 CLU immunoreactive bands in the nuclear 





(Figure 1.1.4.). In contrast, analysis of astrocyte fractions indicates the expression of 5 CLU 
immunoreactive bands in the cytosolic fraction (CLU_70 kDa, CLU_60 kDa, CLU_49 kDa, 





fraction (CLU_60 kDa, CLU_45 kDa, and CLU_39 kDa) and 3 CLU immunoreactive bands in the 
nuclear fraction (CLU_150 kDa, CLU_80 kDa, and CLU_60 kDa) of primary astrocytes (Figure 
1.1.5.). Collectively, the CLU immunoreactive bands detected in the astrocytic and neuronal 




tissue fractionation. These data also reveal similarities and differences between the protein 
expression profiles. For instance, astrocytes do not appear to express the CLU_53 kDa or the 
CLU_68 kDa CLU immunoreactive bands while neurons do not appear to express CLU_70 kDa, 
CLU_45 kDa, or CLU_39 kDa CLU immunoreactive bands. Moreover, while all CLU 
immunoreactive bands are detected, the subcellular localization appears to differ between adult 
cortical tissue and embryonic neurons/astrocytes. For instance, CLU_49 kDa is specifically 
localized to the organelle fraction of adult cortical tissue whereas in embryonic neurons and 
astrocytes the CLU_49 kDa band appears to be exclusively localized to the cytosolic fraction. In 
addition, the CLU_45 kDa band, which is robustly expressed in adult cortex in the organelle 
fraction, is expressed at relatively minute levels in astrocytes. Moreover, the CLU_68 kDa and 
CLU_80 kDa bands, which appear exclusively in the nuclear fraction of adult cortex, are localized 
to both the nucleus and the crude mitochondrial fraction of embryonic neurons (CLU_68 kDa), 
and the cytosol and crude mitochondrial fraction of neurons (CLU_80 kDa). These discrepancies 
may be the result of differing harvest methods/buffers between the two fractionation protocols, 
however, another plausible explanation may be that CLU protein isoforms are redistributed as 
needed with aging to differing subcellular compartments.  
A comparison of CLU immunoreactivity in the cortical organelle fractions isolated from postnatal 
day 1 mouse pups (PN1) and 1-month-old mice (30D) supports this idea. The data indicate that 
both CLU_49 kDa and CLU_45 kDa protein expression is either undetectable or detected at 
extremely low levels in the organelle fraction of PN1 mice. However, the levels of both CLU 
protein isoforms are dramatically increased in the organelle fractions of 30D mice suggesting that 






1.2. Characterization and Validation of CLU Antibodies using Three Biochemical 
Approaches 
As 10 different CLU immunoreactive bands were detected in rodent cortex using polyclonal 
antibodies, it is extremely necessary to ensure that the previously observed immunoreactive bands 
are not the result of antibody artifact. Therefore, the antibodies utilized in the studies presented 
herein were validated using 3 independent biochemical methods: WT vs. CLU-KO mice, CLU-
deficient tissue from a WT animal, and siRNA-mediated knockdown of CLU protein isoforms in 





1.2.1. Biochemical Validation of CLU Antibodies Using CLU-KO Mice.  
The CLU-KO mouse model was generated in 2001 by McLaughlin et al. as a model to study 
autoimmune myocarditis. Initial characterization indicates a phenotypically normal mouse 
exhibiting normal organ morphology and reproductive capabilities. Characterization of CLU 
protein expression in heart, liver, and serum indicates the expression of a 70 kDa CLU protein 
isoform in WT animals that is deficient in CLU-KO animals demonstrating the successful 
generation of the mutant animal. In order to demonstrate antibody specificity, cortical tissues were 
isolated from 6-month-old female WT and CLU-KO mice and probed for CLU protein expression 
using the 3 previously utilized CLU antibodies. WT cortical tissues express all previously observed 





only 2 bands are absent in the CLU-KO brain when compared to WT brain: CLU_60 kDa and 
CLU_39 kDa (Figure 1.2.1.1., middle panel, red lettering).  
Furthermore, while not quantifiable in this study, the expression level of 4 CLU immunoreactive 
bands appears in increase in CLU-KO cortical tissue (Figure 1.2.1.1., blue lettering). While this 
data does indicate the specificity of both the CLU_39 kDa and CLU_60 kDa band, it also generates 
several questions regarding the validity of the “CLU-KO” mouse model, which is repeatedly 
described as an animal that is devoid of CLU mRNA and protein expression. Given the possibility 
of multiple CLU mRNAs being generated during transcription and the genomic location of the 
cassette used to generate CLU-deficient (Exon 2 and part of Exon 1) animals by McLaughlin and 
colleagues, these data suggest that (a) CLU-KO mice are deficient in only 1 CLU mRNA isoform, 
(b) the deficient mRNA isoform translates to CLU_39 kDa, CLU_60 kDa (our data), and CLU_70 
kDa (previous literature), (c) at least 1 alternative CLU mRNA does exist and is transcribed 
beginning in Exon 3 and (d) the remaining CLU immunoreactive bands may be translated from 
alternative CLU mRNAs.   
To confirm the presence of alternative CLU mRNAs in CLU-KO mice, two primer sets were 
generated to amplify specific exons and thus represent different CLU mRNA transcripts. The 
mCLU primer set amplifies Exon 2-containing mRNA and thus represents the mature/secreted 
CLU protein isoform known to be translated from mRNA Isoform 2. The tCLU primer set 
amplifies Exon 3 – Exon 4 and, as the sequence of CLU is identical from Exons 3-9, recognizes 
all CLU mRNAs (Figure 1.2.1.2., Upper Panel). RNA was then isolated from cortical tissues 
harvested from age-matched female WT and CLU-KO mice and rt-qPCR was used to amplify 
Exon 2-containing (mCLU) and Exon 3-4-containing (tCLU) CLU mRNAs as well as β-actin 




mRNA and Exon 3-4-containing (purple line) mRNA in WT brain tissue. As expected Exon 2-
containing mRNA was not present in the CLU-KO animal model, however, rt-qPCR does amplify  
 
Exon 3-4-containing mRNA in CLU-KO cortex indicating that CLU-KO mice do express CLU 
mRNA (Figure 1.2.1.2. Lower Panel). Collectively, this information indicates that the previously 
advertised CLU-KO mouse model is in fact an mRNA Isoform 2-deficient, or mCLU-deficient, 




To confirm these findings, a colony of WT, Heterozygous, and CLU-KO mice were generated 
(genotype confirmed, see methods section) and cortical tissues harvested from each genotype were  
 
analyzed for CLU protein expression using an antibody that specifically detects mCLU protein 
expression. As expected heterozygous animals expressed 50% less CLU_39 kDa and CLU_60 
kDa than WT controls while CLU-KO animals expressed no CLU_39 kDa or CLU_60 kDa. These 
data confirm that the CLU-KO mouse model is deficient in only mCLU and will therefore be 
referred to as mCLU-KO mouse model throughout the remainder of the dissertation.  
1.2.2. Biochemical Validation of CLU Antibodies Using CLU-deficient Tissue.  
As the mCLU-KO mouse model provides information regarding only those isoforms derived from 
Exon 2-containing mRNA, further efforts were made to validate the specificity of CLU antibodies. 
A review of the literature indicates that adult mouse pancreas should be devoid of any CLU mRNA 




from a 9-month-old female mouse and analyzed for CLU immunoreactivity using the rabbit anti-
CLU H-330 antibody. To confirm the presence of protein in both lanes, the blot was stripped and 
re-probed for Gapdh immunoreactivity. In addition, following acquisition, blots were stained with 
TMB to confirm molecular weight. As expected, WT brain tissue expressed the previously 
observed CLU immunoreactive bands: CLU_150 kDa, CLU_49 kDa, CLU_39 kDa, and CLU_36 
kDa. However, examination of pancreatic tissues indicates a complete lack of CLU 





indicating that these 4 CLU immunoreactive bands are indeed CLU protein isoforms (Figure 
1.2.2.1.). 
1.2.3. siRNA-mediated Knockdown of CLU Protein Isoforms in Mouse Neuroblastoma 
Cells. 
 As data from the previous 2 sections indicate the specificity of CLU_150 kDa, CLU_60 kDa, 





characterization indicate the specificity of CLU_70 kDa, siRNA-mediated knockdown was 
utilized to confirm the specificity of the remaining identified CLU immunoreactive bands. 
However, before siRNA studies could be initiated, it was necessary to identify a brain-derived cell 
line with a CLU protein expression pattern that mimicked that of adult brain. Several cell lines 
were cultured, fractioned, and analyzed for CLU protein expression (HT22, SH-SY5Y, and Neuro-
2a) and the mouse neuroblastoma cell line (Neuro-2a) was selected based on the protein expression 
pattern. Briefly, analysis of neuro-2a cell fractions indicate the expression of 7 CLU 
immunoreactive bands including the CLU immunoreactive bands of interest: CLU_80 kDa,  
 
CLU_68 kDa, and CLU_45 kDa (Figure 1.2.3.1., red lettering). Following the identification of a 
suitable cell line, increasing concentrations of Exon 2- and Exon 3-targeting siRNA were 




CLU immunoreactivity. Gapdh-targeting siRNA was used as a positive control for transfection 
and a non-specific scramble siRNA was utilized as a negative control. Both positive and negative 
controls were transfected for the same amount of time at the same concentrations as the Exon 2- 
and 3-targeting siRNA. Analysis of Gapdh expression indicates that transfection of siRNA was 
efficient at low concentrations (25-50 pMol). Transfection of Exon 2-targeting siRNA resulted in 
an approximate 30% decrease in CLU_68 kDa expression with no observable decrease in CLU_68 
kDa expression in cells transfected with equal concentrations of scramble siRNA (Figure 1.2.3.2.). 
In addition, transfection of Exon 3-targeting siRNA resulted in an approximate 60-65% decrease 
in CLU_45 kDa expression (Figure 1.2.3.2., right panel). These data indicate that CLU_68 kDa 
and CLU_45 kDa are both specific CLU protein isoforms. Taken together, the analysis of adult 
cortical tissues, embryonic neurons and embryonic astrocytes as well as the antibody validation 
data indicate that CLU is expressed in rodent brain as 10 different protein isoforms derived from 
at least 2 CLU mRNAs beginning at Exon 2 and Exon 3, respectively.  
1.3. N-linked Glycosylation of at least 2 Individual CLU Precursor Proteins is Responsible 
for the Generation of Several Higher Molecular Weight Protein Isoforms 
Previous data from Harmony and colleagues indicate that CLU protein isoforms are modified by 
N-linked glycosylation. Specifically, a 70 kDa CLU isoform was found to be modified by sialic 
acid-containing complex glycans while a 58 kDa CLU protein isoform was found to be modified 
by high mannose glycans (Burkey et al., 1991). Our protein analysis has identified numerous 
higher molecular weight CLU protein isoforms that are translated from at least 2 CLU mRNAs 
Moreover, calculation of relative molecular weights using the ExPasy MW Calculator indicates 
that a CLU mRNAs containing Exons 2-9 and Exons 3-9 would resolve at approximately 49.4 kDa 




(CLU_150 kDa, CLU_80 kDa, CLU_70 kDa, CLU_68 kDa, CLU_60 kDa, and CLU_53 kDa) are 
glycosylated intermediates of the CLU_49 kDa pre-protein while CLU_45 kDa would remain un-
glycosylated.   
 
In order to test this hypothesis, fractions isolated from cortical tissues, primary neurons, and 
primary astrocytes were enzymatically digested with 2 different endoglycosidases that non-
specifically cleave all N-linked glycans (PNGase F) or specifically cleave high mannose glycans 




Schematic 11. Prior to initiation of experimental reactions, the activity of both PNGase F and Endo 
H was confirmed using an in vitro deglycosylation reaction with RNase B as a substrate. As 
expected, RNase B, which is modified by 1 high mannose glycan, is reduced in size by 
approximately 4 kDa in the presence of both endoglycosidases demonstrating that both enzymes 
are active (Figure 1.3.1). Deglycosylation reactions were performed using the exact experimental 
paradigm used for deglycosylation of RNase B and all control samples were subjected to the same 
reaction conditions as the experimental groups including denaturing and incubation. Controls and 
deglycosylated samples were reduced and analyzed for CLU immunoreactivity using CLU H-330 
and CLU M-18.  
 
Immunoblot analysis of PNGase F and Endo H treated lysates with CLU M-18 indicates the 
reduction of CLU_60 kDa to CLU_49 kDa in cortical tissue, neurons and astrocytes indicating 




CLU_39 kDa is reduced in size to CLU_25 kDa by PNGase F, but not Endo H, indicating that 
CLU_39 kDa is modified by either complex or hybrid glycans (Figure 1.3.2). These data are 
consistent with previous reports which demonstrate that the deglycosylation of the of un-dimerized 
mCLU subunits results in the generation a de-glycosylated 25 kDa CLU immunoreactive band. 
Therefore, these data combined with the absence of CLU_39 kDa in  
 
mCLU-KO mice indicate that CLU_39 kDa, and by extension CLU_36 kDa, represent the un-
dimerized glycosylated alpha and beta subunits of the mCLU isoform. Moreover, as CLU_60 kDa 
was also deficient in mCLU-KO mice and CLU_60 is de-glycosylated to CLU_49 kDa, these data 
suggest that CLU_49 kDa and CLU_60 kDa represent the un-glycosylated pre-protein and a high 
mannose glycosylated intermediate of the mCLU protein isoform. In addition, a side-by-side 




express CLU_39 kDa suggesting that primary neurons do not express the secreted mCLU isoform 
(Figure 1.3.2, middle and right panels). These data are consistent with early reports suggesting that 
the predominant amount secreted mCLU in the brain is derived from astrocytes. However, as 
primary neurons do express both CLU_49 kDa and CLU_60 kDa it appears that CLU protein 
isoforms generated from Exon 2-containing mRNA may possess intracellular functions.  
In addition to observing deglycosylation of CLU_60 kDa and CLU_39 kDa, the data demonstrate 
that 3 CLU protein isoforms observed in astrocytes remained unaffected by either 
endoglycosidase: CLU_45 kDa, CLU_70 kDa, and CLU_80 kDa (Figure 1.3.3, right panel). These 
data both support and refute our initial hypothesis. Based on calculated molecular weights, it was 
anticipated that the CLU_45 kDa band would be unaffected by endoglycosidases. Thus it is highly 
probable that the CLU_45 kDa isoform is indeed translated from a CLU mRNA isoform containing 
Exons 3-9 and thus lacks the ER targeting sequence located in Exon 2. However, the inability to 
deglycosylate the CLU_80 kDa protein isoform by either endoglycosidase is puzzling as validation 
of CLU antibodies reveals that the CLU_80 kDa isoform is not the result of antibody artifact. 
Moreover, the inability to deglycosylate the CLU_70 kDa band conflicts with previous reports that 
show a direct effect on a 70 kDa CLU protein isoform by both PNGase F and Neuraminidase 
(cleaves terminal sialic acids on complex glycans) (Burkey et al., 1991). Two possible reasons for 
a lack of deglycosylation in specific CLU immunoreactive bands may be used to explain these 
findings: (1) the protein lysate used was not fully denatured in the 10 min step prior to enzyme 
addition thus allowing steric hindrance to inhibit or slow the removal of glycans and (2) alternative 
post-translational modifications are responsible for generating CLU immunoreactive higher 
molecular weight isoforms that are unresponsive to N-linked endoglycosidases. As the CLU amino 




this large shift in MW would be the addition of SUMO or ubiquitin motifs. In support of this 
notion, reports have indicated that CLU is targeted by ubiquitin in the cytosol. Moreover, an 
examination of the CLU amino acid sequence reveals 5 possible SUMO consensus motifs 
(SUMOplot™ Analysis Program), 1 of which lies 3 amino acids away from an N-linked 
glycosylation consensus motif. However, despite these findings, more research will be needed to 
definitively identify alternative PTMs on CLU protein isoforms.  
In addition to these data, treatment of an astrocytic lysate results in the generation of the CLU_53 
kDa CLU protein isoform: an isoform not previously observed in our astrocyte fractionation 
(Figure 1.1.5). This band, which is detected by the H-330 antibody, appears to correspond to a 
decrease in the presence of the CLU_68 kDa band, which is detected by the M-18 antibody, 
following treatment with endoglycosidases. These data along with the fact that CLU_53 kDa, 
CLU_68 kDa and CLU_80 kDa appear to increase in mCLU-KO brain (Figure 1.2.1.1.) suggests 
that the CLU_53 kDa band may represent an alternative CLU pre-protein translated from a third 
CLU mRNA transcript which is glycosylated to form CLU_68 kDa and/or CLU_80 kDa. 
Collectively, these data indicate that some, but not all, higher molecular weight CLU protein 
isoforms represent glycosylated CLU protein isoforms with CLU_60 kDa representing a high 
mannose glycan and CLU_36-39 kDa representing the mCLU subunits modified by complex 
glycans. Furthermore, these data suggest that 3 CLU pre-proteins, which are unaffected by 
reducing conditions or endoglycosidase treatment, exist in rodent brain: CLU_49 kDa (Exons 2-
9), CLU_45 kDa (Exons 3-9), and CLU_53 kDa (mRNA isoform unknown).   
1.4. Acute Neurotoxicity Results in a Rapid and Significant Alteration in Intracellular 




Having generated a solid understanding of the expression and localization of brain, neuronal, and 
astrocytic CLU protein isoforms in physiological conditions, the next investigated the impact of 
cellular stress on CLU protein isoform expression and localization? Several publications have 
indicated that CLU mRNA and/or extracellular mCLU protein expression is up-regulated in 
response to cellular stress (Han et al., 2001; Schreiber et al., 1993) (N. Kim, Han, et al., 2012). 
However, at this time, it is unclear how cellular stress or cytotoxic insult impacts individual brain 
CLU protein isoforms, especially intracellular CLU protein isoforms. As neurons are extremely 
prone to cytotoxic insult and appear to express an abundance of intracellular CLU protein isoforms, 
neurons were used as a model to investigate this question. Moreover, as neurons express high 
levels of the N-methyl-D-aspartate (NMDA) receptor and are thus especially prone to 
excitotoxicity, supra-physiological glutamate exposure was utilized as a model of acute toxicity. 
Primary neurons were isolated and cultured for 7 days at which time neurons were exposed to 100 
µM glutamate for 5 min as indicated. Following glutamate exposure, neurons were incubated for 
indicated time points and harvested via subcellular fractionation. Our previous analysis of neuronal 
fractions indicates that neurons do not express robust CLU protein immunoreactivity in the crude 
mitochondrial fraction, therefore, while all fractions were analyzed for CLU immunoreactivity, 
only the nuclear and cytosolic fractions are presented here. To confirm neurotoxic insult, lactate 
dehydrogenase levels were measured in the culture medium prior to subcellular fractionation 
(Figure 1.4.1., Lower right panel). The data indicate a rapid and significant alteration in the levels 
of several neuronal CLU protein isoforms. Specifically, the CLU_49 kDa protein isoform is 
significantly increased in the cytosol with increasing levels of toxicity (Figure 1.4.1.). This 
increase appears to be specific to the CLU_49 kDa isoform as analysis of fractions with CLU B5 








significantly decreased in the cytosolic fraction with increasing levels of toxicity. In addition, we 
observe a toxicity-dependent decrease in the cytosolic CLU_150 kDa band, though this isoform 
was not quantified in this study. Similar to cytosolic CLU_80 kDa, analysis of the nuclear fraction 
indicates a significant decrease in the levels of CLU_68 kDa with increased toxicity (Figure 
1.4.1.). The increase in CLU_49 kDa is consistent with previous reports indicating an increase in 
CLU mRNA (Rozovsky et al., 1994) and at least one CLU protein isoform (Messmer-Joudrier, 
Sagot, Mattenberger, James, & Kato, 1996) following glutamate exposure. Though it is unclear 
which protein isoform was up-regulated in this previous study, it appears that the upregulation of 
both CLU mRNA (previous work) and CLU_49 kDa (our work) represents the upregulation of the 
Exon 2-containing mRNA and the resulting protein isoforms following excitotoxicity. As mCLU 
is known to be rapidly induced following cellular stress, these data are in line with the currently 
available literature. However, as we have previously observed a lack of the mCLU subunits 
(CLU_39 kDa and CLU_36 kDa) in primary neurons, it appears that the up-regulation of CLU_49 
kDa following glutamate exposure does not serve the purpose of generating additional secreted 
extracellular CLU. Rather it appears that up-regulation of CLU_49 kDa following neurotoxic 
challenge serves an intracellular purpose, though that purpose is currently unknown.  
The toxicity-dependent disappearance of several CLU protein isoforms following glutamate 
challenge also provides interesting insight into intracellular CLU protein isoform distribution 
following stress. We originally postulated that the decrease in CLU_80 kDa expression resulted 
from the increased secretion of CLU_80 kDa into the culture medium. However, analysis of the 
culture medium does not indicate the secretion of an 80 kDa band (data not shown) suggesting that 
increased secretion is not the reason for significantly decreased CLU_80 kDa expression. We next 




kDa (55% increase at 6 hrs) expression was due to a toxicity-induced reversal or inhibition of N-
linked glycosylation. However, our previous deglycosylation studies indicate that CLU_80 kDa is 
unaffected by endoglycosidase treatment in both neurons (Figure 1.3.3.) and astrocytes (Figure 
1.3.2.). Furthermore, the significant decrease in CLU_68 kDa expression (73% decrease at 6 hrs) 
cannot be attributed to reversal of deglycosylation as CLU_68 kDa was not found to be de-
glycosylated to CLU_49 kDa in our previous studies. A third possibility does arise to explain the 
decrease in CLU protein isoforms with cellular stress. Previous reports have indicated that, in some 
instances, cellular stress results in the cytosolic localization of certain CLU protein isoforms 
followed by proteasomal targeting and degradation. As the CLU protein isoforms in question are 
not being secreted or deglycosylated and cytosolic CLU protein isoforms have been shown to be 
targeted by ubiquitin via several proposed E3 ligases (Nizard et al., 2007; Fang et al., 2012) we 
hypothesize that the decline in CLU_80 kDa and CLU_68 kDa protein expression following 
toxicity is the result in ubiquitin-mediated proteasomal degradation of intracellular CLU protein 
isoforms, though more work is required to prove this hypothesis.  
1.5. Interim Discussion  and Working Hypothesis 
In this chapter, we have demonstrated that rodent brain expresses 10 different CLU protein 
isoforms translated from at least 2 CLU mRNAs. These CLU protein isoforms are localized to 
defined subcellular compartments in both adult tissues as well as embryonic neurons and astrocytes 
and respond differently to acute neurotoxicity. Furthermore, we find that the distribution of some 
CLU protein isoforms is altered by aging in young mice. Collectively, the widespread distribution 
of CLU protein isoforms in brain tissue, astrocytes, and neurons suggests that CLU protein 
isoforms regulate some aspect of brain homeostasis. Moreover, the observation of age-mediated 




the developed adult brain. In addition, we observe two key differences in the CLU expression 
profile between brain cell types. First, fractionation and deglycosylation studies indicate that 
CLU_39 kDa, which is known to be one of the 2 un-dimerized mCLU subunits, is expressed in 
embryonic astrocytes, but not neurons. These data suggest that astrocytes are capable of generating 
and secreting mCLU, whereas neurons are not. This observation is consistent with the previously 
held notion that astrocytes are primarily responsible for the secretion of extracellular CLU in the 
brain (Cordero-Llana et al., 2011; Zwain et al., 1994). Secondly, while neurons do not express the 





from the same CLU pre-protein as the mCLU subunits (CLU_49 kDa). These data suggest that 
while secreted mCLU is not generated in neurons, an intracellular form of mCLU derived from 
Exon 2-containing mRNA may be generated.  
Based on the data presented in this chapter, we hypothesize that the myriad of observed higher 
molecular weight CLU protein isoforms are generated via PTM and/or proteolytic processing of 
three CLU pre-proteins. These pre-proteins are translated from 3 individual CLU mRNA isoforms 
(Schematic 12.) and translate to the CLU_53 kDa, CLU_49 kDa, and CLU_45 kDa protein 
isoforms. Transcription of CLU mRNA Isoform 1b would be initiated at the ATG in Exon 3 and 
would generate an mRNA isoform containing exons 3-9. The translated pre-protein from this 
proposed mRNA isoform would be 417 amino acids long with a predicted MW of 45 kDa and 
would retain the NLS in exon 3 but lack the ER targeting sequence in exon 2. Based on our 
fractionation and glycosylation studies, we hypothesize that CLU mRNA Isoform 1b is transcribed 
in the nucleus, translated on cytosolic ribosomes to the CLU_45 kDa isoform and is then imported 
into the mitochondria through an unknown import mechanism (Schematic 13). The localization of 
CLU_45 kDa to the mitochondria has been confirmed in this dissertation and will be discussed in 
detail in Chapter 2.  
Transcription of CLU mRNA Isoform 2 would be initiated at the ATG in Exon 2 and would 
generate an mRNA isoform containing exons 2-9. The translated pre-protein from this proposed 
mRNA isoform would be 449 amino acids long with a predicted MW of 49 kDa and would retain 
the NLS in Exon 3 and the ER targeting sequence in Exon 2. We propose that, similar to CLU 
mRNA isoform 1a and 1b, CLU mRNA Isoform 2 is transcribed in the nucleus and translated on 
cytosolic ribosomes for form a 449 amino acid long pre-protein (CLU_49 kDa). CLU_49 kDa is 





including CLU_60 kDa (high mannose glycan), CLU_70 kDa (complex glycan, data not from this 
study), and CLU_39 kDa (complex glycan). Following glycosylation of CLU_49 kDa in astrocytes 
CLU_39 kDa and CLU_36 kDa are heterodimerized and secreted into the extracellular space. In 
neurons, CLU_60 kDa and CLU_70 kDa are translocated to the cytosolic fraction to regulate 
internal neuronal homeostasis (Schematic 14) 
Transcription of CLU mRNA Isoform 1 is initiated at the ATG in Exon 1 and would generate an 
mRNA isoform containing all 9 exons. The translated pre-protein from this proposed mRNA 
isoform would be approximately 491 amino acids long with a predicted MW of 54 kDa and would 
possess both the ER targeting sequence in Exon 2 and the NLS in Exon 3. Based on protein isoform 







cytosolic ribosomes to form CLU_53 kDa and glycosylated in the ER/Golgi pathway to form the 
CLU_68 kDa isoform which is then translocated to the nuclear compartment (Figure 1.5.2.). The 
generation of a third CLU mRNA isoform is supported by recently generated data indicating the 
presence of Exon 1-containing mRNA in WT rodent brain. Moreover, CLU_68 kDa is observed 
in the ER-containing crude mitochondrial and nuclear fractions of primary neurons and the 
exclusive localization of CLU_68 kDa to the nucleus of adult cortex. Moreover, when examining 
CLU protein expression in mCLU-KO mice, one observation was a similar increase in the 




certain CLU transcripts may be upregulated in the absence of mCLU, but also that CLU_53 kDa 
and CLU_68 kDa may be inter-related. In addition, CLU_53 kDa remains unaltered by 
endoglycosidase treatment and the addition of reducing agents during immunoblot analysis thus 





Chapter 2. CLU in Brain Mitochondria 
 
2.1. Identification of a Mitochondria-Localized CLU Protein Isoform 
Preliminary analyses of brain CLU immunoreactivity in cortical neurons indicated diffuse punctate 
CLU staining that appears to overlap with Mitotracker staining in the soma and dendrites of 
primary neurons (Figure 2.1.1.). As multiple CLU protein isoforms were found to be localized to 
the mitochondria and ER-containing organelle fraction of adult cortical tissue, embryonic neurons 
and embryonic astrocytes (Chapter 1, Section 1), and at least one CLU protein isoform is not 
targeted to the ER, the question of a brain mitochondria-localized CLU protein isoform arises. To 
answer this question, pure mitochondria were isolated from 5-7-month-old female cortical tissues  
 
and analyzed via immunoblotting with 2 CLU antibodies. To verify the purity of mitochondrial 
samples, blots were also probed for cytosolic and ER contamination using Gapdh, calnexin, and 





As expected, the whole tissue lysate expressed all previously observed CLU protein isoforms 




expressed (CLU_68 kDa, CLU_60 kDa, CLU_49 kDa, CLU_45 kDa, and CLU_36-39 kDa). 
However, analysis of pure mitochondria, which is characterized as a mitochondrial sample free of 
ER and cytosolic contamination, indicates the expression of only 1 CLU protein isoform in all sets 
of samples analyzed: CLU_45 kDa. These data indicate that CLU_45 kDa is localized to brain 
mitochondria. As we hypothesized that the CLU_45 kDa band is translated from Exon 3-9 
containing mRNA into a pre-protein that remains unaffected by glycosylation (Chapter 1), crude 
and pure mitochondria were treated with the previously utilized endoglycosidases to determine 
whether the MW of the newly identified mitochondrial CLU isoform would be impacted by 





deglycosylated by both PNGase F and Endo H to form the CLU_49 kDa band while the CLU_39 
kDa band is deglycosylated into the CLU_25 kDa band. Moreover, in support of our hypothesis, 
the CLU_45 kDa band, which is expressed more robustly in the pure mitochondrial sample remains 
unaffected by endoglycosidase treatment (Figure 2.1.3.). These data support our proposed 
hypothesis for the generation and mitochondrial targeting of the non-glycosylated CLU protein 
isoform.    
To further investigate the localization of CLU_45 kDa to brain mitochondria, pure mitochondria 
were isolated as previously described and subjected to a Digitonin Mitochondria Sub-fractionation. 
This technique, which results in the opening of the intermembrane space and the matrix in a 
successive manner, allows for the identification of submitochondrial localization by matching the 
expression changes of a protein of interest (i.e. CLU_45 kDa) with that of fraction-specific 
mitochondrial markers: VDAC (outer mitochondrial membrane), Cytochrome C (intermembrane 
space), CoxIV (inner mitochondrial membrane), and Grp75 (matrix). The data indicate prominent 
CLU_45 kDa immunoreactivity in the control group with an approximate 32% decrease in 
CLU_45 kDa expression occurring between the control-treated group and the 0.1%-treated group. 
CLU_45 kDa immunoreactivity decreases slightly between the 0.1%- and 0.2%-treated groups 
(~8% decrease) followed by a sharp decline in the 0.3%-treated group that results in the loss of 
94% of mitochondrial CLU_45 kDa expression. This expression profile change does not match 
that of VDAC which shows the largest change in expression between the 0.1%- and 0.2%-treated 
groups (80% - 32%) with relatively little change occurring between the 0.2%- and 0.3%-treated 
groups (32% - 28%). In addition, CLU_45 kDa expression changes do not match the expression 




indicate that nCLU is not localized to the outer mitochondrial membrane or the intermembrane 
space.  
 
Upon examination of CoxIV immunoreactivity we observe a certain degree of similarity between 
CLU_45 kDa and CoxIV expression changes with increasing concentrations of Digitonin. 
Specifically, both CLU_45 kDa and CoxIV decline sharply between the control group and the 




0.2%-treated groups (8% and 1% change). However, unlike CLU_45 kDa expression, which 
decreases by 54% between the 0.2%- and 0.3%-treated groups, 0.3% Digitonin treatment results 
in only a 10% decrease in CoxIV immunoreactivity when compared to the 0.2%-treated group  
suggesting that CLU_45 kDa is localized to the mitoplast but not specifically to the inner 
mitochondrial membrane. Similar to that of CoxIV, Grp75 immunoreactivity decreases sharply 
between the control and 0.1%-treated group (67% decline) with only a slight decrease occurring 
between the 0.1%- and 0.2%-treated groups (7% decline). However, unlike CoxIV expression, 
0.3% Digitonin treatment results in a much steeper decline in Grp75 expression resulting in an 
expression pattern that is nearly identical to that of CLU_45 kDa. These data indicate that CLU_45 
kDa is localized to the matrix of rodent brain mitochondria. To confirm the similar release patterns 
of CLU_45 kDa and Grp75, the supernatant fraction was examined via immunoblot analysis. As 
indicated in Figure 2.1.4. (Lower Panel), no CLU_45 kDa or Grp75 immunoreactivity is detected 
in either the control or the 0.1% Digitonin-treated groups with only minute protein 
immunoreactivity in the 0.2%-treated group. However, 0.3% Digitonin treatment, which results in 
the major loss of retained Grp75 and CLU_45 kDa (Figure 2.1.4. Upper Panel), results in a similar 
increase in protein immunoreactivity in the supernatant (Figure 2.1.4. Lower Panel) further 
suggesting that CLU_45 kDa is released from the mitochondrial matrix in a manner that is similar 
to that of soluble matrix proteins. Collectively, these data indicate that the CLU_45 kDa protein 
isoform is localized to the mitochondrial matrix of rodent brain mitochondria. To our knowledge 
this is the first report to indicate the localization of an intracellular CLU protein isoform to brain 
mitochondria. However, despite the novelty of this finding, the localization of a CLU protein 
isoform to brain mitochondria generates several important questions that are currently unanswered. 




it is unclear how this protein isoform is imported into the mitochondrial matrix. Second, as we are 
the first to identify mitochondrial CLU localization, the purpose of mitochondrial CLU (i.e. the 
function of CLU_45 kDa in the mitochondria) it is currently unclear. As the bulk of matrix proteins 
are dedicated to either the generation of ATP or the synthesis of mitochondrial encoded genes, it 
is possible that CLU in some way modulates mitochondrial energy production or regulates some 
aspect of central dogma in the mitochondrial matrix; however more research is needed to confirm 
this hypothesis.     
 
2.2. Identification of CLU Mitochondrial Interacting Partners 
 
 
2.2.1. Co-immunoprecipitation of Overexpressed Human CLU in Neuro-2a Cells 
 
As both the import mechanism and function of mitochondrial CLU are currently unknown, we 






CLU_45 kDa protein interacting partners. Full length human clusterin cDNA fused to a C-terminal 





for 96 hrs prior to harvest. Following incubation, cells were harvested via whole cell protein 
extraction and overexpression of the hCLU construct was confirmed via immunoblotting with an 
antibody raised to the v5 epitope tag (Figure 2.2.1.1.). Following confirmation of overexpressed 
hCLU, the transfection was repeated on a larger scale and following incubation, crude 
mitochondria were isolated and resuspended in native, non-reducing buffer that does not disrupt 
protein-protein interactions. CLU and 
its interacting partners were then co-
immunoprecipitated using rabbit-anti-
V5 (IP) with control 
immunoprecipitations being performed 
under the same experimental 
parameters using non-specific rabbit 
IgG (IgG). Samples were eluted in 
reducing denaturing conditions and 
10% of the eluted sample was analyzed 
for CLU immunoreactivity to confirm 
successful immunoprecipitation of 
overexpressed hCLU (Figure 2.2.1.2.). 
The remaining portion of the eluate was 
then resolved in via SDS-PAGE and the 
resulting gel was stained with SYPRO 
Ruby and visualized using UV light 




specific to the experimental IP lane (18 in total, red boxes) were excised, digested, and sent for 
protein identification using Multi-dimensional Protein Identification Technology (MUD-Pit). A 
representation of the entire mitochondrial Co-IP is included in Figure Schematic 16.  
Of the 18 samples that were submitted, >100 mitochondrial proteins were identified as possible 
CLU interacting partners within the following parameters: (a) minimum of 2 unique peptides, (b) 
a minimum of 2% coverage, (c) a molecular weight corresponding to molecular weight of excised 
band, and (d) a protein FDR confidence level above medium (5%). A full list of identified proteins 
with corresponding UniPROT ID numbers, % coverage, and number of unique peptides identified 
is included in Table 15. 
Identified Mitochondrial Proteins 
UniProt Description % Cov # Peptides 
P38647 Stress-70 protein, mitochondrial [OS=Mus musculus] 41 26 
Q91VR2 
ATP synthase subunit gamma, mitochondrial [OS=Mus 
musculus] 33 10 
Q99LC5 
Electron transfer flavoprotein subunit alpha, mitochondrial 
[OS=Mus musculus] 32 8 
P58059 28S ribosomal protein S21, mitochondrial [OS=Mus musculus] 31 2 
Q9CRB9 MICOS complex subunit MIC19 [OS=Mus musculus] 27 9 
Q9Z2I8 
Succinate--CoA ligase [GDP-forming] subunit beta, 
mitochondrial [OS=Mus musculus] 27 7 
Q60932 
voltage-dependent anion-selective channel protein 1 [OS=Mus 
musculus] 27 6 
Q922W5 
Pyrroline-5-carboxylate reductase 1, mitochondrial [OS=Mus 
musculus] 26 5 
Q9DCX2 ATP synthase subunit d, mitochondrial [OS=Mus musculus] 25 5 
Q60930 
Voltage-dependent anion-selective channel protein 2 [OS=Mus 
musculus] 25 6 
Q9DB15 39S ribosomal protein L12, mitochondrial [OS=Mus musculus] 24 2 
Q8QZT1 
Acetyl-CoA acetyltransferase, mitochondrial [OS=Mus 
musculus] 24 6 
Q9DB20 ATP synthase subunit O, mitochondrial [OS=Mus musculus] 24 4 
Q9DCC8 
Mitochondrial import receptor subunit TOM20 homolog 
[OS=Mus musculus] 23 2 
Q925I1 
ATPase family AAA domain-containing protein 3 [OS=Mus 





Mitochondrial import inner membrane translocase subunit 
tim23 [OS=Mus musculus] 22 3 
Q9D1I6 39S ribosomal protein L14, mitochondrial [OS=Mus musculus] 19 2 
Q99L13 
3-hydroxyisobutyrate dehydrogenase, mitochondrial [OS=Mus 
musculus] 19 4 
Q8BK72 28S ribosomal protein S27, mitochondrial [OS=Mus musculus] 18 8 
Q8CD10 calcium uptake protein 2, mitochondrial [OS=Mus musculus] 18 6 
Q9CQN7 39S ribosomal protein L41, mitochondrial [OS=Mus musculus] 17 2 
Q8BFR5 elongation factor Tu, mitochondrial [OS=Mus musculus] 17 5 
Q8R03 
Peptidyl-tRNA hydrolase ICT1, mitochondrial [OS=Mus 
musculus] 17 3 
Q8VEM8 Phosphate carrier protein, mitochondrial [OS=Mus musculus] 17 5 
P35486 
Pyruvate dehydrogenase E1 component subunit alpha, somatic 
form, mitochondrial 17 5 
Q9Z2I9 
Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial [OS=Mus musculus] 17 5 
Q8VE22 28S ribosomal protein S23, mitochondrial [OS=Mus musculus] 16 2 
Q8JZS9 39S ribosomal protein L48, mitochondrial [OS=Mus musculus] 16 3 
Q8BH59 
Calcium-binding mitochondrial carrier protein Aralar1 
[OS=Mus musculus] 16 9 
P48758 Carbonyl reductase [NADPH] 1 [OS=Mus musculus] 16 2 
Q9CQN1 heat shock protein 75 kDa, mitochondrial [OS=Mus musculus] 16 8 
O35857 
Mitochondrial import inner membrane translocase subunit 
TIM44 [OS=Mus musculus] 16 6 
Q9CQF0 39S ribosomal protein L11, mitochondrial [OS=Mus musculus] 15 2 
Q8R4U6 DNA topoisomerase I, mitochondrial [OS=Mus musculus] 15 7 
Q99M87 
DnaJ homolog subfamily A member 3, mitochondrial 
[OS=Mus musculus] 15 5 
P54071 
Isocitrate dehydrogenase [NADP], mitochondrial [OS=Mus 
musculus] 15 5 
Q91VN4 MICOS complex subunit mic25 [OS=Mus musculus] 15 4 
Q9CZW5 
Mitochondrial import receptor subunit TOM70 [OS=Mus 
musculus] 15 5 
Q9D773 39S ribosomal protein L2, mitochondrial [OS=Mus musculus] 14 2 
Q9DB77 
Cytochrome b-c1 complex subunit 2, mitochondrial [OS=Mus 
musculus] 14 5 
Q99MR8 
Methylcrotonoyl-CoA carboxylase subunit alpha, 
mitochondrial [OS=Mus musculus] 14 6 
Q9DC70 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, 
mitochondrial [OS=Mus musculus] 14 3 
Q9D338 39S ribosomal protein L19, mitochondrial [OS=Mus musculus] 13 2 
Q9CQ06 39S ribosomal protein L24, mitochondrial [OS=Mus musculus] 13 2 
O08756 
3-hydroxyacyl-CoA dehydrogenase type-2 [OS=Mus 
musculus] 13 2 





glyceraldehyde-3-phosphate dehydrogenase [OS=Mus 
musculus] 13 3 
Q91VD9 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial [OS=Mus musculus] 13 7 
Q8K2B3 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial [OS=Mus musculus] 13 6 
Q8CIW5 Twinkle protein, mitochondrial [OS=Mus musculus] 13 5 
Q924T2 28S ribosomal protein S2, mitochondrial [OS=Mus musculus] 12 2 
Q80X85 28S ribosomal protein S7, mitochondrial [OS=Mus musculus] 12 2 
Q8K2Y7 39S ribosomal protein L47, mitochondrial [OS=Mus musculus] 12 3 
Q03265 
ATP synthase subunit alpha, mitochondrial [OS=Mus 
musculus] 12 5 
Q3UMR5 Calcium uniporter protein, mitochondrial [OS=Mus musculus] 12 3 
Q8CGK3 Lon protease homolog, mitochondrial [OS=Mus musculus] 12 8 
Q9D6J6 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial [OS=Mus musculus] 12 2 
P40630 Transcription factor A, mitochondrial [OS=Mus musculus] 12 2 
Q8BMS1 
Trifunctional enzyme subunit alpha, mitochondrial [OS=Mus 
musculus] 12 7 
Q60931 
Voltage-dependent anion-selective channel protein 3 [OS=Mus 
musculus] 12 3 
Q9DC71 28S ribosomal protein S15, mitochondrial [OS=Mus musculus] 11 3 
Q9CQQ7 
ATP synthase F(0) complex subunit B1, mitochondrial 
[OS=Mus musculus] 11 3 
Q9D3D9 
ATP synthase subunit delta, mitochondrial [OS=Mus 
musculus] 11 2 
Q9D0M3 
Cytochrome c1, heme protein, mitochondrial [OS=Mus 
musculus] 11 2 
Q8BGX2 
Mitochondrial import inner membrane translocase subunit 
Tim29 [OS=Mus musculus] 11 2 
Q9CPR5 39S ribosomal protein L15, mitochondrial [OS=Mus musculus] 10 2 
P56480 ATP synthase subunit beta, mitochondrial [OS=Mus musculus] 10 3 
O35658 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial [OS=Mus musculus] 10 2 
Q8CAQ8 MICOS complex subunit Mic60 [OS=Mus musculus] 10 6 
Q3V3R1 
Monofunctional C1-tetrahydrofolate synthase, mitochondrial 
[OS=Mus musculus] 10 8 
Q9DCN2 NADH-cytochrome b5 reductase 3 [OS=Mus musculus] 10 3 
Q9D1B9 39S ribosomal protein L28, mitochondrial [OS=Mus musculus] 9 2 
Q9CZU6 citrate synthase, mitochondrial [OS=Mus musculus] 9 3 
Q91WD5 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial [OS=Mus musculus] 9 3 
Q8BH04 
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial 
[OS=Mus musculus] 9 4 
Q9D051 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial [OS=Mus musculus] 9 2 





Leucine-rich PPR motif-containing protein, mitochondrial 
[OS=Mus musculus] 8 12 
Q8CGK3 Lon protease homolog, mitochondrial [OS=Mus musculus] 8 6 
Q78IK4 MICOS complex subunit MIC27 [OS=Mus musculus] 8 2 
Q8K009 
Mitochondrial 10-formyltetrahydrofolate dehydrogenase 
[OS=Mus musculus] 8 5 
Q9WUM5 
Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, 
mitochondrial [OS=Mus musculus] 8 2 
Q80XN0 
D-beta-hydroxybutyrate dehydrogenase, mitochondrial 
[OS=Mus musculus] 7 2 
Q9D6M3 Mitochondrial glutamate carrier 1 [OS=Mus musculus] 7 2 
Q99KI0 Aconitate hydratase, mitochondrial [OS=Mus musculus] 6 3 
Q9ESW4 Acylglycerol kinase, mitochondrial [OS=Mus musculus] 6 2 
Q9Z0X1 
Apoptosis-inducing factor 1, mitochondrial [OS=Mus 
musculus] 6 3 
P45952 
medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial [OS=Mus musculus] 6 2 
Q62167 ATP-dependent RNA helicase DDX3X [OS=Mus musculus] 5 3 
D3Z7P3 
Glutaminase kidney isoform, mitochondrial [OS=Mus 
musculus] 5 2 
Q8K411 Presequence protease, mitochondrial [OS=Mus musculus] 5 5 
Q9JHS4 
ATP-dependent Clp protease ATP-binding subunit clpX-like, 
mitochondrial [OS=Mus musculus] 4 2 
Q8BMF4 
Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex 4 2 
Q60597 
Isoform 3 of 2-oxoglutarate dehydrogenase, mitochondrial 
[OS=Mus musculus] 4 3 
O08715 
Isoform 4 of A-kinase anchor protein 1, mitochondrial 
[OS=Mus musculus] 4 2 
Q91ZA3 
Propionyl-CoA carboxylase alpha chain, mitochondrial 
[OS=Mus musculus] 4 2 
Q91V92 ATP-citrate synthase [OS=Mus musculus] 3 3 
P52825 
Carnitine O-palmitoyltransferase 2, mitochondrial [OS=Mus 
musculus] 3 2 
Q8BKF1 
DNA-directed RNA polymerase, mitochondrial [OS=Mus 
musculus] 3 2 
Q61941 NAD(P) transhydrogenase, mitochondrial [OS=Mus musculus] 3 3 
Q05920 pyruvate carboxylase, mitochondrial [OS=Mus musculus] 2 2 
 
Table 15. A Complete List of Proteins Identified Following Co-immunoprecipitation of 
Overexpressed Human CLU. Proteins are listed with accompanying UniPROT identification 
numbers as well as the total percent coverage and number of unique peptides identified for each 
protein. List is organized by percent coverage (highest at top) and is divided into two groups: >10% 









2.2.2. Bioinformatic Analysis of Identified Proteins.  
In order to identify possible enriched mitochondrial processes/pathways in the list of possible 
interacting proteins, bioinformatics analysis was performed using the STRING Pathway Analysis 
Software. STRING is a database containing experimental and curated protein-protein interaction 
data from over 9 million proteins derived from 2000+ organisms (Szklarczyk et al., 2015). 
Parameters for generation of the protein interaction network were restricted to include only those 
interactions verified by direct experimental evidence or textmining. The minimum required 
interaction score was set to medium confidence and proteins that were not connected to the protein 
interaction network were removed from the group. The resulting protein interaction network 
indicates the enrichment (over 10 proteins) of 4 mitochondrial processes (Figure 2.2.2.1): (1) TCA 
Cycle (red circles): Cs (Q9CZU6), Aco2 (Q99KI0), Idh2 (P54071), Pdha1 (P35486), Pck2 
(Q8BH04), Pdhb (Q9D051), Dlat (Q8BMF4), Sdha (Q8K2B3), Suclg1 (Q9WUM5), Sucla2 
(Q9Z2I9), Suclg2 (Q9Z2I8), Acly (Q91V92), Pcx (Q05920), and Ogdh (Q60597) (2) Oxidative 
Phosphorylation (green circles): Atp5f1 (Q9CQQ7), Atp5a1 (Q03265), Atp5b (P56480), Atp5h 
(Q9DCX2), Atp5d (Q9D3D9), Atp5c1 (Q91VR2), Atp5o (Q9DB20), Ndufv2 (Q9D6J6), Ndufs2 
(Q91WD5), Ndufs7 (Q9DC70), Ndufs1 (Q91VD9), Uqcrc2 (Q9DB77) and Cyc1 (Q9D0M3) (3) 
Mitochondrial Transport (blue circles): Chchd3 (Q9CRB9), Chchd6 (Q91VN4), Apool 
(Q78IK4), Immt (Q8CAQ8), Timm 44 (O35857), Tomm20 (Q9DCC8), Tomm70a (Q9CZW5), 
Tim23 (Q9WTQ8), Vdac1 (Q60932), Vdac 2 (Q60930), and Vdac 3 (Q60931) and (4) 
Mitochondrial Ribosomes (purple circles):  Mrps15 (Q9DC71), Mrps2 (Q924T2), Mrps21 
(P58059), Mrps23 (Q8VE22), Mrps27 (Q8BK72), Mrps7 (Q80X85), Mrpl11 (Q9CQF0), Mrpl12 
(Q9DB15), Mrpl14 (Q9D1I6), Mrpl15 (Q9CPR5), Mrpl19 (Q9D338), Mrpl2 (Q9D773), Mrpl24 










Mrpl48 (Q8JZS9). These data indicate that mitochondrial CLU, in some way, interacts with energy 
metabolism and gene expression pathways in the mitochondrial matrix. In addition, the interaction 




the unknown matrix-targeted import pathway of CLU_45 kDa. However, as it is not feasible for 
CLU_45 kDa to independently interact with over 100 mitochondrial proteins, enriched 
mitochondrial protein groups were individually analyzed to determine possible proteins that could 
mediate the interaction between CLU_45 kDa and the identified mitochondrial pathways. These 
analyses reveal that the mitochondrial chaperone protein Hspa9 (Grp75), one of the most 
abundantly identified proteins (46% coverage, 26 unique peptides), may be a central mediator of 
multiple CLU protein interactions. Specifically, Grp75 (Figure 2.2.2.2., black circle) interacts with 
key mediators of Mitochondrial Transport (Tomm20, Tomm70a, Timm44, Timm23), components 
of mitochondrial ATP synthase (Atp5a1 and Atp5b), and TCA cycle-associated proteins Acly and 
Sdha (Figure 2.2.2.2.). These data suggest that CLU_45 kDa may interact with mitochondrial 
energy metabolism pathways via direct interaction with the mitochondrial matrix protein, Grp75 
and thus provide rationale for further investigation of a CLU_45 kDa-Grp75 protein interaction in 
rodent brain.  
 
In addition to Grp75, several components of the MICOS complex, a complex of proteins that 
regulate the stability of the cristae and, in coordination with the SAM complex, form the 
mitochondrial intermembrane space bridging (MIB) complex, were also identified. Specifically, 
MICOS 19 (27% coverage, 9 unique peptides) and MICOS 60 (10 coverage, 6 unique peptides),  
which have been identified as the “most important subunits of the MIB complex” were identified.  
Analysis of protein-protein interactions indicates that Immt (MICOS 60) interacts with 
components of mitochondrial protein import machinery (Tomm20 and Timm23) as well as two 
subunits of the mitochondrial ATP synthase (Atp5c1 and Atp5a1) and thus highlights MICOS 60 





2.2.3. Secondary Confirmation of Selected Interacting Partners 
It is well-established that overexpression of proteins in vitro may result in artificial protein-protein 
interactions. Therefore, to ensure the identified proteins are in fact CLU interacting partners, 
secondary confirmation was performed on select proteins using crude brain mitochondria isolated 
from adult mice under physiological conditions. Based on bioinformatics analysis, Grp75 and 
MICOS 60 were selected for secondary confirmation. Crude brain mitochondria were isolated and 
subjected to co-immunoprecipitation using antibodies against MICOS 60, and Grp75, and CLU 
followed by immunoblot analysis for CLU or Grp75. The data indicate an interaction between 
CLU_45 kDa and MICOS 60 in vivo (Figure 2.2.3.1.). Interestingly, an interaction between 
CLU_39 kDa and MICOS 60 was also detected suggesting that both mitochondrial and mature 
CLU interact with the MICOS complex. In contrast, immunoprecipitation with a Grp75 antibody 
reveals no interaction between CLU_45 kDa and Grp75 (data not shown). The lack of in vivo 
interaction between CLU_45 kDa and Grp75 was confirmed by performing the reverse co-
immunoprecipitation using goat anti-CLU M-18 (Figure 2.2.3.3.). As expected, Grp75 





mitochondria. However, co-immunoprecipitation with MICOS 60 does result in the detection of 
Grp75 immunoreactivity indicating that Grp75, while not interacting with CLU_45 kDa, does 
interact with the MICOS complex in rodent brain (Figure 2.2.3.2.). While were unable to detect 
an interaction between CLU_45 kDa and Grp75 in vivo, the fact that MICOS 60 interacts with 
both Grp75 and CLU_45 kDa under physiological conditions solidifies MICOS 60 as a novel 
mitochondrial CLU interacting partner and indicates that the proteins identified as possible CLU 
interacting partners are likely not due to the generation of false positives. 
 
In addition to confirming an interaction between CLU_45 kDa and MICOS 60, we also chose to 
confirm the possible interaction between mitochondrial CLU and key components of the 
mitochondrial protein import machinery. As the CLU amino acid sequence contains no canonical 




confirmation of protein interaction in vivo. Co-immunoprecipitation was performed using 
Tomm70 or MICOS 60 (positive control for CLU_45 kDa interaction) and eluates were probed  
 
for CLU immunoreactivity. The data indicate similar CLU immunoreactivity profiles between 
samples immunoprecipitated with MICOS 60 and Tomm70 indicating that CLU_45 kDa interacts 
with Tomm70 in rodent brain mitochondria (Figure 2.2.3.3.)  
 
2.3. Assessment of Mitochondrial Respiratory Function in mCLU-deficient Mice 
As CLU_45 kDa was found to be localized in the mitochondrial matrix and bioinformatics 
analyses indicate an interaction between CLU and proteins involved in ATP Synthesis and 





mitochondrial respiration using High Resolution Respirometry (OROBOROS Oxygraph 2K). As 
a model of CLU_45 kDa deficiency is not currently available and Exon 2-containing mRNA is 
most predominant in brain tissue, the previously characterized mCLU-KO mouse model was 
utilized in these experiments. Crude intact mitochondria were isolated from age/sex-matched WT 
and mCLU-KO mice by differential centrifugation. Protein concentration was determined and 300 
µg crude mitochondria was analyzed for mitochondrial respiration. As this study is the first to 
examine mitochondrial respirometry capacity in mCLU-KO mice, the overall process of oxidative 
phosphorylation rather than the activity of individual respiratory complexes was analyzed. 
Baseline respiration was established following the injection of mitochondria and pre-determined 
concentrations of substrates/compounds/inhibitors were added in the following order at the 
indicated concentrations (Table 12): pyruvate (Pyr, Complex I), malate (Mal, Complex I), 
succinate (Succ, Complex II), ADP (Complex V), Oligomycin (Oligo, ATP synthase inhibitor), 
FCCP (Uncoupler), Rotenone (Rot, Complex I inhibitor), and Antimycin A (AA, Complex III 









female mCLU-deficient animals when compared to WT controls. Specifically, mCLU-KO mice 
exhibit significantly decreased baseline respiration (WT = 10.19, mCLU-KO = 6.14, 39.75% 
decrease), as well as significantly lower average OCR values following administration of the 
complex I substrate Pyruvate (WT = 27.11, mCLU-KO = 20.15, 25.68% decrease), the complex 
II substrate Succinate (WT = 91.72, mCLU-KO = 67.64, 26.26% decrease), the complex V 
substrate ADP (WT = 226.24, mCLU-KO = 174.47, 22.89% decrease), the ATP synthase inhibitor 




uncoupler FCCP (WT = 203.19, mCLU-KO = 151.17, 25.61% decrease). These data indicate 
significantly reduced respiratory capacity in female brain mitochondria and confirm that brain 
CLU is, in part, associated with or involved in brain bioenergetics in adult female brain.  
While protein concentration was determined just prior to respirometry, it is possible that the 
observed decrease in OCR between WT and mCLU-KO mice could be attributed to a difference 
in the total mitochondrial mass within each crude mitochondrial sample. Therefore, the expression 
levels of mitochondrial proteins were evaluated to confirm equal loading of mitochondria in each 
chamber. Specifically, VDAC and GRP75 protein expression levels were examined in aliquots of 
the same samples used for high resolution respirometry. In addition, as mCLU deficiency is known 
to result in elevated mitochondrial Bax expression (Trougakos et al., 2009; H. Zhang et al., 2005), 
Bax protein levels were utilized as a positive control. Hsp60 which is present in the mitochondria 
and known to be unaffected by CLU deficiency (Chaiwatanasirikul & Sala, 2011) was utilized as 
a loading control in this experiment. Despite an approximate 25% decrease in mitochondrial 
respirometry, the data indicate a significant increase in the expression of both Grp75 and Bax in 
mCLU-KO mitochondria with no change 
occurring in the expression of VDAC 
(Figure 2.3.2.). In addition, the activity of 
glutamate dehydrogenase, an enzyme 
that converts glutamate to α-ketoglutarate 
in the mitochondrial matrix, was not 
significantly altered between WT and 
mCLU-KO mitochondrial samples 




indicate that the observed decline in brain mitochondrial respiration is in fact due to decreased 
respiratory capacity and not a decrease in total mitochondrial mass.  
2.4. Interim Discussion  and Working Hypothesis 
In this chapter we have identified a novel mitochondria-localized CLU protein isoform (CLU_45 kDa, 
Figure 2.1.1) and determined the submitochondrial localization of this isoform to be the mitochondrial 
matrix (Figure 2.1.2.). In addition, overexpression and co-immunoprecipitation studies indicate that 
mitochondrial CLU interacts with some aspect of mitochondrial energy metabolism, gene expression, 
and/or mitochondrial protein import (Section 2.2) and high resolution respirometry confirms that young 
female mCLU-deficient mice exhibit significantly reduced brain mitochondrial respiration. These data 
provide insight into two relatively important questions pertaining to CLU in the mitochondria: How is the 
CLU_45 kDa protein isoform transported into the mitochondria? and What is the function of mitochondria-
localized CLU? 
2.4.1. CLU in the Mitochondria: A Possible Protein Import Mechanism.  
The protein import pathway for matrix-localized proteins has been relatively well characterized in 
numerous articles. Briefly, proteins synthesized with a mitochondrial targeting sequence or a mitochondrial 
pre-sequence are recognized by the translocase of outer membrane (TOM) complex, transported through 
the outer mitochondrial membrane (OMM), recognized by the translocase of inner membrane 
23/presequence translocase-associated motor (TIM23/PAM) complex, and transported into the 
mitochondrial matrix where mitochondrial chaperone proteins assist in the proper folding of matrix-targeted 
proteins. However, as the amino acid sequence that comprises CLU does not contain a mitochondrial 
targeting sequence, the mechanism of protein recognition and import has been somewhat elusive until now. 
Our studies indicate that CLU_45 kDa interacts with a key component of the TOM complex in normal 
female rodent brain: Tomm70. Moreover, though not yet confirmed in physiological conditions, 




Tomm20 and Tomm70 have been shown to preferentially target specific structural domains of 
mitochondrial targeted proteins this presents two possible protein import pathways for mitochondrial  
 
CLU (Schematic 17). Tomm70 has been shown to preferentially recognize internal hydrophobic import 
sequences (Wu & Sha, 2006). As CLU is known to contain 2 intrinsically disordered molten globule 
domains that are exposed to the cytosolic surface and facilitate hydrophobic interactions (Bailey et al., 
2001; Dunker et al., 2001), it is possible that Tomm70 recognizes CLU_45 kDa through one or both of 
these hydrophobic domains. In contrast, Tomm20 has been shown to preferentially recognize positively 
charged amphipathic α-helices within a protein’s secondary structure (Abe et al., 2000; Saitoh et al., 2007). 
Therefore, a second possible mechanism would be that Tomm20 recognizes one of the 5 α-helices that are 
predicted to compose 50-60% of the secondary structure of CLU (Bailey et al., 2001; Rohne et al., 2014; 
Stewart et al., 2007) and, as Tomm20 and Tomm70 are components of the same complex, the Tomm70-
CLU_45 kDa interaction detected in vivo is, in actuality, a secondary interaction. While not performed in 
this study, the possibility of a direct interaction between CLU_45 kDa and Tomm20 should be investigated 




2.4.2. CLU in the Mitochondria: Insights into Protein Function. 
In addition to providing insight into the possible import mechanism of mitochondrial CLU, the data 
presented in this chapter provide insight into a possible function for CLU in the mitochondrial matrix. Co-
immunoprecipitation indicates an interaction between CLU and mitochondrial bioenergetics; specifically 
components of the TCA Cycle and Oxidative Phosphorylation. In addition, high resolution respirometry 
confirms a functional deficiency in brain mitochondria of mCLU-KO animals. However, one major 
drawback of these studies is that while a reduction in general mitochondrial respiration is evident, it is not 
clear if the reduction in respiratory capacity can be attributed to one complex in the respiratory chain or is 
the result of general mitochondrial decline. Moreover, the mCLU-KO mouse model that was used in this 
study does not lack the mitochondria-localized CLU isoform indicating that the reduction in mitochondrial 
energy production is due to a deficiency in mCLU, not mitochondrial CLU. Taken together, these data 
suggest that both cytosolic mCLU and mitochondria-localized CLU function to protect mitochondrial 
function through differing mechanisms. First, secondary confirmation of preliminary co-
immunoprecipitation data indicates a direct interaction between CLU_45 kDa and at least one key 
component of the mitochondrial contact site and cristae organizing system, or MICOS, complex: MICOS 
60. The MICOS complex is crucial in the formation and maintenance of the cristae on the inner 
mitochondrial membrane and is thus essential in facilitating oxidative phosphorylation (van der Laan, 
Horvath, & Pfanner, 2016). Therefore, it is possible that mitochondrial CLU interacts with the MICOS 
complex to regulate the integrity of the inner mitochondrial membrane. Secondly, mCLU has been shown 
to sequester cytosolic Bax thereby preventing Bax-induced translocation and apoptosis (Trougakos et al., 
2009; H. Zhang et al., 2005). Parallel to these findings, a reduction in cytosolic mCLU has been shown to 
increase apoptosis by through the release of Bax from the KU70/Bax complex thus resulting in Bax 
translocation and insertion into the outer mitochondrial membrane (Trougakos et al., 2009). Consistent with 
previous publications, our data indicate a 22% increase in mitochondrial Bax expression in mice lacking 




stress. Parallel to these finding, we observe an 18% increase in mitochondrial Grp75 expression in mCLU-
KO brain. Previous publications have repeatedly demonstrated that Grp75 overexpression reduces the rate 
and severity of oxidative stress mediated by glucose deprivation (Y. Liu, Liu, Song, & Zuo, 2005) and H2O2 
toxicity (E, Liu, Liu, Liu, & Zuo, 2013) and therefore provides some measure of mitochondrial protection. 
Therefore, it is possible that increased mitochondrial stress triggered by intracellular mCLU deficiency 
results in a compensatory increase in mitochondrial Grp75. The proposed relationship between mCLU and 
Grp75 is confirmed by co-immunoprecipitation data indicating a direct interaction between Grp75 and 
CLU_70 kDa in crude brain mitochondria. While it is unclear how mCLU deficiency results in in vivo 
alterations in Bax and Grp75 expression, these data do indicate that both mitochondrial CLU (CLU_45 






Chapter 3: CLU and Sex Hormones 
3.1. The Regulation of mCLU by Estrogens and Androgens in Rodent Brain.  
Preliminary data from our lab indicate that CLU mRNA expression is significantly and irreversibly reduced 
in normally aging female, but not male, rodent brain (Figure 3.1.1.). Specifically, we observed a 47%  
 
decrease in CLU mRNA in female brain between the ages of 6 and 9 months whereas CLU mRNA in male 
brain was altered by only 4%. The observed decrease in CLU mRNA remained consistent from 9 to 12 
months (~10% decline) and from 12 to 15 months indicating that CLU mRNA is negatively impacted by 
early aging in specifically the female brain. One key difference between the aging male and female brain 
is the alteration in sex hormone patterns with age. For instance, aging negatively impacts male sex hormones 




In contrast, female sex hormones are known to be significantly and irreversibly depleted during menopausal 
onset (reproductive aging). Therefore, it is possible that the observed differences in the trajectory of CLU 
mRNA rodent brain may be due to differences in circulating male and female sex hormones. Therefore, 
based on this information we hypothesized that CLU protein expression levels are positively regulated by 
androgens and estrogens in rodent brain.   
To test this hypothesis, primary neurons were isolated, cultured for 7 DIV, and treated with increasing 
concentrations (10 nM – 100 nM) of the female sex hormones 17β-estradiol (E2) and progesterone (P4) or 
the male sex hormones testosterone and dihydrotestosterone (DHT) for 48 hours. Cells were harvested via 
whole cell protein extraction and analyzed for CLU immunoreactivity using SDS-PAGE. As this is the first 
study to explore the possibility of sex-hormone-mediated regulation of a CLU protein isoform in the brain, 
we chose to focus on the CLU_49 kDa isoform as Exon 2-containing mRNA appears to be predominant in 
brain tissue. The data indicate a significant increase in the expression of CLU_49 kDa in neurons treated 
with 100 nM E2 (58% increase), whereas no increase was observed in P4-treated cells (Figure 3.1.2., Upper 
Panel). While results pertaining to estrogen-mediated regulation of CLU have been mixed, the up-regulation 
of CLU_49 kDa by E2 treatment is consistent with previous reports which demonstrate an increase in CLU 
mRNA following E2 treatment in RUCA-1, KLE, and EEC-1 cells (Won, Lee, Yeo, & Park, 2012; 
Wunsche, Tenniswood, Schneider, & Vollmer, 1998). In contrast, treatment with testosterone and its 
metabolite DHT resulted in a significant decrease in CLU_49 kDa expression at 10 nM (24-25% decrease) 
and 100 nM (28% decrease) indicating that androgens, in general, repress mCLU expression in primary 
neurons (Figure 3.1.2., Lower Panel). While these data do not support our original hypothesis, androgen-
mediated suppression of CLU is primary neurons is consistent with previous reports that demonstrate a 
decrease in CLU mRNA in androgen treated LNCap cells (Waters, Safe, & Gaido, 2001) and an increase 
in CLU mRNA expression following androgen depletion in human prostate cancer tissue (July et al., 2002). 




found to positively regulate CLU_45 kDa protein expression, the remainder of the studies in this chapter 
will focus on the relationship between CLU_49 kDa and estrogens in the brain.    
 
3.2. Differential Regulation of mCLU Expression by ERα and ERβ-mediated Signaling.  
To determine the mechanism by which estrogens regulate CLU_49 kDa expression, primary neurons were 




The data indicate a non-significant decrease in CLU_49 kDa expression in PPT-treated cells (13% decrease, 
p=0.26) while neurons treated with the ERβ agonist DPN exhibited significantly increased CLU_49 kDa 
expression (28% increase, p=0.0178, Figure 3.2.1.). These data suggest that E2 signaling may 
differentially impact mCLU expression through the activation of different ERs with ERα-mediated 
signaling resulting in negative regulation and ERβ signaling resulting in positive regulation. In addition, as 
estrogen treatment results in an upregulation of CLU_49 kDa expression, it appears that ERβ-mediated 





pre-treatment of primary neurons with the ERα-specific inhibitor MPP enhances the E2-mediated 
upregulation of CLU_49 kDa (Figure 3.2.2.) thereby confirming the predominant positive regulation of 
CLU_49 kDa via ERβ agonism and the proposed negative regulation of CLU_49 kDa via ERα agonism.  
To determine if ERβ deficiency impacts CLU_49 kDa in vivo, cortical tissues harvested from 10-month-
old ERβ-KO rats and WT littermates were analyzed for CLU_49 kDa expression. The data indicate that 10-
month-old female ERβ-KO rat cortex expresses significantly lower CLU_49 kDa expression when 
compared to WT littermates (24% decrease, p=0.0331, Figure 3.2.3.) suggesting that ERβ remains an active 
and positive regulator of mCLU expression in vivo.    
 
The data presented thus far demonstrate that ERβ positively and significantly up-regulates CLU_49 kDa 
protein expression in primary neurons. However, at this time, no known estrogen response element has 
been identified within the CLU promoter. Therefore, in silico promoter analysis was performed on the 
human and rodent CLU promoters using Genomatix MatInspector Software.  In silico promoter analysis 





of human and murine CLU suggesting that estrogens regulate CLU_49 kDa expression via direct 
transcriptional regulation (Table 13). To determine if the CLU promoter does contain an unidentified ERE, 
ER-CLU DNA interactions were examined in treated and un-treated and SH-SY5Y cells. The SH-SY5Y 
cell line was chosen as a model based on the following 3 criteria: (1) SH-SY5Y is a human cell line thus 
rendering the findings in this study applicable to human mCLU, (2) intracellular mCLU is detected in SH-
SY5Y cell lysates, and (3) both ERα and ERβ are expressed in this cell line. SH-SY5Y cells were treated 





corresponding methods section and/or Schematic 18. Treated and untreated cell lysates were 
immunoprecipitated using antibodies against ERα or ERβ along with the indicated positive and negative 





primer sets were utilized: ER-alpha primer and ER-beta primer.  For specific information on the location 
of EREs within the CLU promoter and the area to which generated ER-specific primers bind, see Schematic 
19. For specific primer sequences, see the corresponding methods section. Rt-qPCR of immunoprecipitated 
DNA indicates an increased interaction between CLU and ERβ in cells treated with DPN (2.1 fold 
enrichment). As expected amplification with the ERβ primer did not result in an increase in the fold 
enrichment in either sample immunoprecipitated with ERα (Figure 3.2.4.). Interestingly, amplification of 
immunoprecipitated DNA with the ER-alpha primer set resulted in an increase in fold enrichment in both 
ligand-treated groups with DPN-treated cells exhibiting a higher fold enrichment than PPT-treated cells: 
DPN = 2.47 fold enrichment, PPT = 1.47 fold enrichment (Figure 3.2.5.) Collectively, these data indicate 
that estrogen receptors regulate mCLU protein expression via direct interaction with one or more EREs in 






3.3. Interim Discussion and Working Hypothesis 
In this chapter we have demonstrated both estrogen- and androgen-mediated regulation of CLU_49 kDa in 
primary cortical neurons (Figure 3.1.2.). The observed estrogenic signaling resulted in a significant 
upregulation of CLU_49 kDa protein expression that was mediated through ERβ activation (Figure 3.2.1). 
Furthermore, inhibition of ERα in the presence of E2 resulted in a significant increase over the E2-treated 
cells (Figure 3.2.2.) suggesting that ERα-mediated signaling negatively impacts mCLU expression in 
primary neurons. In addition, in vivo deletion of ERβ results in significantly reduced CLU_49 kDa 
expression (Figure 3.2.3.) further suggesting that E2 signaling mediated through ERα negatively impacts 
CLU_49 kDa expression. These data are particularly interesting as the differential regulation of mCLU 
expression by ERα and ERβ provides some explanation for the discrepancies pertaining to estrogen-
mediated regulation of CLU in certain cancer cell lines. For instance, as previously stated, the upregulation 
of CLU following E2 treatment in our studies is consistent with findings in three cancer cell lines (Won et 
al., 2012; Wunsche et al., 1998). In contrast, the down-regulation of CLU by ERα-mediated signaling is 
consistent with reports indicating a repression of CLU mRNA following E2 treatment in ovariectomized 
rats and mouse uterine tissue (Heikaus, Winterhager, Traub, & Grummer, 2002; Waters et al., 2001) and 
reports indicating and up-regulation of CLU expression following estrogen depletion in MCF-7 cells (So, 
Sinnemann, Huntsman, Fazli, & Gleave, 2005). As ERs are not uniformly expressed throughout the body 
or in immortalized cell lines [Reviewed in (Zhao, Woody, & Chhibber, 2015)], the differing results in the 
previously mentioned studies are likely due to the differing levels or specific estrogen receptors within the 
cell types tested. In support of this notion, an examination of tissue-specific ER expression using the Human 
Protein Atlas Database (www.proteinatlas.org) indicates the prominent expression of ERα, but not ERβ in 
the uterus and endometrium. Therefore, administration of E2 to these tissues would likely result in the 
suppression of CLU expression through ERα agonism. While the ratio of ER expression pertaining to all 
immortalized cell lines is not currently established, the differential regulation of CLU_49 kDa expression 




tissue types. In addition, our data demonstrate that E2-mediated regulation occurs via direct transcriptional 
regulation of CLU through one or more EREs in the CLU promoter. While these data are the first to provide 
evidence for the presence of EREs in the CLU promoter, one weakness of this study is that, while a ligand-
mediated interaction clearly occurs between ERs and CLU DNA, the exact location and number of the 
ERE(s) is still unknown. The average length of the sheared chromatin in this study was 200-250 bp. 
Moreover, while the ER-beta primer was centered on bp -297, the size of the generated amplimer indicates 
a range of ±75 bp from position -297 meaning that, while we have an idea of the approximate location of 
the ER-beta ERE we cannot ascertain its exact location. Moreover, enrichment of the ERβ-CLU interaction 
was observed using both sets of CLU primers (ER-alpha and ER-beta). As the predicted ERβ binding site 
is several hundred bp upstream from area amplified by the ER-alpha primer set, the enrichment of the ERβ-
CLU interaction was unexpected in this set of experiments. Three possibilities exist to explain this 
observation: (1) the sheared chromatin containing the predicted ERE is long enough that it directly overlaps 
with the region of CLU DNA being amplified by the ER-beta primer, (2) there is an alternative CLU ERE 
that was not recognized during the in silico prediction, or (3) the predicted ER-alpha binding site at ~100 
bp allows for the interaction between both ERs and CLU DNA. While more research is needed to establish 
the exact location(s) of EREs in the CLU promoter, these data confirm the direct estrogenic regulation of 
CLU in human neuroblastoma cells.  
The data in this chapter also indicate that CLU expression which is regulated by E2 in both embryonic and 
adult brain is negatively affected by aging specifically in young female mice (Figure 3.1.1.). As female 
mice tend to enter the human equivalent of perimenopause (a period of time prior to menopause 
characterized by irregularities in the hormonal cycle) by 8-9 months of age (Finch, Felicio, Mobbs, & 
Nelson, 1984), these data indicate that reproductive aging negatively impacts brain CLU gene expression 
in female mice. While more work is needed to definitively prove the concepts postulated in this chapter, it 
is clear that CLU gene and protein expression is regulated in a sex-dependent manner. Moreover, as 




Discussion and Future Directions 
CLU is currently the third most significant genetic risk factor for the development of LOAD with multiple 
clinical studies demonstrating the association between the rs11136000 C SNP and the development of 
LOAD pathology. In addition, clinical investigations have indicated that the CLU AD risk allele is 
associated with reduced circulating CLU, faster cognitive decline (Thambisetty et al., 2013), and alterations 
in synaptic connectivity (Erk et al., 2011) and brain structure (Thambisetty et al., 2012; Ruossotte et al., 
2014). However, despite clinical findings, the mechanism(s) by which reduced CLU levels confer increased 
LOAD risk are not yet described. In addition, while CLU has been heavily studied in metastatic cancer, an 
extensive gap exists in the literature pertaining to the physiological distribution, expression, and function(s) 
of CLU protein isoforms in the brain. Moreover, the tendency to refer to CLU as a single protein or mRNA 
isoforms has resulted in the generation of conflicting reports pertaining to protein and gene expression 
profiles as well as protein function. Therefore, before the therapeutic potential of CLU in the brain can be 
ascertained, it is vital that these key deficiencies are addressed on a neurophysiological level. To address 
the identified deficiencies, we have conducted an in-depth examination of brain CLU protein isoform 
expression, distribution, and glycosylation status under physiological conditions. The data generated from 
these studies fill a significant gap in the understanding of CLU in a healthy non-stressed brain and provide 
key foundational information for future studies pertaining to alterations in CLU protein isoform expression 
and distribution in various neuropathological conditions. The following sections will include a brief 
summary of our overall findings and a discussion of our major findings in the context of the currently 
available literature. In addition, based upon the data presented in this dissertation, we propose an overall 
working hypothesis that presents a possible mechanism whereby reduced CLU may confer increased LOAD 
risk. Finally, we present several future directions to directly test the proposed hypothesis as well as two 





Summary of Overall Findings. The data generated in Chapter 1 demonstrate that CLU exists in the brain 
as multiple CLU protein isoforms translated from at least 3 potential CLU mRNA transcripts. The 3 
translated pre-proteins proposed in this dissertation (CLU_45 kDa, CLU_49 kDa, and CLU_53 kDa) are 
differentially modified by N-linked glycosylation (complex glycan vs. high-mannose glycan vs. non-
glycosylated) with the resulting modified and unmodified protein isoforms exhibiting distinct cellular 
localizations in both adult brain tissue and embryonic brain cell types. Moreover, we find that the cellular 
localization of multiple CLU protein isoforms is altered by aging and acute toxicity demonstrating the 
dynamic nature of CLU protein isoforms within the brain. These data contribute significantly to the 
resolution of 3 key controversies that currently exist in the literature: (1) the source of brain CLU, (2) the 
presence of a “nuclear” CLU protein isoform, and (3) the disregarded importance of those CLU protein 
isoforms that are referred to as “minor” or “intracellular” in previous publications.   
 
The data from Chapter 2 identify, for the first time, a mitochondria-localized CLU protein isoform: CLU_45 
kDa. This protein isoform is unaffected by endoglycosidase treatment and corresponds to the predicted MW 
of a pre-protein translated from an mRNA isoform containing Exons 3-9. Furthermore, the CLU_45 kDa 
protein isoforms, which is localized to the mitochondrial matrix, physically interacts with components of 
the MICOS and TOM complexes under physiological conditions suggesting not only a possible protein 
import pathway but also a possible function for this newly identified mitochondrial isoform. In addition, 
we find that mCLU, in general, is associated with mitochondrial bioenergetics as a deficiency in mature 
secreted CLU results in significantly reduced brain mitochondrial respiratory capacity. These data provide 
solid rationale for novel investigations into the relationship between CLU_45 kDa and the regulation of 
mitochondrial stability and the relationship between non-mitochondrial CLU and brain bioenergetics. 
 
The data from Chapter 3, which investigated the possible estrogenic regulation of CLU protein isoforms in 




expression via ERβ-mediated signaling. In addition, the data suggest that ERα-mediated signaling exerts a 
negative impact on CLU_49 kDa expression. Moreover, we show that the ligand-mediated regulation of 
CLU_49 kDa by ER signaling occurs via direct DNA-protein interaction between the CLU promoter and 
ER proteins.  These data indicate that estrogens exert an overall positive effect on the mCLU pre-protein in 
the brain. Additionally, while both ERs were shown to regulate CLU, albeit in opposing manners, the fact 
that E2 treatment resulted in a significant up-regulation of CLU_49 kDa suggests that ERβ-mediated 
signaling is the predominant estrogenic regulatory pathway for CLU in cortical tissues. Collectively, the 
data presented in this chapter provide rationale for the further investigation between CLU protein 
expression and reproductive aging.  
 
Discussion of Major Findings.  
The Relationship Between Astrocyte-Derived and Neuron-Generated mCLU. As previously discussed, 
the presence of CLU in the brain has been largely attributed to the generation and secretion of CLU from 
astrocytes in manner that is similar to ApoE (DeMattos et al., 2001; Zwain et al., 1994). In contrast, reports 
have also indicated the expression of CLU within astrocyte-free cultures of primary neurons suggesting that 
neurons are capable of generating de novo CLU (O'Bryan, Cheema, Bartlett, Murphy, & Pearse, 1993; 
Pasinetti et al., 1994). Our data suggest that both neurons and astrocytes are capable of generating CLU 
protein however, analysis of  the expression and glycosylation status of CLU protein isoforms in both 
primary neurons and astrocytes demonstrates that astrocytes, but not neurons, express the mCLU subunits 
(CLU_39 kDa and CLU_36 kDa). As it is established that the two mCLU subunits represent the 
glycosylated, non-dimerized subunits of secreted mCLU (Burkey et al., 1991; Burkey, Stuart, & Harmony, 
1992; de Silva, Stuart, et al., 1990), these data suggest that astrocytes are responsible for generating and 
secreting mCLU into the extracellular space. This notion is consistent with previous reports indicating that 
astrocyte-derived secreted mCLU functions to regulate aspects of neuronal development in the extracellular 




several key physiological processes including, but not limited to, clearance of extracellular glutamate 
(Jensen, Fahlke, Bjorn-Yoshimoto, & Bunch, 2015), regulation of pH and ion homeostasis (Barres, 1991; 
Orkand, Nicholls, & Kuffler, 1966) (Belanger & Magistretti, 2009), contribution of energy substrates 
(Mosienko, Teschemacher, & Kasparov, 2015; Teschemacher, Gourine, & Kasparov, 2015), protection 
from oxidative stress (Belanger & Magistretti, 2009), regulation of the BBB (Alvarez, Katayama, & Prat, 
2013; Haseloff, Blasig, Bauer, & Bauer, 2005), regulation of the synapse (Guillamon-Vivancos, Gomez-
Pinedo, & Matias-Guiu, 2015), and secretion of neurotrophic factors (B. Liu, Teschemacher, & Kasparov, 
2017). Moreover, extracellular mCLU, which is known clear extracellular debris and protect from oxidative 
stress (H. O. Jun et al., 2011; Trougakos, 2013; Viard et al., 1999), has been implicated in neuronal process 
formation, elongation, and plasticity in primary spinal cord cell cultures (Cordero-Llana et al., 2011) and 
neurite outgrowth in PC12 cells (Kang et al., 2005). Therefore, it is highly plausible that astrocyte-derived 
extracellular mCLU confers some level of neuroprotection via reduction of oxidative stress, clearance of 
cellular debris, and positive regulation of synaptic function and/or formation.  
While primary neurons do not appear to express the secreted mCLU subunits, our analysis does indicate 
the expression of both CLU_49 kDa and CLU_60 kDa in cultures of primary neurons; two protein isoforms 
that represent the mCLU pre-protein and a high mannose-modified mCLU intermediate. Therefore, these 
data suggest that primary neurons are capable of generating mCLU protein isoforms that remain non-
secreted (i.e. intracellular mature CLU). While the exact function of the intracellular mCLU protein 
isoforms is yet to be determined, it is clear that these intracellular isoforms do play some role in the response 
to neurotoxic stimuli. Our data demonstrate a rapid and significant decrease in cytosolic CLU_80 kDa and 
nuclear CLU_68 kDa protein expression in primary neurons following acute excitotoxic insult. In contrast, 
we see a rapid and significant increase in the expression of cytosolic CLU_49 kDa, but not CLU_53 kDa 
expression. As NMDA receptor-mediated excitotoxicity is known to increase the heat shock response 
(Rordorf, Koroshetz, & Bonventre, 1991) and CLU gene expression is known to be transcriptionally 




isoform could be the result of a general increase in the transcription of Exon 2-9 containing mRNA mediated 
by increased heat shock protein signaling. However, this HSP-mediated up-regulation does not correspond 
with the observations associated with either CLU_80 kDa or CLU_68 kDa following administration of 
supraphysiological glutamate. Our data indicate a relatively rapid and significant decrease in protein 
expression cannot be attributed to a reversal of N-linked glycosylation or increased secretion of a mCLU 
protein isoform. Therefore, alternative mechanisms of toxicity-induced protein degradation must be 
considered. Two such mechanisms could be the proteasomal and/or lysosomal breakdown of toxin-bound 
intracellular CLU proteins following neurotoxic insult. It has been previously demonstrated that inhibition 
of proteasomal and lysosomal function results in the accumulation of multiple intracellular CLU protein 
isoforms (Balantinou, Trougakos, Chondrogianni, Margaritis, & Gonos, 2009) indicating that intracellular 
CLU protein isoforms are degraded by one or more cellular breakdown processes. As the targeting and 
degradation of intracellular proteins by the ubiquitin-proteasome pathway occurs in rapidly (Cooper, 2000) 
and CLU is a known target of ubiquitin (Xue et al., 2012), it is feasible to hypothesize that the rapid 
disappearance of intracellular CLU_80 kDa and/or CLU_68 kDa protein isoforms is due to the poly-
ubiquitination and subsequent proteasomal degradation of the aforementioned CLU protein isoforms 
following excitotoxic challenge. Moreover, a recent report indicates that at least 1 intracellular neuronal 
CLU protein isoform is degraded by the lysosome via interaction with sortilin following the administration 
of Aβ1-42 (Y. Wang, Qin, & Paudel, 2017). Therefore, it is also feasible that the observed changes in protein 
expression are the result of lysosomal degradation. However, as no aspects of proteolytic breakdown were 
investigated in the studies presented in this dissertation, more research is needed to explain the alterations 
in CLU protein expression following excitotoxic challenge. Whatever the mechanism, our data suggest a 
mechanism whereby intracellular and extracellular mCLU protein isoforms confer neuroprotection with 





Nuclear and Intracellular CLU Protein Isoforms. While it is generally agreed that at least 1 Exon 2-
deficient CLU protein isoform is generated, the importance of this and other alternative CLU protein 
isoforms has been diminished in the currently available literature. It is suggested that this Exon 2-deficient 
CLU protein isoform represents the nuclear pro-apoptotic CLU protein that is commonly associated with 
increased cancer cell death (Debure et al., 2003; Dia & Mejia, 2010; Leskov et al., 2003), however, results 
pertaining to this protein are controversial at best. Our data demonstrate that there is indeed a nuclear CLU 
protein isoform as well as several other intracellular CLU protein isoforms that can be defined by distinct 
targeted subcellular localizations (cytosolic, mitochondrial, nuclear, etc…) and modifications (high 
mannose glycan, complex glycan, non-glycosylated). While the confirmed existence of a nucleus-targeted 
CLU protein isoform parallels previous reports, the exact isoform targeted to the nucleus has been 
misinterpreted in previous studies. These investigations suggest that “nuclear CLU” is derived from the 
Exon 3-9 mRNA isoform which translates a non-glycosylated protein that shuttles between the cytosol and 
nucleus (Leskov et al., 2003; Reddy et al., 1996). However, our data indicate that the nucleus-targeted CLU 
protein isoform is a high mannose glycan (CLU_68 kDa) derived from the CLU_53 kDa pre-protein which 
we hypothesize to be translated from a CLU mRNA containing Exons 1-9. These discrepancies are likely 
due to the fact that the numerous possible CLU mRNA transcripts and the corresponding translated proteins 
are yet to be fully characterized. Prior to this investigation, the widely accepted view was that all CLU 
protein isoforms were translated from 2 CLU mRNA transcripts: Exon 2-9 and Exon 3-9 (Reddy et al., 
1996). However, as canonical translational start sites exist in Exons 1, 2, and 3, and studies in immortalized 
cell lines indicate the inducible expression of several intracellular CLU immunoreactive proteins between 
45-53 kDa (Nizard et al., 2007), it is highly plausible that 3 or more CLU coding mRNA transcripts are 
produced from the CLU gene. In addition, previous studies pertaining to the function of “nuclear CLU” 
indicate that this alternative protein isoform is solely pro-apoptotic in nature (Dia & Mejia, 2010; N. Kim, 
Han, et al., 2012; N. Kim, Yoo, et al., 2012; Leskov et al., 2003; Yang et al., 2000). However, our data 
indicate that these alternative intracellular CLU protein isoforms, which are nearly ubiquitous in the brain 




homeostasis in the subcellular compartments to which they are targeted. In addition, our examination of 
CLU protein immunoreactivity in mCLU-KO mice suggests that the alternative CLU pre-proteins are up-
regulated in the absence of mCLU. While it is possible that the observed up-regulation of alternative CLU 
protein isoforms results in cellular stress or increased apoptosis, another explanation of this up-regulation 
can be hypothesized. It is possible that in the absence of mCLU, the expression of intracellular CLU protein 
isoforms may be increased to compensate for the reduction in mCLU-mediated cyto-protection. This is a 
particularly intriguing observation as the notion of increased alternative CLU mRNAs could be translated 
to the clinical setting. Clinical investigations have indicated an increase in one or more CLU mRNA 
transcripts in patients who carry the rs11136000 and/or the rs9331888 CLU SNPs (Szymanski, Wang, 
Bassett, & Avramopoulos, 2011). Interestingly, the transcripts shown to be up-regulated in carriers of the 
rs11136000 SNP have either been removed from the NCBI database (NCBI Accession #CR617497) or are 
indicated to be a non-coding RNA (NCBI Accession #NM_203339). Therefore, it is possible that 
possession of the CLU AD risk genotype may result in the up-regulation of one or more CLU mRNA 
transcript which results in a significantly altered CLU protein expression profile. While this notion requires 
further testing, these data underscore the importance of (a) identifying all CLU mRNA transcripts in the 
healthy brain, (b) determining the translated proteins of each identified mRNA, and (c) examining the 
function(s) of individual CLU protein isoforms with particular emphasis on separating information 
pertaining to intracellular CLU protein isoforms and the secreted extracellular mCLU. 
 
Mitochondrial CLU: A Novel Avenue of CLU Research. The mitochondrial cascade hypothesis of AD 
postulates that an individual’s genetic makeup determines their baseline mitochondrial function which is 
differentially impacted though time by inherited and/or environmental factors to regulate the chronology of 
AD. (Swerdlow & Khan, 2004). Since the proposal of this hypothesis, several studies have demonstrated 
significant alterations in mitochondrial function in mouse models and human cell lines containing genetic 




of whole brain mitochondria in 3-month-old female WT and 3xTg-AD (a triple-transgenic AD mouse 
model that exhibits age-related amyloid accumulation) mice indicates a significant increase in lipid 
peroxidation and oxidative stress in 3xTg-AD mice prior to the onset of AD pathology (Yao et al., 2009). 
Furthermore, embryonic neurons cultured from the same mouse model indicate significantly lower baseline 
OCR and maximal respiratory capacity in hippocampal neurons cultured from 3xTg-AD mice (Yao et al., 
2009). Parallel to these findings, human AD cytoplasmic hybrid (cybrid) cells (a cell line that contains 
mitochondrial DNA from either AD or control platelets) exhibit increased oxidative stress, decreased 
mitochondrial membrane potential, and reduced ATP levels in the absence of amyloid pathology (Cardoso, 
Santana, Swerdlow, & Oliveira, 2004). Our data, which demonstrate functional abnormalities in oxidative 
phosphorylation in 6-month-old female mCLU-KO mice, indicate that brain mitochondrial bioenergetics 
are negatively impacted by the genetic depletion of CLU at a young age; a finding that further supports the 
relationship between genetic predisposition and mitochondrial dysfunction. However, it is important to note 
that the newly identified mitochondrial CLU protein isoform (CLU_45 kDa) is still present in the mCLU-
KO mouse model utilized in our mitochondrial respirometry studies. Therefore, these data indicate that the 
observed alterations in mitochondrial respiration are due to the lack of mCLU: a protein isoform that is not 
localized to pure mitochondria. While increased bioenergetic stress mediated by mCLU deficiency presents 
another possible mechanism whereby reduced CLU may confer increased LOAD risk, these data give rise 
to the important question of how a non-mitochondrial protein may negatively impact mitochondrial energy 
production; a process that occurs on the inner mitochondrial membrane. As discussed in Chapter 2, it is 
possible that the lack of mCLU results in increased mitochondrial Bax translocation and thus results in 
increased activation of intrinsic apoptotic pathways. However, while increased mitochondrial Bax 
expression was observed in cortical mitochondrial isolated from mCLU-KO mice no aspects of apoptosis 
were investigated in this study and thus more research is needed to confirm this hypothesis. It is also 
possible that mCLU-KO mice are more prone to mitochondria-generated oxidative stress due to the lack of 
mCLU, which is known to protect from oxidative stress in several cell lines and animals models. A 





Schematic 20. Proposed Mechanism to Explain the Relationship between Brain Mitochondria and both 
Mitochondrial and Non-Mitochondrial CLU Protein Isoforms. Our data indicate that both mitochondrial and 
non-mitochondrial CLU are associated with mitochondrial function. As discussed in Chapter 2, we hypothesize 
that CLU_45 kDa is imported into the mitochondrial matrix through the TOM70/TIM23/PAM pathway. We 
hypothesize that CLU_45 kDa assists in the regulation of the stability and structure of the inner mitochondrial 
membrane via its interaction with the MICOS complex. In reference to non-mitochondrial CLU (CLU_39 kDa), 
we hypothesize that the observed interaction between CLU_39 kDa and MICOS 60 in brain mitochondria is 
mediated through the interaction between CLU_39 kDa and a MICOS 60 interacting partner localized to the outer 
mitochondrial membrane, such as the TOM or SAM complex. Moreover, we hypothesize that CLU_39 is 
associated with the mitochondria and functions to reduce mitochondria-generated oxidative stress and/or Bax 
stabilization in the cytosol. Collectively, both CLU protein isoforms function to optimize oxidative 
phosphorylation via regulation of inner mitochondrial membrane stability and structure, reduction in oxidative 





(E et al., 2013; Y. Liu et al., 2005), supports the idea of increased oxidative stress in young female mCLU-
KO mice, however, as ROS levels were not examined in this study, this mechanism is yet to be tested.  
 
In addition to demonstrating the localization of a mitochondrial CLU protein isoform and reduced brain 
mitochondrial respiration in mCLU-KO mice, our co-immunoprecipitation studies demonstrate a physical 
interaction between components of the TOM and MICOS complexes and both mitochondrial and mature 
CLU (CLU_45 kDa and CLU_39 kDa) under physiological conditions. While an interaction between 
mitochondrial proteins and the CLU_45 kDa protein isoform was expected, the interaction between 
CLU_39 kDa and mitochondrial proteins was not. The question again becomes, how a non-mitochondrial 
CLU protein isoform interacts with a protein complex that is specifically localized to the inner 
mitochondrial membrane. One possibility is that the lysis and immunoprecipitation buffer used in these 
experiments, which does not disrupt protein-protein interactions, results in the interaction between CLU_39 
kDa and MICOS 60 via its interaction with another mitochondrial protein on the outer mitochondrial 
membrane (i.e. a secondary interaction). As both the SAM complex and the TOM complex have been 
shown to physically interact with the MICOS complex (Ding et al., 2015; von der Malsburg et al., 2011) 
and our data indicate an interaction between CLU_39 kDa and TOM70 (Schematic 20, black arrows) it is 
possible that CLU_39 kDa interacts with MICOS 60 through its interaction with the TOM complex 
(Schematic 20), though this hypothesis requires further testing. In addition, the list of possible CLU protein 
interacting partners and the protein interacting partners that were confirmed in physiological conditions 
present several potential functions for CLU within the mitochondria. One such function would be the 
regulation of mitochondrial gene expression through the interaction with mitochondrial ribosomes. 
Mitochondrial ribosomes, which are anchored to the matrix side of the inner mitochondrial membrane 
(Greber & Ban, 2016), are essential in the generation of mitochondrial proteins encoded by mitochondrial 




a direct interaction between CLU_45 kDa and mitochondrial translation machinery represents a novel and 
insightful avenue of research into mitochondrial CLU function. Another possible function for mitochondrial 
CLU is the regulation of IMM formation through an interaction with the MICOS complex. The MICOS 
complex, which is integral to mitochondrial energy production, is crucial in the formation of the IMM and 
thus regulates OXPHOS via formation and stabilization of cristae (van der Laan et al., 2016). As both our 
preliminary and secondary analysis indicate a physical interaction between CLU_45 kDa and MICOS 60 it 
is therefore possible that mitochondrial CLU regulates some aspect of IMM stability. Collectively, we 
hypothesize that mCLU and mitochondrial CLU regulate different aspects of brain mitochondrial function 
with mCLU impacting some aspect of mitochondrial respiration and mitochondrial CLU regulating inner 
mitochondrial membrane stability. While several aspects of the relationship between CLU and 
mitochondria are yet to be examined, one key obstacle will be the inability to selectively silence the 
expression or inhibit the localization of the CLU_45 kDa protein. However, as brain bioenergetics are 
integrally linked to the pathology of LOAD, it is essential that the relationship between CLU and 
mitochondrial function be evaluated in the future.    
 
Brain CLU and Estrogen: a Novel Regulatory Mechanism. An emerging topic in the study of AD is the 
impact of sex on the development and progression of LOAD. As previously discussed, the female 
population is more susceptible to developing LOAD and the risk conferred by some genetic factors, such 
as APOE, is greater in females (Altmann et al., 2014). While the AD risk conferred by the CLU risk variant 
has not been indicated to be sex-dependent, our data indicate that CLU gene expression is significantly and 
irreversibly altered during a time that corresponds to the onset of irregular cycling in normally aging female 
mice. Furthermore, normally aging male mice exhibited no decrease in CLU gene expression indicating 
that reproductive aging may be integrally involved in the regulation of CLU in the brain. As chronological 
aging is also known to negatively impact CLU protein isoform expression, these data lead us to wonder 




the female brain during menopausal onset. This exacerbation could contribute to the female vulnerability 
that is associated with LOAD development. However, one inconsistency does arise. Previous studies and 
our own data indicate that androgens significantly repress CLU protein expression in the brain and 
reproductive tissues (Cochrane, Wang, Muramaki, Gleave, & Nelson, 2007; July et al., 2002). Therefore, 
if decreased CLU expression results in increased vulnerability to AD, one would expect males to exhibit 
increased CLU-mediated AD risk until the onset of andropause when the CLU gene would be free of 
androgen-mediated repression. While the mechanisms underlying differing trajectories in CLU expression 
are not yet understood, these data underscore the importance of including sex as a variable in the study of 
risk factors that mediate the development of LOAD.  
 
The CLU-KO Animal Model: Not a Total Knockout. Several studies in recent years have utilized the 
CLU-KO mouse model to demonstrate the involvement of CLU in a myriad of pathological conditions 
including, but not limited to, diabetes (Byun et al., 2014; Zeng, Lu, Lee, & Friedman, 2015), cardiovascular 
disease (Shirasawa et al., 2009), ischemia (Imhof et al., 2006), Creutzfeldt-Jakob Disease (Sasaki, Doh-ura, 
Ironside, Mabbott, & Iwaki, 2006), cancer (Chayka et al., 2009), kidney disease or injury (Ghiggeri et al., 
2002; Jung et al., 2012; Zhou et al., 2010), and atherosclerosis (Hamada et al., 2011; Seo et al., 2013). In 
addition, this mouse model has been used to implicate CLU in developmental processes (Jiao et al., 2011; 
J. H. Kim, Kim, Yu, Min, & Kim, 2007) as well as the regulation of inflammation (Hong et al., 2016; 
Savkovic et al., 2007) and oxidative stress (Mishima et al., 2012). However, few studies have included an 
in-house validation of the CLU-KO mouse model. Those studies which have verified the absence of CLU 
protein in the animals used in their studies examine only the mature secreted form of CLU represented as 
CLU_60 kDa and/or CLU_39 kDa; a finding that is consistent with our own data. However, further 
characterization of the CLU-KO mouse model on both the protein and gene level indicate that this mouse 
model, which is indicated to be completely devoid of CLU protein and mRNA, contains at least 1 CLU 




the CLU-KO mouse model indicates that the mutant cassette used to create the CLU-KO animal blocks 
transcription starting in Exon 2 (McLaughlin et al., 2000). Therefore, the remaining mRNA transcripts must 
be initiated at Exon 3 or possibly in Exon 1. However, our protein data do not match the expected outcome 
of this mouse model. For instance, while our data indicate the expected deficiency in CLU_60 kDa and 
CLU_39 kDa, the mCLU pre-protein (CLU_49 kDa) is still expressed in mCLU-KO mice. Therefore, these 
data suggest that, while the mCLU pre-protein is still translated, the glycosylation and maturation of mCLU 
is inhibited in this mouse model. This discovery is potentially problematic as it changes our entire 
interpretation of the studies that have identified potential protein functions, properties, and/or regulatory 
pathways pertaining to CLU. Instead of identifying basic molecular properties of CLU in general, 
researchers have instead been identifying physiological functions pertaining to only the mature secreted 
CLU protein isoform meaning that we know even less about protein isoforms that are translated from 
alternative mRNA transcripts. While the generation of a total CLU knockout mouse model is proposed in 
the future directions, the accidental knockout of only mCLU does provide a tool that could be unknowingly 
used to study the combined effects of aging, sex, and mCLU deficiency on neurocognitive decline from 
both a biochemical and behavioural standpoint. While these animals have been extensively utilized in the 
past and are phenotypically and reproductively normal, no published study, to date, has performed a 
behavioural characterization of this mouse model. Moreover, as our mitochondrial data clearly indicate 
differences between WT and mCLU-KO animals at a young age, it would be extremely interesting to 
perform a long-term behavioural and biochemical study using normally aging male and female WT and 
mCLU-KO mice. This study should include a sex-dependent examination of neurocognitive behaviour and 
mitochondrial function at 3, 6, 10, and 15 months of age. Data derived from this study would provide a 
plethora of insight pertaining to the understanding of the interaction between sex, brain bioenergetics, aging, 






Working Hypothesis and Future Directions. Based on the data presented in this dissertation, we 
hypothesize that possession of CLU AD risk SNPs result in significantly lower levels of astrocyte-derived 
extracellular and neuron-generated intracellular CLU in young adult brain rendering neurons more 
vulnerable to extracellular insult and/or neurotoxic damage. In addition, reduced intracellular CLU results 
in increased bioenergetic stress in young adult brain which is exacerbated by the loss of estrogen and 
estrogen-mediated CLU regulation associated with reproductive aging. Collectively, an increase in the level 
of mitochondrial stress and a decrease in the amount of secreted, intracellular, and mitochondrial CLU 
significantly contributes to neurodegenerative decline in the preclinical phase of LOAD in female brain 
(Schematic 21). While this hypothesis seems quite complex, a breakdown of the overall hypothesis into 4 
individual working hypotheses will allow for the successful testing of the aforementioned mechanism. The 
following 4 sections will discuss the short- and long-term future directions that will significantly contribute 





Working Hypothesis Part I: Possession of a CLU AD risk SNP results in an altered CLU mRNA 
and/or protein expression profile. While studies have indicated alterations in the expression of plasma 
CLU in carriers of the CLU AD risk allele, the impact of CLU AD SNP possession on individual mRNA 
transcript levels and protein isoform expression have not been characterized. However, as altered 
Schematic 21. Proposed Overall Working Hypothesis. Based on the data presented in this dissertation we 
hypothesize that possession of a CLU AD risk SNP results in significantly reduced astrocyte-derived extracellular 
and neuron-generated young adult brain rendering neurons more vulnerable to extracellular insult and/or 
neurotoxic damage. In addition, reduced intracellular CLU results in increased bioenergetic stress in young adult 
brain which is exacerbated by the loss of estrogen and estrogen-mediated CLU regulation associated with 
reproductive aging. Collectively, an increase in the level of mitochondrial stress and a decrease in the amount of 
secreted, intracellular, and mitochondrial CLU significantly contributes to neurodegenerative decline in the 




expression of at least 1 CLU mRNA transcript has been observed in carriers of two identified CLU AD-
related SNPs, it is possible that possession of CLU SNP results in significant alterations at the messenger 
or protein level. As the single mutation of one nucleotide with in an intron is technically improbable at this 
time, we will focus on the creation of a cDNA overexpression construct that contains the risk-conferring 
rs9331888 SNP (G allele), which is located in Exon 1 of CLU mRNA (chromosomal location 27611345). 
It has been demonstrated that 1 copy of the G allele results in a significant reduction in CLU mRNA and 
protein levels (Xing et al., 2012), therefore our experiment will aim to generate a cDNA construct that 
possesses the CG genotype at the aforementioned chromosomal location. Full length human CLU cDNA 
derived from the pLX304-hCLU-v5 cDNA overexpression construct will be sequence analyzed to 
determine the existing genotype at the appropriate location (CC, CG, or GG). Primer sets will then be 
generated to create the CC-containing cDNA construct (if genotype is CG or GG) or the CG-containing 
cDNA construct (if genotype is CC) and site directed mutagenesis will be performed with generated 
primers. Mutations will be confirmed via DNA sequencing and overexpression constructs will be 
transfected into one or more human cells lines. Total RNAs and protein will be isolated and alterations in 
protein and/or mRNA levels will be detected via rt-qPCR or SDS-PAGE. The data generated from these 
studies will directly demonstrate the impact of at least 1 CLU AD-associated SNP on human CLU protein 
and mRNA levels.  
 
Working Hypothesis Part II: Reduced astrocyte-derived extracellular CLU renders neurons more 
vulnerable to extracellular insult/neurotoxic damage. While the discovery that the previously described 
total CLU-KO mouse was in fact a mCLU-KO animal was unexpected, the knockout of only mCLU does 
actually prove beneficial in testing the first part of our hypothesis. We propose the generation of an 
astrocyte-neuron co-culture using postnatal day 1 WT and mCLU-KO mouse pups. These co-cultures will 






for pre-determined amounts of time and neurons will be assessed for neuronal toxicity and degeneration 
using the LDH Assay and Fluoro-Jade Staining. Fluoro-Jade staining was selected based on the preferred 
staining of both degenerating neurons and reactive microglia: both of which should be visible in this 
experiment. Moreover, Fluoro-Jade Staining has been shown to be an effective tool for staining both acutely 
and chronically degenerating neurons. In addition to assessing neurotoxicity and neurodegeneration, CLU 
levels will be assessed in the culture medium at each time point to ensure the loss in mCLU secretion in 
mCLU-KO co-cultures and the increase in mCLU secretion from WT co-cultures (positive control). 
Moreover, neurons and astrocytes will be subjected to subcellular fractionation and analyzed for CLU 
immunoreactivity to examine the impact of acute and chronic toxicity on intracellular CLU protein isoforms 
across both co-culture models (Schematic 21). Following the completion of these preliminary experiments 
and the establishment of a consistent response, this experiment can be repeated with the addition of 
exogenously purified secreted mCLU. The data generated from these experiments are expected to answer 
two very important questions: (1) Does genetic deficiency in the mCLU isoform result in exacerbated 
Schematic 22. Proposed Experimental Plan to Investigate Working Hypothesis Part II. Astrocyte-neuron co-
cultures will be isolated from WT and mCLU-KO mouse pups and treated with acute or chronic neurodegenerative 
stimuli in the presence of absence of exogenously added purified secreted CLU. Neurotoxicity and 
neurodegeneration will then be assessed with the indicated assays and CLU protein expression will be evaluated 




neuronal damage under acute/chronic neurotoxic conditions? and (2) Can the addition of purified mCLU 
attenuate the exacerbated neuronal degeneration? 
 
Working Hypothesis Part III: Reduced intracellular CLU results in increased bioenergetic stress and 
reduced mitochondrial stability in young adult brain. Our previous data indicate that mCLU-KO mice 
exhibit significantly reduced brain mitochondrial respiration. However, as this mouse model is known to 
be deficient in only a portion of CLU protein, the next part of our working hypothesis will examine the 
impact of intracellular CLU deficiency on brain bioenergetics. We propose a two-step evaluation using an 
in vitro and in vivo system. For the first part of our proposed experimental plan, primary cultures of neurons 
or astrocytes will be isolated from E18 rat pups and grown to maturity as described in this dissertation. 
Lentiviral vectors targeting Exon 1, Exon 2, or Exon 3 of CLU will be used to silence specific CLU protein 
isoforms in each model followed by the confirmation of CLU knockdown. As we propose that 
mitochondrial CLU (CLU_45 kDa) plays some role in the regulation of the stability of the inner 
mitochondrial membrane in coordination with the MICOS complex, mitochondrial stability will be initially 
examined using TMRM staining. In addition, mitochondrial respiration will be examined using high-
resolution respirometry coupled with safranin dye to further assess the mitochondrial membrane potential. 
In addition, changes in CLU protein expression will be assessed using immunoblot analysis in both culture 
models.  
 
Pending the positive outcome of the in vitro experimentation, we will proceed with the in vivo portion of 
our experimental plan. Exon 3-targeting lentivirus will be injected into WT and mCLU-KO female mice. 
While there are several types of viral delivery vectors, lentivirus was selected based previous publications 
indicating that recombinant lentiviral vectors are applicable for stable, long-term gene delivery to neurons 
in vivo (Osten, Dittgen, & Licznerski, 2006). Moreover, preliminary rt-qPCR studies aimed at 




transcribed, therefore, only Exon 3-targeting lentivirus will be utilized in our in vivo experimentation. 
Following the delivery of lentivirus, crude mitochondria will be isolated and analyzed for mitochondrial 
respirometry using the protocol established in this dissertation. As stated in the previous section,  
 
respirometry will be performed in conjunction with the assessment of mitochondrial membrane potential 
using Safranin in a protocol similar to that of Chowdhury and colleagues (Chowdhury, Djordjevic, Albensi, 
& Fernyhough, 2015).  Similar to that of our previous experimentation, changes in CLU protein isoform 
expression will be evaluated/confirmed via immunoblot analysis. The data generated from these studies is 




bioenergetics: (1) Does knockdown of intracellular CLU in general impact respiratory capacity or 
mitochondrial stability in primary astrocytes and/or neurons? (2) Which brain cell type is more significantly 
bioenergetically impacted by CLU deficiency? (3) Does deficiency in intracellular CLU exacerbate the 
respiratory deficiencies previously observed in mCLU-KO mice? and (4) Does CLU deficiency negatively 
impact mitochondrial stability? 
 
Working Hypothesis Part IV: Loss of estrogen signaling exacerbates bioenergetic stress mediated by 
mCLU deficiency. Data presented in this dissertation indicate that CLU_49 kDa is significantly regulated 
by estrogen signaling in the brain. While we have yet to examine whether estrogen signaling regulates 
CLU_45 kDa and/or CLU_53 kDa, these data demonstrate that all CLU protein isoforms derived from the 
CLU_49 kDa band are regulated by estrogen signaling in one way or another. Indeed, though not presented 
in this dissertation, we did observe significant alterations in the expression of CLU_80 kDa following E2 
treatment in primary cortical neurons. Moreover, based on the location of the predicted EREs in the CLU 
promoter (upstream of Exon 1), it is feasible to suspect that estrogenic signaling may regulate the expression 
of all three predicted CLU pre-proteins and likewise, loss of estrogen signaling may negatively affect the 
expression of all three pre-proteins and the resultant higher molecular weight CLU protein isoforms. 
Therefore, the possible estrogenic regulation of both CLU_53 kDa and CLU_45 kDa will be examined in 
primary cortical neurons using the protocols established in this dissertation. Following the completion of 
preliminary studies, we will determine whether estrogen depletion exacerbates the previously observed 
bioenergetic stress in mCLU-KO mice, using an in vivo experiment designed to directly assess the 
interaction between sex, CLU, and brain metabolism. Briefly, 3-month-old female WT and mCLU-KO 
mice will be subjected to a sham surgery or ovariectomized (OVX) to create 4 different experimental 
groups: WT – Sham = Total control, WT – OVX = Control for estrogen loss, CLU-KO – Sham = Control 
for CLU deficiency, and CLU-KO – OVX – Experimental Group. Crude mitochondria will be isolated from 




previously described. In addition, CLU pre-protein expression levels will also be examined in each group 
to determine the impact of estrogen deficiency on the expression of CLU_45 kDa and CLU_53 kDa. The 
data generated from these studies is expected to answer the following 2 questions: (1) Are all CLU pre-
proteins positively regulated by estrogenic signaling in cortical neurons? (2) Are the observed mCLU-KO-
dependent deficiencies in brain mitochondrial respiration exacerbated by loss of estrogen signaling in young 
female brain?  
 
 
The Generation of a Total CLU-KO Mouse Model. As previously discussed, the assumed commercially 
available CLU-KO mouse model is not in fact a total CLU-KO. Therefore, we propose the generation of a 
truly CLU-deficient animal model via targeted deletion of Exons 1-3. Targeted disruption or deletion of 
Exons 1-3 would eliminate the transcription of any CLU mRNA isoform generating a total CLU knockout 
animal. A total knockout mouse model, which could be used in conjunction with WT and mCLU-KO 
animals, would be an invaluable tool for investigating the impact of not only total CLU deficiency, but also 
the impact of mitochondrial CLU deficiency on brain function.  
 
Schematic 24. Proposed Experimental Plan to Investigate Working Hypothesis Part IV. Female WT and 
mCLU-KO mice will be subjected to either Sham surgery or ovariectomized to create the indicated 4 groups. 
Mitochondrial respirometry, membrane potential and mitochondrial oxidative stress will then be measured in each 




The Compensatory Relationship Between CLU and APOE. It is particularly interesting that 2 of the top 
5 genetic risk factors associated with the development of LOAD are members of the apolipoprotein family: 
APOE and CLU. Therefore, another avenue of research to be considered in the AD field is the possibility 
of intersecting or overlapping risk pathways mediated by similar genetic risk factors. Studies have shown 
that APOE and CLU share a number of important physiological characteristics. For instance, they are 
among the few proteins associated with brain lipoproteins (Elliott, Weickert, & Garner, 2010; Koch et al., 
2001). They interact with a shared set of cell-surface receptors (Kounnas et al., 1995) and both APOE and 
CLU promote neurite outgrowth (Kang et al., 2005; Nathan et al., 1994). Moreover, elimination of either 
protein in an AD mouse model results in increased accumulation of Aβ (DeMattos et al., 2004). 
Furthermore, presence of the C-allele of the CLU AD-risk SNP has been shown to exacerbate the APOE 
ε4-mediated decrease in brain activity during executive attention tasks in young healthy dementia-free 
adults (Green et al., 2014). In addition, the genetic variance that results in increased AD risk from both 
genes is also associated with compromised or reduced protein expression and/or binding capabilities. Our 
preliminary data indicate that APOE protein expression levels are significantly increased in 6-month-old 
female mCLU-KO mice. However, mCLU expression levels are significantly reduced in 6-month-old 
female human APOE ε4 gene targeted-replacement mice when compared to APOE ε3 mice indicating that 
reduced CLU expression may contribute to APOE ε4-mediated AD risk. Collectively, these studies indicate 
that APOE and CLU could share common risk pathways that contribute to the development of LOAD. 
Delineation of such pathways will potentially provide valuable insights for an increased understanding of 
the etiology of LOAD and ultimately help to devise therapeutic strategies to prevent or reduce the risk of 





Abe, Y., Shodai, T., Muto, T., Mihara, K., Torii, H., Nishikawa, S., . . . Kohda, D. (2000). Structural basis 
of presequence recognition by the mitochondrial protein import receptor Tom20. Cell, 100(5), 
551-560.  
Aging, N. I. o. (2015). Alzheimer's Disease. 1-8.  
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., . . . Wyss-Coray, T. (2000). 
Inflammation and Alzheimer's disease. Neurobiol Aging, 21(3), 383-421.  
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging 
Initiative, I. (2014). Sex modifies the APOE-related risk of developing Alzheimer disease. Ann 
Neurol, 75(4), 563-573. doi: 10.1002/ana.24135 
Alvarez, J. I., Katayama, T., & Prat, A. (2013). Glial influence on the blood brain barrier. Glia, 61(12), 
1939-1958. doi: 10.1002/glia.22575 
Alzheimer's, A. (2015). 2015 Alzheimer's disease facts and figures. Alzheimers Dement, 11(3), 332-384.  
Amy S. Yokoyama, J. C. R. a. V. M. (2017). DNA methylation alterations in Alzheimer's Disease. 
Environmental Epigenetics, 3(2), 1-11. doi: 10.1093/eep/dvx008 
Baghirova, S., Hughes, B. G., Hendzel, M. J., & Schulz, R. (2015). Sequential fractionation and isolation 
of subcellular proteins from tissue or cultured cells. MethodsX, 2, 440-445. doi: 
10.1016/j.mex.2015.11.001 
Bailey, R. W., Dunker, A. K., Brown, C. J., Garner, E. C., & Griswold, M. D. (2001). Clusterin, a binding 
protein with a molten globule-like region. Biochemistry, 40(39), 11828-11840.  
Balantinou, E., Trougakos, I. P., Chondrogianni, N., Margaritis, L. H., & Gonos, E. S. (2009). 
Transcriptional and posttranslational regulation of clusterin by the two main cellular proteolytic 
pathways. Free Radic Biol Med, 46(9), 1267-1274.  
Barres, B. A. (1991). Glial ion channels. Curr Opin Neurobiol, 1(3), 354-359.  
Bartl, M. M., Luckenbach, T., Bergner, O., Ullrich, O., & Koch-Brandt, C. (2001). Multiple receptors 
mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp Cell 
Res, 271(1), 130-141. doi: 10.1006/excr.2001.5358 
Beer, T. M., Hotte, S. J., Saad, F., Alekseev, B., Matveev, V., Flechon, A., . . . Fizazi, K. (2017). 
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and 
prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated 
with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncol. 
doi: 10.1016/S1470-2045(17)30605-8 
Belanger, M., & Magistretti, P. J. (2009). The role of astroglia in neuroprotection. Dialogues Clin 
Neurosci, 11(3), 281-295.  
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. 
(2007). Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and 
apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab, 27(5), 
909-918. doi: 10.1038/sj.jcbfm.9600419 
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007). Systematic meta-analyses 
of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet, 39(1), 17-23. 
doi: 10.1038/ng1934 
Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C., Harrell, L. E., . . . Tanzi, R. (1997). 
ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology, 48(1), 
139-147.  
Bradley-Whitman, M. A., & Lovell, M. A. (2013). Epigenetic changes in the progression of Alzheimer's 
disease. Mech Ageing Dev, 134(10), 486-495. doi: 10.1016/j.mad.2013.08.005 
Braskie, M. N., Jahanshad, N., Stein, J. L., Barysheva, M., McMahon, K. L., de Zubicaray, G. I., . . . 
Thompson, P. M. (2011). Common Alzheimer's disease risk variant within the CLU gene affects 





Burkey, B. F., deSilva, H. V., & Harmony, J. A. (1991). Intracellular processing of apolipoprotein J 
precursor to the mature heterodimer. J Lipid Res, 32(6), 1039-1048.  
Burkey, B. F., Stuart, W. D., & Harmony, J. A. (1992). Hepatic apolipoprotein J is secreted as a 
lipoprotein. J Lipid Res, 33(10), 1517-1526.  
Byun, K., Gil, S. Y., Namkoong, C., Youn, B. S., Huang, H., Shin, M. S., . . . Kim, M. S. (2014). 
Clusterin/ApoJ enhances central leptin signaling through Lrp2-mediated endocytosis. EMBO Rep, 
15(7), 801-808. doi: 10.15252/embr.201338317 
Cao, X., Yeo, G., Muotri, A. R., Kuwabara, T., & Gage, F. H. (2006). Noncoding RNAs in the 
mammalian central nervous system. Annu Rev Neurosci, 29, 77-103. doi: 
10.1146/annurev.neuro.29.051605.112839 
Cardoso, S. M., Santana, I., Swerdlow, R. H., & Oliveira, C. R. (2004). Mitochondria dysfunction of 
Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem, 89(6), 1417-1426. doi: 
10.1111/j.1471-4159.2004.02438.x 
Cartharius, K., Frech, K., Grote, K., Klocke, B., Haltmeier, M., Klingenhoff, A., . . . Werner, T. (2005). 
MatInspector and beyond: promoter analysis based on transcription factor binding sites. 
Bioinformatics, 21(13), 2933-2942. doi: 10.1093/bioinformatics/bti473 
Cascella, R., Conti, S., Tatini, F., Evangelisti, E., Scartabelli, T., Casamenti, F., . . . Cecchi, C. (2013). 
Extracellular chaperones prevent Abeta42-induced toxicity in rat brains. Biochim Biophys Acta, 
1832(8), 1217-1226. doi: 10.1016/j.bbadis.2013.04.012 
Cervellera, M., Raschella, G., Santilli, G., Tanno, B., Ventura, A., Mancini, C., . . . Sala, A. (2000). 
Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol 
Chem, 275(28), 21055-21060. doi: 10.1074/jbc.M002055200 
Chaiwatanasirikul, K. A., & Sala, A. (2011). The tumour-suppressive function of CLU is explained by its 
localisation and interaction with HSP60. Cell Death Dis, 2, e219. doi: 10.1038/cddis.2011.99 
Chapman, R. M., Mapstone, M., Gardner, M. N., Sandoval, T. C., McCrary, J. W., Guillily, M. D., . . . 
DeGrush, E. (2011). Women have farther to fall: gender differences between normal elderly and 
Alzheimer's disease in verbal memory engender better detection of Alzheimer's disease in 
women. J Int Neuropsychol Soc, 17(4), 654-662. doi: 10.1017/S1355617711000452 
Chayka, O., Corvetta, D., Dews, M., Caccamo, A. E., Piotrowska, I., Santilli, G., . . . Sala, A. (2009). 
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst, 
101(9), 663-677. doi: 10.1093/jnci/djp063 
Chen, L. H., Kao, P. Y., Fan, Y. H., Ho, D. T., Chan, C. S., Yik, P. Y., . . . Song, Y. Q. (2012). 
Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a 
southern Chinese population. Neurobiol Aging, 33(1), 210 e211-217. doi: 
10.1016/j.neurobiolaging.2011.09.016 
Chi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., . . . Gleave, M. E. (2005). 
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl 
antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer 
Inst, 97(17), 1287-1296. doi: 10.1093/jnci/dji252 
Chi, K. N., Higano, C. S., Blumenstein, B. A., Reeves, J. A., Feyerabend, S., Gravis, G., . . . Investigators, 
S. (2015). Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) 
with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. Journal of 
Clinical Oncology, 33(15).  
Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D., Eigl, B. J., Tannock, I., . . . Eisenhauer, E. A. (2010). 
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients 
with metastatic castration-resistant prostate cancer. J Clin Oncol, 28(27), 4247-4254. doi: 
10.1200/JCO.2009.26.8771 
Chi, K. N., Siu, L. L., Hirte, H., Hotte, S. J., Knox, J., Kollmansberger, C., . . . Eisenhauer, E. (2008). A 
phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in 





Chia, S., Dent, S., Ellard, S., Ellis, P. M., Vandenberg, T., Gelmon, K., . . . Eisenhauer, E. A. (2009). 
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer 
Res, 15(2), 708-713. doi: 10.1158/1078-0432.CCR-08-1159 
Choi, N. H., Mazda, T., & Tomita, M. (1989). A serum protein SP40,40 modulates the formation of 
membrane attack complex of complement on erythrocytes. Mol Immunol, 26(9), 835-840.  
Choi, N. H., Nakano, Y., Tobe, T., Mazda, T., & Tomita, M. (1990). Incorporation of SP-40,40 into the 
soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol, 2(5), 413-417.  
Chouliaras, L., Mastroeni, D., Delvaux, E., Grover, A., Kenis, G., Hof, P. R., . . . van den Hove, D. L. 
(2013). Consistent decrease in global DNA methylation and hydroxymethylation in the 
hippocampus of Alzheimer's disease patients. Neurobiol Aging, 34(9), 2091-2099. doi: 
10.1016/j.neurobiolaging.2013.02.021 
Chowdhury, S. R., Djordjevic, J., Albensi, B. C., & Fernyhough, P. (2015). Simultaneous evaluation of 
substrate-dependent oxygen consumption rates and mitochondrial membrane potential by TMRM 
and safranin in cortical mitochondria. Biosci Rep, 36(1), e00286. doi: 10.1042/BSR20150244 
Cochrane, D. R., Wang, Z., Muramaki, M., Gleave, M. E., & Nelson, C. C. (2007). Differential regulation 
of clusterin and its isoforms by androgens in prostate cells. J Biol Chem, 282(4), 2278-2287. doi: 
10.1074/jbc.M608162200 
Connor, J. R., Kumar, S., Sathe, G., Mooney, J., O'Brien, S. P., Mui, P., . . . Lark, M. W. (2001). 
Clusterin expression in adult human normal and osteoarthritic articular cartilage. Osteoarthritis 
Cartilage, 9(8), 727-737. doi: 10.1053/joca.2001.0475 
Cooper, G. a. S. M. (2000). Protein Degradation The Cell: A Molecular Approach (2nd Edition ed.): 
Sinauer Associates. 
Coppieters, N., Dieriks, B. V., Lill, C., Faull, R. L., Curtis, M. A., & Dragunow, M. (2014). Global 
changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. 
Neurobiol Aging, 35(6), 1334-1344. doi: 10.1016/j.neurobiolaging.2013.11.031 
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Jr., . . . 
et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. 
Nat Genet, 7(2), 180-184. doi: 10.1038/ng0694-180 
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., . . . 
Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of 
Alzheimer's disease in late onset families. Science, 261(5123), 921-923.  
Cordero-Llana, O., Scott, S. A., Maslen, S. L., Anderson, J. M., Boyle, J., Chowhdury, R. R., . . . 
Caldwell, M. A. (2011). Clusterin secreted by astrocytes enhances neuronal differentiation from 
human neural precursor cells. Cell Death Differ, 18(5), 907-913. doi: 10.1038/cdd.2010.169 
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., . . . Huentelman, M. J. 
(2010). Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically 
characterized and neuropathologically verified individuals. Hum Mol Genet, 19(16), 3295-3301. 
doi: 10.1093/hmg/ddq221 
Dabbs, R. A., & Wilson, M. R. (2014). Expression and purification of chaperone-active recombinant 
clusterin. PLoS One, 9(1), e86989. doi: 10.1371/journal.pone.0086989 
de Silva, H. V., Harmony, J. A., Stuart, W. D., Gil, C. M., & Robbins, J. (1990). Apolipoprotein J: 
structure and tissue distribution. Biochemistry, 29(22), 5380-5389.  
de Silva, H. V., Stuart, W. D., Park, Y. B., Mao, S. J., Gil, C. M., Wetterau, J. R., . . . Harmony, J. A. 
(1990). Purification and characterization of apolipoprotein J. J Biol Chem, 265(24), 14292-14297.  
Debure, L., Vayssiere, J. L., Rincheval, V., Loison, F., Le Drean, Y., & Michel, D. (2003). Intracellular 
clusterin causes juxtanuclear aggregate formation and mitochondrial alteration. J Cell Sci, 116(Pt 
15), 3109-3121. doi: 10.1242/jcs.00619 
DeMattos, R. B., Brendza, R. P., Heuser, J. E., Kierson, M., Cirrito, J. R., Fryer, J., . . . Holtzman, D. M. 
(2001). Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing 
lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int, 39(5-6), 415-425.  




D. M. (2004). ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence 
that ApoE regulates extracellular Abeta metabolism in vivo. Neuron, 41(2), 193-202.  
DeMattos, R. B., O'Dell M, A., Parsadanian, M., Taylor, J. W., Harmony, J. A., Bales, K. R., . . . 
Holtzman, D. M. (2002). Clusterin promotes amyloid plaque formation and is critical for neuritic 
toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 99(16), 10843-
10848. doi: 10.1073/pnas.162228299 
Dia, V. P., & Mejia, E. G. (2010). Lunasin promotes apoptosis in human colon cancer cells by 
mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer Lett, 
295(1), 44-53. doi: 10.1016/j.canlet.2010.02.010 
Dietzsch, E., Murphy, B. F., Kirszbaum, L., Walker, I. D., & Garson, O. M. (1992). Regional localization 
of the gene for clusterin (SP-40,40; gene symbol CLI) to human chromosome 8p12-->p21. 
Cytogenet Cell Genet, 61(3), 178-179.  
Ding, C., Wu, Z., Huang, L., Wang, Y., Xue, J., Chen, S., . . . Chen, S. (2015). Mitofilin and CHCHD6 
physically interact with Sam50 to sustain cristae structure. Sci Rep, 5, 16064. doi: 
10.1038/srep16064 
Drzezga, A., Grimmer, T., Henriksen, G., Muhlau, M., Perneczky, R., Miederer, I., . . . Kurz, A. (2009). 
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. 
Neurology, 72(17), 1487-1494. doi: 10.1212/WNL.0b013e3181a2e8d0 
Drzezga, A., Riemenschneider, M., Strassner, B., Grimmer, T., Peller, M., Knoll, A., . . . Kurz, A. (2005). 
Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology, 
64(1), 102-107. doi: 10.1212/01.WNL.0000148478.39691.D3 
Dukic, L., Simundic, A. M., Martinic-Popovic, I., Kackov, S., Diamandis, A., Begcevic, I., & Diamandis, 
E. P. (2016). The role of human kallikrein 6, clusterin and adiponectin as potential blood 
biomarkers of dementia. Clin Biochem, 49(3), 213-218. doi: 10.1016/j.clinbiochem.2015.10.014 
Dunker, A. K., Lawson, J. D., Brown, C. J., Williams, R. M., Romero, P., Oh, J. S., . . . Obradovic, Z. 
(2001). Intrinsically disordered protein. J Mol Graph Model, 19(1), 26-59.  
E, Q., Liu, X., Liu, Y., Liu, W., & Zuo, J. (2013). Over-expression of GRP75 inhibits liver injury induced 
by oxidative damage. Acta Biochim Biophys Sin (Shanghai), 45(2), 129-134. doi: 
10.1093/abbs/gms098 
Elliott, D. A., Weickert, C. S., & Garner, B. (2010). Apolipoproteins in the brain: implications for 
neurological and psychiatric disorders. Clin Lipidol, 51(4), 555-573. doi: 10.2217/CLP.10.37 
Erk, S., Meyer-Lindenberg, A., Opitz von Boberfeld, C., Esslinger, C., Schnell, K., Kirsch, P., . . . Walter, 
H. (2011). Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. 
J Neurosci, 31(49), 18180-18184. doi: 10.1523/JNEUROSCI.4960-11.2011 
Essabbani, A., Margottin-Goguet, F., & Chiocchia, G. (2010). Identification of clusterin domain involved 
in NF-kappaB pathway regulation. J Biol Chem, 285(7), 4273-4277. doi: 
10.1074/jbc.C109.057133 
Esteller, M. (2011). Non-coding RNAs in human disease. Nat Rev Genet, 12(12), 861-874. doi: 
10.1038/nrg3074 
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., . . . van Duijn, C. M. 
(1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype 
and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis 
Consortium. JAMA, 278(16), 1349-1356.  
Ferrari, R., Moreno, J. H., Minhajuddin, A. T., O'Bryant, S. E., Reisch, J. S., Barber, R. C., & Momeni, P. 
(2012). Implication of common and disease specific variants in CLU, CR1, and PICALM. 
Neurobiol Aging, 33(8), 1846 e1847-1818. doi: 10.1016/j.neurobiolaging.2012.01.110 
Finch, C. E., Felicio, L. S., Mobbs, C. V., & Nelson, J. F. (1984). Ovarian and steroidal influences on 
neuroendocrine aging processes in female rodents. Endocr Rev, 5(4), 467-497. doi: 10.1210/edrv-
5-4-467 
Fleisher, A., Grundman, M., Jack, C. R., Jr., Petersen, R. C., Taylor, C., Kim, H. T., . . . Alzheimer's 




in mild cognitive impairment. Arch Neurol, 62(6), 953-957. doi: 10.1001/archneur.62.6.953 
Fritz, I. B., Burdzy, K., Setchell, B., & Blaschuk, O. (1983). Ram rete testis fluid contains a protein 
(clusterin) which influences cell-cell interactions in vitro. Biol Reprod, 28(5), 1173-1188.  
Fu, Y., Lai, Y., Wang, Q., Liu, X., He, W., Zhang, H., . . . Yang, G. (2013). Overexpression of clusterin 
promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer. Mol 
Med Rep, 7(6), 1726-1732. doi: 10.3892/mmr.2013.1436 
Gao, S., Hendrie, H. C., Hall, K. S., & Hui, S. (1998). The relationships between age, sex, and the 
incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry, 55(9), 809-
815.  
Ghiggeri, G. M., Bruschi, M., Candiano, G., Rastaldi, M. P., Scolari, F., Passerini, P., . . . Ponticelli, C. 
(2002). Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int, 62(6), 
2184-2194. doi: 10.1046/j.1523-1755.2002.00664.x 
Ghiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N. H., Tomita, M., Wisniewski, T., & Frangione, B. 
(1993). The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-
40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J, 
293 ( Pt 1), 27-30.  
Ghosh, P., Hale, E. A., & Lakshman, M. R. (2001). Plasma sialic-acid index of apolipoprotein J (SIJ): a 
new alcohol intake marker. Alcohol, 25(3), 173-179.  
Golenkina, S. A., Gol'tsov, A., Kuznetsova, I. L., Grigorenko, A. P., Andreeva, T. V., Reshetov, D. A., . . 
. Rogaev, E. I. (2010). [Analysis of clusterin gene (CLU/APOJ) polymorphism in Alzheimer's 
disease patients and in normal cohorts from Russian populations]. Mol Biol (Mosk), 44(4), 620-
626.  
Greber, B. J., & Ban, N. (2016). Structure and Function of the Mitochondrial Ribosome. Annu Rev 
Biochem, 85, 103-132. doi: 10.1146/annurev-biochem-060815-014343 
Green, A. E., Gray, J. R., Deyoung, C. G., Mhyre, T. R., Padilla, R., Dibattista, A. M., & William 
Rebeck, G. (2014). A combined effect of two Alzheimer's risk genes on medial temporal activity 
during executive attention in young adults. Neuropsychologia, 56, 1-8. doi: 
10.1016/j.neuropsychologia.2013.12.020 
Guillamon-Vivancos, T., Gomez-Pinedo, U., & Matias-Guiu, J. (2015). Astrocytes in neurodegenerative 
diseases (I): function and molecular description. Neurologia, 30(2), 119-129. doi: 
10.1016/j.nrl.2012.12.007 
Gutacker, C., Klock, G., Diel, P., & Koch-Brandt, C. (1999). Nerve growth factor and epidermal growth 
factor stimulate clusterin gene expression in PC12 cells. Biochem J, 339 ( Pt 3), 759-766.  
Hamada, N., Miyata, M., Eto, H., Ikeda, Y., Shirasawa, T., Akasaki, Y., . . . Tei, C. (2011). Loss of 
clusterin limits atherosclerosis in apolipoprotein E-deficient mice via reduced expression of Egr-1 
and TNF-alpha. J Atheroscler Thromb, 18(3), 209-216.  
Han, B. H., DeMattos, R. B., Dugan, L. L., Kim-Han, J. S., Brendza, R. P., Fryer, J. D., . . . Holtzman, D. 
M. (2001). Clusterin contributes to caspase-3-independent brain injury following neonatal 
hypoxia-ischemia. Nat Med, 7(3), 338-343. doi: 10.1038/85487 
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., . . . Williams, J. 
(2009). Genome-wide association study identifies variants at CLU and PICALM associated with 
Alzheimer's disease. Nat Genet, 41(10), 1088-1093. doi: 10.1038/ng.440 
Haseloff, R. F., Blasig, I. E., Bauer, H. C., & Bauer, H. (2005). In search of the astrocytic factor(s) 
modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol 
Neurobiol, 25(1), 25-39.  
Hassan, M. K., Watari, H., Han, Y., Mitamura, T., Hosaka, M., Wang, L., . . . Sakuragi, N. (2011). 
Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting 
clusterin improves response to paclitaxel. J Exp Clin Cancer Res, 30, 113. doi: 10.1186/1756-
9966-30-113 
He, L. R., Liu, M. Z., Li, B. K., Rao, H. L., Liao, Y. J., Zhang, L. J., . . . Xie, D. (2009). Clusterin as a 




carcinoma. Cancer Sci, 100(12), 2354-2360. doi: 10.1111/j.1349-7006.2009.01349.x 
Heikaus, S., Winterhager, E., Traub, O., & Grummer, R. (2002). Responsiveness of endometrial genes 
Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor 
modulators, phyto- and xenoestrogens. J Mol Endocrinol, 29(2), 239-249.  
Higano, C. S. (2013). Potential use of custirsen to treat prostate cancer. Onco Targets Ther, 6, 785-797. 
doi: 10.2147/OTT.S33077 
Hoeller, C., Pratscher, B., Thallinger, C., Winter, D., Fink, D., Kovacic, B., . . . Jansen, B. (2005). 
Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol, 124(6), 1300-1307. doi: 
10.1111/j.0022-202X.2005.23720.x 
Hof, P. R., & Morrison, J. H. (1990). Quantitative analysis of a vulnerable subset of pyramidal neurons in 
Alzheimer's disease: II. Primary and secondary visual cortex. J Comp Neurol, 301(1), 55-64. doi: 
10.1002/cne.903010106 
Hong, G. H., Kwon, H. S., Moon, K. A., Park, S. Y., Park, S., Lee, K. Y., . . . Cho, Y. S. (2016). Clusterin 
Modulates Allergic Airway Inflammation by Attenuating CCL20-Mediated Dendritic Cell 
Recruitment. J Immunol, 196(5), 2021-2030. doi: 10.4049/jimmunol.1500747 
Hsu, Y. T., Wolter, K. G., & Youle, R. J. (1997). Cytosol-to-membrane redistribution of Bax and Bcl-
X(L) during apoptosis. Proc Natl Acad Sci U S A, 94(8), 3668-3672.  
Imhof, A., Charnay, Y., Vallet, P. G., Aronow, B., Kovari, E., French, L. E., . . . Giannakopoulos, P. 
(2006). Sustained astrocytic clusterin expression improves remodeling after brain ischemia. 
Neurobiol Dis, 22(2), 274-283. doi: 10.1016/j.nbd.2005.11.009 
Irvine, K., Laws, K. R., Gale, T. M., & Kondel, T. K. (2012). Greater cognitive deterioration in women 
than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol, 34(9), 989-998. 
doi: 10.1080/13803395.2012.712676 
Jenne, D. E., & Tschopp, J. (1989). Molecular structure and functional characterization of a human 
complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated 
glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A, 86(18), 7123-7127.  
Jensen, A. A., Fahlke, C., Bjorn-Yoshimoto, W. E., & Bunch, L. (2015). Excitatory amino acid 
transporters: recent insights into molecular mechanisms, novel modes of modulation and new 
therapeutic possibilities. Curr Opin Pharmacol, 20, 116-123. doi: 10.1016/j.coph.2014.10.008 
Jiao, S., Dai, W., Lu, L., Liu, Y., Zhou, J., Li, Y., . . . Duan, C. (2011). The conserved clusterin gene is 
expressed in the developing choroid plexus under the regulation of notch but not IGF signaling in 
zebrafish. Endocrinology, 152(5), 1860-1871. doi: 10.1210/en.2010-1183 
Jin, G., & Howe, P. H. (1997). Regulation of clusterin gene expression by transforming growth factor 
beta. J Biol Chem, 272(42), 26620-26626.  
Jin, G., & Howe, P. H. (1999). Transforming growth factor beta regulates clusterin gene expression via 
modulation of transcription factor c-Fos. Eur J Biochem, 263(2), 534-542.  
Jongbloed, W., van Dijk, K. D., Mulder, S. D., van de Berg, W. D., Blankenstein, M. A., van der Flier, 
W., & Veerhuis, R. (2015). Clusterin Levels in Plasma Predict Cognitive Decline and Progression 
to Alzheimer's Disease. J Alzheimers Dis, 46(4), 1103-1110. doi: 10.3233/JAD-150036 
July, L. V., Akbari, M., Zellweger, T., Jones, E. C., Goldenberg, S. L., & Gleave, M. E. (2002). Clusterin 
expression is significantly enhanced in prostate cancer cells following androgen withdrawal 
therapy. Prostate, 50(3), 179-188.  
Jun, G., Naj, A. C., Beecham, G. W., Wang, L. S., Buros, J., Gallins, P. J., . . . Schellenberg, G. D. 
(2010). Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and 
reveals interactions with APOE genotypes. Arch Neurol, 67(12), 1473-1484. doi: 
10.1001/archneurol.2010.201 
Jun, H. O., Kim, D. H., Lee, S. W., Lee, H. S., Seo, J. H., Kim, J. H., . . . Kim, K. W. (2011). Clusterin 
protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/GSK-3beta 
signaling pathway. Exp Mol Med, 43(1), 53-61. doi: 10.3858/emm.2011.43.1.006 
Jung, G. S., Kim, M. K., Jung, Y. A., Kim, H. S., Park, I. S., Min, B. H., . . . Lee, I. K. (2012). Clusterin 





Kamboh, M. I., Minster, R. L., Demirci, F. Y., Ganguli, M., Dekosky, S. T., Lopez, O. L., & Barmada, 
M. M. (2012). Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol 
Aging, 33(3), 518-521. doi: 10.1016/j.neurobiolaging.2010.04.015 
Kang, S. W., Shin, Y. J., Shim, Y. J., Jeong, S. Y., Park, I. S., & Min, B. H. (2005). Clusterin interacts 
with SCLIP (SCG10-like protein) and promotes neurite outgrowth of PC12 cells. Exp Cell Res, 
309(2), 305-315. doi: 10.1016/j.yexcr.2005.06.012 
Kapron, J. T., Hilliard, G. M., Lakins, J. N., Tenniswood, M. P., West, K. A., Carr, S. A., & Crabb, J. W. 
(1997). Identification and characterization of glycosylation sites in human serum clusterin. 
Protein Sci, 6(10), 2120-2133. doi: 10.1002/pro.5560061007 
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., . . . Lovestone, S. (2014). 
Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK 
pathway. Mol Psychiatry, 19(1), 88-98. doi: 10.1038/mp.2012.163 
Kim, J. H., Kim, J. H., Yu, Y. S., Min, B. H., & Kim, K. W. (2007). The role of clusterin in retinal 
development and free radical damage. Br J Ophthalmol, 91(11), 1541-1546. doi: 
10.1136/bjo.2007.115220 
Kim, N., Han, J. Y., Roh, G. S., Kim, H. J., Kang, S. S., Cho, G. J., . . . Choi, W. S. (2012). Nuclear 
clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. 
Alcohol Clin Exp Res, 36(1), 72-82. doi: 10.1111/j.1530-0277.2011.01588.x 
Kim, N., Yoo, J. C., Han, J. Y., Hwang, E. M., Kim, Y. S., Jeong, E. Y., . . . Choi, W. S. (2012). Human 
nuclear clusterin mediates apoptosis by interacting with Bcl-XL through C-terminal coiled coil 
domain. J Cell Physiol, 227(3), 1157-1167. doi: 10.1002/jcp.22836 
Kimura, K., Asami, K., & Yamamoto, M. (1997). Effect of heat shock treatment on the production of 
variant testosterone-repressed prostate message-2 (TRPM-2) mRNA in culture cells. Cell 
Biochem Funct, 15(4), 251-257. doi: 10.1002/(SICI)1099-0844(199712)15:4<251::AID-
CBF748>3.0.CO;2-3 
Kirszbaum, L., Bozas, S. E., & Walker, I. D. (1992). SP-40,40, a protein involved in the control of the 
complement pathway, possesses a unique array of disulphide bridges. FEBS Lett, 297(1-2), 70-
76.  
Klimkowicz-Mrowiec, A., Sado, M., Dziubek, A., Dziedzic, T., Pera, J., Szczudlik, A., & Slowik, A. 
(2013). Lack of association of CR1, PICALM and CLU gene polymorphisms with Alzheimer 
disease in a Polish population. Neurol Neurochir Pol, 47(2), 157-160.  
Koch, S., Donarski, N., Goetze, K., Kreckel, M., Stuerenburg, H. J., Buhmann, C., & Beisiegel, U. 
(2001). Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res, 
42(7), 1143-1151.  
Koltai, T. (2014). Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther, 
7, 447-456. doi: 10.2147/OTT.S58622 
Komatsu, M., Shibata, N., Kuerban, B., Ohnuma, T., Baba, H., & Arai, H. (2011). Genetic association 
between clusterin polymorphisms and Alzheimer's disease in a Japanese population. 
Psychogeriatrics, 11(1), 14-18. doi: 10.1111/j.1479-8301.2010.00346.x 
Kounnas, M. Z., Loukinova, E. B., Stefansson, S., Harmony, J. A., Brewer, B. H., Strickland, D. K., & 
Argraves, W. S. (1995). Identification of glycoprotein 330 as an endocytic receptor for 
apolipoprotein J/clusterin. J Biol Chem, 270(22), 13070-13075.  
Kumita, J. R., Poon, S., Caddy, G. L., Hagan, C. L., Dumoulin, M., Yerbury, J. J., . . . Dobson, C. M. 
(2007). The extracellular chaperone clusterin potently inhibits human lysozyme amyloid 
formation by interacting with prefibrillar species. J Mol Biol, 369(1), 157-167. doi: 
10.1016/j.jmb.2007.02.095 
L, I. J., Dekker, L. J., Koudstaal, P. J., Hofman, A., Sillevis Smitt, P. A., Breteler, M. M., & Luider, T. M. 
(2011). Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J 
Proteome Res, 10(4), 2006-2010. doi: 10.1021/pr101221h 




(2002). Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry, 
41(1), 282-291.  
Lambert, J. C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., . . . Amouyel, P. (2009). 
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's 
disease. Nat Genet, 41(10), 1094-1099. doi: 10.1038/ng.439 
Lancaster, T. M., Baird, A., Wolf, C., Jackson, M. C., Johnston, S. J., Donev, R., . . . Linden, D. E. 
(2011). Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. 
Eur Neuropsychopharmacol, 21(12), 880-884. doi: 10.1016/j.euroneuro.2011.02.001 
Lancaster, T. M., Brindley, L. M., Tansey, K. E., Sims, R. C., Mantripragada, K., Owen, M. J., . . . 
Linden, D. E. (2015). Alzheimer's disease risk variant in CLU is associated with neural 
inefficiency in healthy individuals. Alzheimers Dement, 11(10), 1144-1152. doi: 
10.1016/j.jalz.2014.10.012 
Langbaum, J. B., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., . . . Alzheimer's Disease 
Neuroimaging, I. (2009). Categorical and correlational analyses of baseline fluorodeoxyglucose 
positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative 
(ADNI). Neuroimage, 45(4), 1107-1116. doi: 10.1016/j.neuroimage.2008.12.072 
Laskin, J. J., Nicholas, G., Lee, C., Gitlitz, B., Vincent, M., Cormier, Y., . . . Hao, D. (2012). Phase I/II 
trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and 
platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J 
Thorac Oncol, 7(3), 579-586. doi: 10.1097/JTO.0b013e31823f459c 
Lau, S. H., Sham, J. S., Xie, D., Tzang, C. H., Tang, D., Ma, N., . . . Guan, X. Y. (2006). Clusterin plays 
an important role in hepatocellular carcinoma metastasis. Oncogene, 25(8), 1242-1250. doi: 
10.1038/sj.onc.1209141 
Law, G. L., & Griswold, M. D. (1994). Activity and form of sulfated glycoprotein 2 (clusterin) from 
cultured Sertoli cells, testis, and epididymis of the rat. Biol Reprod, 50(3), 669-679.  
Lee, C. H., Jin, R. J., Kwak, C., Jeong, H., Park, M. S., Lee, N. K., & Lee, S. E. (2002). Suppression of 
clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells. 
Urology, 60(3), 516-520.  
Lee, J. H., Cheng, R., Barral, S., Reitz, C., Medrano, M., Lantigua, R., . . . Mayeux, R. (2011). 
Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in 
Caribbean Hispanic individuals. Arch Neurol, 68(3), 320-328. doi: 10.1001/archneurol.2010.292 
Leeb, C., Eresheim, C., & Nimpf, J. (2014). Clusterin is a ligand for apolipoprotein E receptor 2 
(ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-
signaling pathway. J Biol Chem, 289(7), 4161-4172. doi: 10.1074/jbc.M113.529271 
Lemansky, P., Brix, K., & Herzog, V. (1999). Subcellular distribution, secretion, and posttranslational 
modifications of clusterin in thyrocytes. Exp Cell Res, 251(1), 147-155. doi: 
10.1006/excr.1999.4555 
Leskov, K. S., Klokov, D. Y., Li, J., Kinsella, T. J., & Boothman, D. A. (2003). Synthesis and functional 
analyses of nuclear clusterin, a cell death protein. J Biol Chem, 278(13), 11590-11600. doi: 
10.1074/jbc.M209233200 
Li, J., Jia, L., Zhao, P., Jiang, Y., Zhong, S., & Chen, D. (2012). Stable knockdown of clusterin by 
vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and 
metastasis. J Int Med Res, 40(2), 545-555. doi: 10.1177/147323001204000216 
Lidstrom, A. M., Bogdanovic, N., Hesse, C., Volkman, I., Davidsson, P., & Blennow, K. (1998). 
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in 
Alzheimer's disease. Exp Neurol, 154(2), 511-521. doi: 10.1006/exnr.1998.6892 
Lin, Y. L., Chen, S. Y., Lai, L. C., Chen, J. H., Yang, S. Y., Huang, Y. L., . . . Chen, Y. C. (2012). 
Genetic polymorphisms of clusterin gene are associated with a decreased risk of Alzheimer's 
disease. Eur J Epidemiol. doi: 10.1007/s10654-012-9650-5 
Liu, B., Han, M. T., Zhang, J., Lu, P., Li, J., Song, N., . . . Zhang, W. (2013). Downregulation of clusterin 





Liu, B., Teschemacher, A. G., & Kasparov, S. (2017). Neuroprotective potential of astroglia. J Neurosci 
Res, 95(11), 2126-2139. doi: 10.1002/jnr.24140 
Liu, C. C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, 
mechanisms and therapy. Nat Rev Neurol, 9(2), 106-118. doi: 10.1038/nrneurol.2012.263 
Liu, Y., Liu, W., Song, X. D., & Zuo, J. (2005). Effect of GRP75/mthsp70/PBP74/mortalin 
overexpression on intracellular ATP level, mitochondrial membrane potential and ROS 
accumulation following glucose deprivation in PC12 cells. Mol Cell Biochem, 268(1-2), 45-51.  
Loison, F., Debure, L., Nizard, P., le Goff, P., Michel, D., & le Drean, Y. (2006). Up-regulation of the 
clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem J, 
395(1), 223-231. doi: 10.1042/BJ20051190 
Londou, A., Mikrou, A., & Zarkadis, I. K. (2008). Cloning and characterization of two clusterin isoforms 
in rainbow trout. Mol Immunol, 45(2), 470-478. doi: 10.1016/j.molimm.2007.05.027 
Lu, S. J., Li, H. L., Sun, Y. M., Liu, Z. J., Yang, P., & Wu, Z. Y. (2014). Clusterin variants are not 
associated with southern Chinese patients with Alzheimer's disease. Neurobiol Aging, 35(11), 
2656 e2659-2611. doi: 10.1016/j.neurobiolaging.2014.05.015 
Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., . . . Laskowitz, D. T. 
(2003). APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous 
system inflammatory response. J Biol Chem, 278(49), 48529-48533. doi: 
10.1074/jbc.M306923200 
Ma, J. F., Liu, L. H., Zhang, Y., Wang, Y., Deng, Y. L., Huang, Y., . . . Chen, S. D. (2011). Association 
study of clusterin polymorphism rs11136000 with late onset Alzheimer's disease in Chinese Han 
population. Am J Alzheimers Dis Other Demen, 26(8), 627-630. doi: 10.1177/1533317511432735 
Masoodi, T. A., Al Shammari, S. A., Al-Muammar, M. N., Alhamdan, A. A., & Talluri, V. R. (2013). 
Exploration of deleterious single nucleotide polymorphisms in late-onset Alzheimer disease 
susceptibility genes. Gene, 512(2), 429-437. doi: 10.1016/j.gene.2012.08.026 
Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., & Rogers, J. (2010). Epigenetic 
changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging, 31(12), 2025-
2037. doi: 10.1016/j.neurobiolaging.2008.12.005 
Mastroeni, D., McKee, A., Grover, A., Rogers, J., & Coleman, P. D. (2009). Epigenetic differences in 
cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One, 
4(8), e6617. doi: 10.1371/journal.pone.0006617 
Matsubara, E., Soto, C., Governale, S., Frangione, B., & Ghiso, J. (1996). Apolipoprotein J and 
Alzheimer's amyloid beta solubility. Biochem J, 316 ( Pt 2), 671-679.  
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990). 
Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and 
in response to experimental lesions in rat. Neuron, 5(6), 831-839.  
McBride, R. (2012). Pharma counts just 3 Alzheimer's drug wins in 13 years (101 losses!) [Press release] 
McGeer, P. L., Klegeris, A., Walker, D. G., Yasuhara, O., & McGeer, E. G. (1994). Pathological proteins 
in senile plaques. Tohoku J Exp Med, 174(3), 269-277.  
McLaughlin, L., Zhu, G., Mistry, M., Ley-Ebert, C., Stuart, W. D., Florio, C. J., . . . Aronow, B. J. (2000). 
Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest, 
106(9), 1105-1113. doi: 10.1172/JCI9037 
Messmer-Joudrier, S., Sagot, Y., Mattenberger, L., James, R. W., & Kato, A. C. (1996). Injury-induced 
synthesis and release of apolipoprotein E and clusterin from rat neural cells. Eur J Neurosci, 
8(12), 2652-2661.  
Michel, D., Chabot, J. G., Moyse, E., Danik, M., & Quirion, R. (1992). Possible functions of a new 
genetic marker in central nervous system: the sulfated glycoprotein-2 (SGP-2). Synapse, 11(2), 
105-111. doi: 10.1002/syn.890110203 
Michel, D., Chatelain, G., North, S., & Brun, G. (1997). Stress-induced transcription of the clusterin/apoJ 




Min, B. H., Jeong, S. Y., Kang, S. W., Crabo, B. G., Foster, D. N., Chun, B. G., . . . Park, I. S. (1998). 
Transient expression of clusterin (sulfated glycoprotein-2) during development of rat pancreas. J 
Endocrinol, 158(1), 43-52.  
Mishima, K., Inoue, H., Nishiyama, T., Mabuchi, Y., Amano, Y., Ide, F., . . . Saito, I. (2012). 
Transplantation of side population cells restores the function of damaged exocrine glands through 
clusterin. Stem Cells, 30(9), 1925-1937. doi: 10.1002/stem.1173 
Miyake, H., Chi, K. N., & Gleave, M. E. (2000). Antisense TRPM-2 oligodeoxynucleotides 
chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. 
Clin Cancer Res, 6(5), 1655-1663.  
Miyake, H., Gleave, M., Kamidono, S., & Hara, I. (2002). Overexpression of clusterin in transitional cell 
carcinoma of the bladder is related to disease progression and recurrence. Urology, 59(1), 150-
154.  
Miyake, H., Gleave, M. E., Arakawa, S., Kamidono, S., & Hara, I. (2002). Introducing the clusterin gene 
into human renal cell carcinoma cells enhances their metastatic potential. J Urol, 167(5), 2203-
2208.  
Mosienko, V., Teschemacher, A. G., & Kasparov, S. (2015). Is L-lactate a novel signaling molecule in the 
brain? J Cereb Blood Flow Metab, 35(7), 1069-1075. doi: 10.1038/jcbfm.2015.77 
Mukaetova-Ladinska, E. B., Abdel-All, Z., Andrade, J., Alves da Silva, J., O'Brien, J. T., & Kalaria, R. N. 
(2015). Plasma and platelet clusterin ratio is altered in Alzheimer's disease patients with distinct 
neuropsychiatric symptoms: findings from a pilot study. Int J Geriatr Psychiatry, 30(4), 368-375. 
doi: 10.1002/gps.4145 
Mukaetova-Ladinska, E. B., Abdel-All, Z., Dodds, S., Andrade, J., Alves da Silva, J., Kalaria, R. N., & 
O'Brien, J. T. (2012). Platelet immunoglobulin and amyloid precursor protein as potential 
peripheral biomarkers for Alzheimer's disease: findings from a pilot study. Age Ageing, 41(3), 
408-412. doi: 10.1093/ageing/afr171 
Murphy, B. F., Kirszbaum, L., Walker, I. D., & d'Apice, A. J. (1988). SP-40,40, a newly identified 
normal human serum protein found in the SC5b-9 complex of complement and in the immune 
deposits in glomerulonephritis. J Clin Invest, 81(6), 1858-1864. doi: 10.1172/JCI113531 
Nair, J. R., & McGuire, J. J. (2005). Submitochondrial localization of the mitochondrial isoform of 
folylpolyglutamate synthetase in CCRF-CEM human T-lymphoblastic leukemia cells. Biochim 
Biophys Acta, 1746(1), 38-44. doi: 10.1016/j.bbamcr.2005.08.004 
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., & Pitas, R. E. (1994). 
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science, 264(5160), 
850-852.  
Niu, Z., Li, X., Hu, B., Li, R., Wang, L., Wu, L., & Wang, X. (2012). Small interfering RNA targeted to 
secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim 
Biophys Sin (Shanghai), 44(12), 991-998. doi: 10.1093/abbs/gms091 
Nizard, P., Tetley, S., Le Drean, Y., Watrin, T., Le Goff, P., Wilson, M. R., & Michel, D. (2007). Stress-
induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic, 8(5), 554-565. doi: 
10.1111/j.1600-0854.2007.00549.x 
Nuutinen, T., Suuronen, T., Kyrylenko, S., Huuskonen, J., & Salminen, A. (2005). Induction of 
clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem Int, 47(8), 
528-538. doi: 10.1016/j.neuint.2005.07.007 
O'Bryan, M. K., Cheema, S. S., Bartlett, P. F., Murphy, B. F., & Pearse, M. J. (1993). Clusterin levels 
increase during neuronal development. J Neurobiol, 24(4), 421-432. doi: 10.1002/neu.480240402 
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., . . . et al. (1995). 
Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly 
sedimenting A beta complexes that cause oxidative stress. Exp Neurol, 136(1), 22-31.  
Orkand, R. K., Nicholls, J. G., & Kuffler, S. W. (1966). Effect of nerve impulses on the membrane 
potential of glial cells in the central nervous system of amphibia. J Neurophysiol, 29(4), 788-806.  




Vivo. In J. T. Kittler & S. J. Moss (Eds.), The Dynamic Synapse: Molecular Methods in 
Ionotropic Receptor Biology. Boca Raton (FL). 
Park, D. C., Yeo, S. G., Wilson, M. R., Yerbury, J. J., Kwong, J., Welch, W. R., . . . Wong, K. K. (2008). 
Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia, 
10(9), 964-972.  
Pasinetti, G. M., Johnson, S. A., Oda, T., Rozovsky, I., & Finch, C. E. (1994). Clusterin (SGP-2): a 
multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat 
brain. J Comp Neurol, 339(3), 387-400. doi: 10.1002/cne.903390307 
Payami, H., Montee, K. R., Kaye, J. A., Bird, T. D., Yu, C. E., Wijsman, E. M., & Schellenberg, G. D. 
(1994). Alzheimer's disease, apolipoprotein E4, and gender. JAMA, 271(17), 1316-1317.  
Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., Bird, T. D., . . . Schellenberg, G. D. 
(1996). Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a 
possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet, 58(4), 
803-811.  
Pedraza, O., Allen, M., Jennette, K., Carrasquillo, M., Crook, J., Serie, D., . . . Ertekin-Taner, N. (2014). 
Evaluation of memory endophenotypes for association with CLU, CR1, and PICALM variants in 
black and white subjects. Alzheimers Dement, 10(2), 205-213. doi: 10.1016/j.jalz.2013.01.016 
Phipps, A. J., Vickers, J. C., Taberlay, P. C., & Woodhouse, A. (2016). Neurofilament-labeled pyramidal 
neurons and astrocytes are deficient in DNA methylation marks in Alzheimer's disease. Neurobiol 
Aging, 45, 30-42. doi: 10.1016/j.neurobiolaging.2016.05.003 
Poon, S., Easterbrook-Smith, S. B., Rybchyn, M. S., Carver, J. A., & Wilson, M. R. (2000). Clusterin is 
an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed 
proteins in a folding-competent state. Biochemistry, 39(51), 15953-15960.  
Poon, S., Rybchyn, M. S., Easterbrook-Smith, S. B., Carver, J. A., Pankhurst, G. J., & Wilson, M. R. 
(2002). Mildly acidic pH activates the extracellular molecular chaperone clusterin. J Biol Chem, 
277(42), 39532-39540. doi: 10.1074/jbc.M204855200 
Prochnow, H., Gollan, R., Rohne, P., Hassemer, M., Koch-Brandt, C., & Baiersdorfer, M. (2013). Non-
secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants 
and do not affect Bax-mediated apoptosis or the NF-kappaB signaling pathway. PLoS One, 8(9), 
e75303. doi: 10.1371/journal.pone.0075303 
Purrello, M., Bettuzzi, S., Di Pietro, C., Mirabile, E., Di Blasi, M., Rimini, R., . . . Sichel, G. (1991). The 
gene for SP-40,40, human homolog of rat sulfated glycoprotein 2, rat clusterin, and rat 
testosterone-repressed prostate message 2, maps to chromosome 8. Genomics, 10(1), 151-156.  
Rao, J. S., Keleshian, V. L., Klein, S., & Rapoport, S. I. (2012). Epigenetic modifications in frontal cortex 
from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry, 2, e132. doi: 
10.1038/tp.2012.55 
Reddy, K. B., Jin, G., Karode, M. C., Harmony, J. A., & Howe, P. H. (1996). Transforming growth factor 
beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. 
Biochemistry, 35(19), 6157-6163. doi: 10.1021/bi952981b 
Redondo, M., Villar, E., Torres-Munoz, J., Tellez, T., Morell, M., & Petito, C. K. (2000). Overexpression 
of clusterin in human breast carcinoma. Am J Pathol, 157(2), 393-399. doi: 10.1016/S0002-
9440(10)64552-X 
Rohne, P., Prochnow, H., Wolf, S., Renner, B., & Koch-Brandt, C. (2014). The chaperone activity of 
clusterin is dependent on glycosylation and redox environment. Cell Physiol Biochem, 34(5), 
1626-1639. doi: 10.1159/000366365 
Rordorf, G., Koroshetz, W. J., & Bonventre, J. V. (1991). Heat shock protects cultured neurons from 
glutamate toxicity. Neuron, 7(6), 1043-1051.  
Roussotte, F. F., Gutman, B. A., Madsen, S. K., Colby, J. B., Thompson, P. M., & Alzheimer's Disease 
Neuroimaging, I. (2014). Combined effects of Alzheimer risk variants in the CLU and ApoE 





Rozovsky, I., Morgan, T. E., Willoughby, D. A., Dugichi-Djordjevich, M. M., Pasinetti, G. M., Johnson, 
S. A., & Finch, C. E. (1994). Selective expression of clusterin (SGP-2) and complement C1qB 
and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience, 62(3), 741-758.  
Rumi, M. A. K., Singh, P., Roby, K. F., Zhao, X., Iqbal, K., Ratri, A., . . . Soares, M. J. (2017). Defining 
the Role of Estrogen Receptor beta in the Regulation of Female Fertility. Endocrinology, 158(7), 
2330-2343. doi: 10.1210/en.2016-1916 
Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., . . . Canadian Uro-Oncology, G. (2011). 
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or 
mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer 
progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res, 17(17), 5765-5773. 
doi: 10.1158/1078-0432.CCR-11-0859 
Saitoh, T., Igura, M., Obita, T., Ose, T., Kojima, R., Maenaka, K., . . . Kohda, D. (2007). Tom20 
recognizes mitochondrial presequences through dynamic equilibrium among multiple bound 
states. EMBO J, 26(22), 4777-4787. doi: 10.1038/sj.emboj.7601888 
Sasaki, K., Doh-ura, K., Ironside, J., Mabbott, N., & Iwaki, T. (2006). Clusterin expression in follicular 
dendritic cells associated with prion protein accumulation. J Pathol, 209(4), 484-491. doi: 
10.1002/path.2009 
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., . . . Dobson, R. J. (2014). 
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. 
Alzheimers Dement, 10(6), 724-734. doi: 10.1016/j.jalz.2013.09.016 
Saunders, A. M., Schmader, K., Breitner, J. C., Benson, M. D., Brown, W. T., Goldfarb, L., . . . et al. 
(1993). Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in 
other amyloid-forming diseases. Lancet, 342(8873), 710-711.  
Savkovic, V., Gantzer, H., Reiser, U., Selig, L., Gaiser, S., Sack, U., . . . Bodeker, H. (2007). Clusterin is 
protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem 
Biophys Res Commun, 356(2), 431-437. doi: 10.1016/j.bbrc.2007.02.148 
Schmidt, R., Kienbacher, E., Benke, T., Dal-Bianco, P., Delazer, M., Ladurner, G., . . . Wehringer, C. 
(2008). [Sex differences in Alzheimer's disease]. Neuropsychiatr, 22(1), 1-15.  
Schnabel, J. (2013). Why Do All the Large Alzheimer’s Drug Trials Fail? [Press release] 
Schreiber, S. S., Tocco, G., Najm, I., & Baudry, M. (1993). Seizure activity causes a rapid increase in 
sulfated glycoprotein-2 messenger RNA in the adult but not the neonatal rat brain. Neurosci Lett, 
153(1), 17-20.  
Schrijvers, E. M., Koudstaal, P. J., Hofman, A., & Breteler, M. M. (2011). Plasma clusterin and the risk 
of Alzheimer disease. JAMA, 305(13), 1322-1326. doi: 10.1001/jama.2011.381 
Schurmann, B., Wiese, B., Bickel, H., Weyerer, S., Riedel-Heller, S. G., Pentzek, M., . . . Jessen, F. 
(2011). Association of the Alzheimer's disease clusterin risk allele with plasma clusterin 
concentration. J Alzheimers Dis, 25(3), 421-424. doi: 10.3233/JAD-2011-110251 
Seo, H. Y., Kim, M. K., Jung, Y. A., Jang, B. K., Yoo, E. K., Park, K. G., & Lee, I. K. (2013). Clusterin 
decreases hepatic SREBP-1c expression and lipid accumulation. Endocrinology, 154(5), 1722-
1730. doi: 10.1210/en.2012-2009 
Seshadri, S., Fitzpatrick, A. L., Ikram, M. A., DeStefano, A. L., Gudnason, V., Boada, M., . . . 
Consortium, E. (2010). Genome-wide analysis of genetic loci associated with Alzheimer disease. 
JAMA, 303(18), 1832-1840. doi: 10.1001/jama.2010.574 
Shi, H., Deng, J. H., Wang, Z., Cao, K. Y., Zhou, L., & Wan, H. (2013). Knockdown of clusterin inhibits 
the growth and migration of renal carcinoma cells and leads to differential gene expression. Mol 
Med Rep, 8(1), 35-40. doi: 10.3892/mmr.2013.1470 
Shirasawa, T., Miyata, M., Eto, H., Hamada, N., Akasaki, Y., Miyauchi, T., . . . Tei, C. (2009). 
Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury. J Atheroscler 
Thromb, 16(6), 772-781.  
Shuai, P., Liu, Y., Lu, W., Liu, Q., Li, T., & Gong, B. (2015). Genetic associations of CLU rs9331888 





Silajdzic, E., Minthon, L., Bjorkqvist, M., & Hansson, O. (2012). No diagnostic value of plasma clusterin 
in Alzheimer's disease. PLoS One, 7(11), e50237. doi: 10.1371/journal.pone.0050237 
So, A., Sinnemann, S., Huntsman, D., Fazli, L., & Gleave, M. (2005). Knockdown of the cytoprotective 
chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol 
Cancer Ther, 4(12), 1837-1849. doi: 10.1158/1535-7163.MCT-05-0178 
Song, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., . . . Sachdev, P. S. (2012). 
Plasma apolipoprotein levels are associated with cognitive status and decline in a community 
cohort of older individuals. PLoS One, 7(6), e34078. doi: 10.1371/journal.pone.0034078 
Stewart, E. M., Aquilina, J. A., Easterbrook-Smith, S. B., Murphy-Durland, D., Jacobsen, C., Moestrup, 
S., & Wilson, M. R. (2007). Effects of glycosylation on the structure and function of the 
extracellular chaperone clusterin. Biochemistry, 46(5), 1412-1422. doi: 10.1021/bi062082v 
Swerdlow, R. H., & Khan, S. M. (2004). A "mitochondrial cascade hypothesis" for sporadic Alzheimer's 
disease. Med Hypotheses, 63(1), 8-20. doi: 10.1016/j.mehy.2003.12.045 
Sylvester, S. R., Skinner, M. K., & Griswold, M. D. (1984). A sulfated glycoprotein synthesized by 
Sertoli cells and by epididymal cells is a component of the sperm membrane. Biol Reprod, 31(5), 
1087-1101.  
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., . . . von Mering, 
C. (2015). STRING v10: protein-protein interaction networks, integrated over the tree of life. 
Nucleic Acids Res, 43(Database issue), D447-452. doi: 10.1093/nar/gku1003 
Szymanski, M., Wang, R., Bassett, S. S., & Avramopoulos, D. (2011). Alzheimer's risk variants in the 
clusterin gene are associated with alternative splicing. Transl Psychiatry, 1. doi: 
10.1038/tp.2011.17 
Tang, M., Li, J., Liu, B., Song, N., Wang, Z., & Yin, C. (2013). Clusterin expression and human testicular 
seminoma. Med Hypotheses, 81(4), 635-637. doi: 10.1016/j.mehy.2013.07.019 
Teschemacher, A. G., Gourine, A. V., & Kasparov, S. (2015). A Role for Astrocytes in Sensing the Brain 
Microenvironment and Neuro-Metabolic Integration. Neurochem Res, 40(12), 2386-2393. doi: 
10.1007/s11064-015-1562-9 
Thambisetty, M., An, Y., Kinsey, A., Koka, D., Saleem, M., Guntert, A., . . . Resnick, S. M. (2012). 
Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive 
impairment. Neuroimage, 59(1), 212-217. doi: 10.1016/j.neuroimage.2011.07.056 
Thambisetty, M., Beason-Held, L. L., An, Y., Kraut, M., Nalls, M., Hernandez, D. G., . . . Resnick, S. M. 
(2013). Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry, 73(5), 399-
405. doi: 10.1016/j.biopsych.2012.05.026 
Tobe, T., Minoshima, S., Yamase, S., Choi, N. H., Tomita, M., & Shimizu, N. (1991). Assignment of a 
human serum glycoprotein SP-40,40 gene (CLI) to chromosome 8. Cytogenet Cell Genet, 57(4), 
193-195.  
Toral-Rios, D., Franco-Bocanegra, D., Rosas-Carrasco, O., Mena-Barranco, F., Carvajal-Garcia, R., 
Meraz-Rios, M. A., & Campos-Pena, V. (2015). Evaluation of inflammation-related genes 
polymorphisms in Mexican with Alzheimer's disease: a pilot study. Front Cell Neurosci, 9, 148. 
doi: 10.3389/fncel.2015.00148 
Tropschug, M., Nicholson, D. W., Hartl, F. U., Kohler, H., Pfanner, N., Wachter, E., & Neupert, W. 
(1988). Cyclosporin A-binding protein (cyclophilin) of Neurospora crassa. One gene codes for 
both the cytosolic and mitochondrial forms. J Biol Chem, 263(28), 14433-14440.  
Trougakos, I. P. (2013). The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative 
stress: implications in therapeutic approaches - a mini-review. Gerontology, 59(6), 514-523. doi: 
10.1159/000351207 
Trougakos, I. P., & Gonos, E. S. (2006). Regulation of clusterin/apolipoprotein J, a functional homologue 
to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free 
Radic Res, 40(12), 1324-1334. doi: 10.1080/10715760600902310 




Gonos, E. S. (2009). Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-
activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer 
Res, 15(1), 48-59. doi: 10.1158/1078-0432.CCR-08-1805 
Van Beek, J., Chan, P., Bernaudin, M., Petit, E., MacKenzie, E. T., & Fontaine, M. (2000). Glial 
responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia, 
31(1), 39-50.  
van der Laan, M., Horvath, S. E., & Pfanner, N. (2016). Mitochondrial contact site and cristae organizing 
system. Curr Opin Cell Biol, 41, 33-42. doi: 10.1016/j.ceb.2016.03.013 
Viard, I., Wehrli, P., Jornot, L., Bullani, R., Vechietti, J. L., Schifferli, J. A., . . . French, L. E. (1999). 
Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and 
oxidative stress. J Invest Dermatol, 112(3), 290-296. doi: 10.1046/j.1523-1747.1999.00531.x 
von der Malsburg, K., Muller, J. M., Bohnert, M., Oeljeklaus, S., Kwiatkowska, P., Becker, T., . . . van 
der Laan, M. (2011). Dual role of mitofilin in mitochondrial membrane organization and protein 
biogenesis. Dev Cell, 21(4), 694-707. doi: 10.1016/j.devcel.2011.08.026 
von Mering, C., Jensen, L. J., Snel, B., Hooper, S. D., Krupp, M., Foglierini, M., . . . Bork, P. (2005). 
STRING: known and predicted protein-protein associations, integrated and transferred across 
organisms. Nucleic Acids Res, 33(Database issue), D433-437. doi: 10.1093/nar/gki005 
Wang, X., Luo, L., Dong, D., Yu, Q., & Zhao, K. (2014). Clusterin plays an important role in clear renal 
cell cancer metastasis. Urol Int, 92(1), 95-103. doi: 10.1159/000351923 
Wang, Y., Qin, X., & Paudel, H. K. (2017). Amyloid beta peptide promotes lysosomal degradation of 
clusterin via sortilin in hippocampal primary neurons. Neurobiol Dis, 103, 78-88. doi: 
10.1016/j.nbd.2017.04.003 
Waters, K. M., Safe, S., & Gaido, K. W. (2001). Differential gene expression in response to methoxychlor 
and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. Toxicol 
Sci, 63(1), 47-56.  
Wehrli, P., Charnay, Y., Vallet, P., Zhu, G., Harmony, J., Aronow, B., . . . Giannakopoulos, P. (2001). 
Inhibition of post-ischemic brain injury by clusterin overexpression. Nat Med, 7(9), 977-979. doi: 
10.1038/nm0901-977 
Wei, L., Xue, T., Wang, J., Chen, B., Lei, Y., Huang, Y., . . . Xin, X. (2009). Roles of clusterin in 
progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer, 125(4), 791-
806. doi: 10.1002/ijc.24316 
Won, Y. S., Lee, S. J., Yeo, S. G., & Park, D. C. (2012). Effects of female sex hormones on clusterin 
expression and paclitaxel resistance in endometrial cancer cell lines. Int J Med Sci, 9(1), 86-92.  
Wong, P., Pineault, J., Lakins, J., Taillefer, D., Leger, J., Wang, C., & Tenniswood, M. (1993). Genomic 
organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J 
Biol Chem, 268(7), 5021-5031.  
Wu, Y., & Sha, B. (2006). Crystal structure of yeast mitochondrial outer membrane translocon member 
Tom70p. Nat Struct Mol Biol, 13(7), 589-593. doi: 10.1038/nsmb1106 
Wunsche, W., Tenniswood, M. P., Schneider, M. R., & Vollmer, G. (1998). Estrogenic regulation of 
clusterin mRNA in normal and malignant endometrial tissue. Int J Cancer, 76(5), 684-688.  
Wyatt, A., Yerbury, J., Poon, S., Dabbs, R., & Wilson, M. (2009). Chapter 6: The chaperone action of 
Clusterin and its putative role in quality control of extracellular protein folding. Adv Cancer Res, 
104, 89-114. doi: 10.1016/S0065-230X(09)04006-8 
Wyatt, A. R., Yerbury, J. J., & Wilson, M. R. (2009). Structural characterization of clusterin-chaperone 
client protein complexes. J Biol Chem, 284(33), 21920-21927. doi: 10.1074/jbc.M109.033688 
Xie, Z., Harris-White, M. E., Wals, P. A., Frautschy, S. A., Finch, C. E., & Morgan, T. E. (2005). 
Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. J Neurochem, 93(4), 
1038-1046. doi: 10.1111/j.1471-4159.2005.03065.x 
Xing, Y. Y., Yu, J. T., Cui, W. Z., Zhong, X. L., Wu, Z. C., Zhang, Q., & Tan, L. (2012). Blood clusterin 
levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J Alzheimers Dis, 29(3), 




Xiu, P., Dong, X. F., Li, X. P., & Li, J. (2015). Clusterin: Review of research progress and looking ahead 
to direction in hepatocellular carcinoma. World J Gastroenterol, 21(27), 8262-8270. doi: 
10.3748/wjg.v21.i27.8262 
Xue, J., Lv, D. D., Jiao, S., Zhao, W., Li, X., Sun, H., . . . Fang, J. (2012). pVHL mediates K63-linked 
ubiquitination of nCLU. PLoS One, 7(4), e35848. doi: 10.1371/journal.pone.0035848 
Yang, C. R., Leskov, K., Hosley-Eberlein, K., Criswell, T., Pink, J. J., Kinsella, T. J., & Boothman, D. A. 
(2000). Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. 
Proc Natl Acad Sci U S A, 97(11), 5907-5912.  
Yang, C. R., Yeh, S., Leskov, K., Odegaard, E., Hsu, H. L., Chang, C., . . . Boothman, D. A. (1999). 
Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res, 27(10), 2165-2174.  
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009). Mitochondrial 
bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's 
disease. Proc Natl Acad Sci U S A, 106(34), 14670-14675. doi: 10.1073/pnas.0903563106 
Yerbury, J. J., Poon, S., Meehan, S., Thompson, B., Kumita, J. R., Dobson, C. M., & Wilson, M. R. 
(2007). The extracellular chaperone clusterin influences amyloid formation and toxicity by 
interacting with prefibrillar structures. FASEB J, 21(10), 2312-2322. doi: 10.1096/fj.06-7986com 
Yu, J. T., Li, L., Zhu, Q. X., Zhang, Q., Zhang, W., Wu, Z. C., . . . Tan, L. (2010). Implication of CLU 
gene polymorphisms in Chinese patients with Alzheimer's disease. Clin Chim Acta, 411(19-20), 
1516-1519. doi: 10.1016/j.cca.2010.06.013 
Yu, J. T., Ma, X. Y., Wang, Y. L., Sun, L., Tan, L., Hu, N., & Tan, L. (2013). Genetic variation in 
clusterin gene and Alzheimer's disease risk in Han Chinese. Neurobiol Aging, 34(7), 1921 e1917-
1923. doi: 10.1016/j.neurobiolaging.2013.01.010 
Zeng, W., Lu, Y. H., Lee, J., & Friedman, J. M. (2015). Reanalysis of parabiosis of obesity mutants in the 
age of leptin. Proc Natl Acad Sci U S A, 112(29), E3874-3882. doi: 10.1073/pnas.1510378112 
Zhang, D., Sun, B., Zhao, X., Cui, Y., Xu, S., Dong, X., . . . Chi, J. (2012). Secreted CLU is associated 
with the initiation of triple-negative breast cancer. Cancer Biol Ther, 13(5), 321-329. doi: 
10.4161/cbt.19072 
Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C. Y. (2005). Clusterin inhibits 
apoptosis by interacting with activated Bax. Nat Cell Biol, 7(9), 909-915. doi: 10.1038/ncb1291 
Zhang, S., Li, X., Ma, G., Jiang, Y., Liao, M., Feng, R., . . . Liu, G. (2015). CLU rs9331888 
Polymorphism Contributes to Alzheimer's Disease Susceptibility in Caucasian But Not East 
Asian Populations. Mol Neurobiol. doi: 10.1007/s12035-015-9098-1 
Zhao, L., & Brinton, R. D. (2005). Structure-based virtual screening for plant-based ERbeta-selective 
ligands as potential preventative therapy against age-related neurodegenerative diseases. J Med 
Chem, 48(10), 3463-3466. doi: 10.1021/jm0490538 
Zhao, L., Mao, Z., & Brinton, R. D. (2009). A select combination of clinically relevant phytoestrogens 
enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in 
vivo. Endocrinology, 150(2), 770-783. doi: 10.1210/en.2008-0715 
Zhao, L., Mao, Z., Woody, S. K., & Brinton, R. D. (2016). Sex differences in metabolic aging of the 
brain: insights into female suceptibility to Alzheimer's disease Neurobiol Aging, 1-11. doi: 
10.1016/j.neurobiolaging.2016.02.011 
Zhao, L., Woody, S. K., & Chhibber, A. (2015). Estrogen receptor beta in Alzheimer's disease: From 
mechanisms to therapeutics. Ageing Res Rev. doi: 10.1016/j.arr.2015.08.001 
Zhao, L., Wu, T. W., & Brinton, R. D. (2004). Estrogen receptor subtypes alpha and beta contribute to 
neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res, 
1010(1-2), 22-34. doi: 10.1016/j.brainres.2004.02.066 
Zhao, L., Yao, J., Mao, Z., Chen, S., Wang, Y., & Brinton, R. D. (2011). 17beta-Estradiol regulates 
insulin-degrading enzyme expression via an ERbeta/PI3-K pathway in hippocampus: relevance to 
Alzheimer's prevention. Neurobiol Aging, 32(11), 1949-1963. doi: 
10.1016/j.neurobiolaging.2009.12.010 




clusterin expression worsens renal ischemia-reperfusion injury. Am J Physiol Renal Physiol, 
298(3), F568-578. doi: 10.1152/ajprenal.00399.2009 
Zoubeidi, A., Ettinger, S., Beraldi, E., Hadaschik, B., Zardan, A., Klomp, L. W., . . . Gleave, M. E. 
(2010). Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity 
in prostate cancer cells. Mol Cancer Res, 8(1), 119-130. doi: 10.1158/1541-7786.MCR-09-0277 
Zwain, I. H., Grima, J., & Cheng, C. Y. (1994). Regulation of clusterin secretion and mRNA expression 







List of Publications  
Research Articles: 
Sarah K. Woody, Anindit Chhibber, and Liqin Zhao. Identification and Characterization of Brain CLU 
Protein Isoforms. (In progress) 
Sarah K. Woody and Liqin Zhao. Estrogen Receptor beta (ERβ) Regulates Mature CLU in Rodent 
Brain. (In Progress) 
Chhibber A, Woody SK, Karim Rumi MA, Soares MJ, Zhao L., Estrogen receptor β deficiency impairs 
BDNF-5-HT2A signaling in the hippocampus of female brain: A possible mechanism for menopausal 
depression.. Psychoneuroendocrinology. 2017 Aug;82:107-116. doi: 10.1016/j.psyneuen.2017.05.016 
Woody, S.K., Zhou, H., Ibrahimi, S., Dong, Y., Zhao, L. Human Apolipoprotein E ε2 (APOE2) Promotes 
RegulatoryMechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-Type H+-
ATPase. J Alzheimers Dis. 2016 Jun 18;53(3):1015-31. doi: 10.3233/JAD-16030 
Liqin Zhao, Zisu Mao, Sarah K. Woody, Roberta D. Brinton. Sex Differences in Metabolic Aging of the 
Brain: Insights into Female Susceptibility to Alzheimer’s disease. Neurobiol Aging. 2016 June; 42:69-79. 
doi:10.1016/j.neurobiolaging.2016.02.011 
Sun, M, Cui, W, Woody, S. K, Staudinger, J. Pregnane x receptor modulates the inflammatory response 




Zhao, L., Woody, S.K., Chhibber, A. Estrogen Receptor β in Alzheimer’s disease: From Mechanisms to 
Therapeutics. Ageing Res Rev. 2015 Nov; 24(B): 178-90. doi:10.1016/j.arr.2015.08.001 
 
Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. 




Sarah K. Woody and Liqin Zhao (2016). Clusterin (APOJ) in Alzheimer’s Disease: An Old Molecule with 




Honors and Awards 
Lecturer, 2017 
32nd Annual Graduate Honors Symposium, University of Kansas School of Pharmacy 
Topic: The impact of neurodegeneration on CLU brain isoform distribution 
Pre-doctoral Fellowship in the Pharmaceutical Sciences, 2016-2017 
American Foundation for Pharmaceutical Education 
Amount: $10,000.00 
A.D. Sobel Education Fund Trainee Travel Award, 2016 





Summer Research Fellowship, 2015 
University of Kansas 
Amount: $5,000.00 
Trainee Professional Development Award, 2015 
Society for Neuroscience 
Amount: $1,500.00 
Graduate Scholarly Presentation Travel Award, 2015 
University of Kansas 
Amount: $500.00 
Junior Speaker, 2014 
Experimental Biology Meeting, San Diego, CA 
Session Title: “Nuclear Receptors as Therapeutic Targets” 
Lecture Title:  SUMO-Modification of Pregnane X Receptor Alters Protein-Cofactor Interactions 
12th Annual K-INBRE Symposium Award of Excellence, 2014 
Kansas IDeA Network of Biomedical Research Excellence 
Topic: CLU protein isoforms and redistribution in neurodegeneration 
 
